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1.1 Muscarinic receptors 
At the beginning of the 20
th century it was suggested for the first time that the 
physiological effects elicited by acetylcholine (ACh) (Fig. 1.3) were mediated by two 
different receptor populations, later named nicotinic and muscarinic receptors 
according to their stimulating agents nicotine and muscarine (Fig. 1.3), respectively 
(Dale, 1914). Nicotinic receptors turned out later to be members of the family of 
ligand-gated ion channels and were soon further divided into a neuronal and 
muscular subtype family (for review see Paterson and Nordberg, 2000). In the case 
of muscarinic receptors, diversity was more complex and clarification needed until 
the end of the 1980’s. First reports about heterogeneity within the muscarinic 
receptors were given in the 1950’s with the cardio-selective compound gallamine 
(Riker and Wescoe, 1951) and later with the ganglionic stimulant McN-A-343 
(Roszkowski, 1961). With the development of pirenzepine the first compound 
displaying real selectivity was found (Hammer et al., 1980) and the existence of at 
least two distinct muscarinic receptors was clearly confirmed, named M1 and M2 
(Hammer and Giachetti, 1982). Further reports about additional heterogeneity within 
the M2 subtype accumulated, but it was not before cloning techniques came up that 
the existence of all additional subtypes could be clearly confirmed. Cloning of the 
porcine M1 receptor (Kubo et al., 1986) was the beginning of this new era in the field 
of muscarinic receptors. Ensuing in the following years the cDNA of four additional 
human receptors, M2 - M5, were cloned (Bonner et al., 1987, 1988). The coding 
regions for hM1-5 receptors were shown to be intronless. The Nomenclature 
Committee of the International Union of Pharmacology (NC-IUPHAR) for muscarinic 
receptors summarised that M1 - M4 receptors could be clearly discriminated 
pharmacologically, with gene products related to a functional property in humans or 
animals (Caulfield and Birdsall, 1998). In the case of the M5 subtype, the receptor 
was cloned, stably expressed in CHO cells and characterised in binding studies 
(Buckley et al., 1989). However, a functional model for endogenous M5 receptors is 
still missing. Actually, there is no evidence for further subtypes within the muscarinic 
receptor family and it is likely that all muscarinic receptors are identified to date. 
Recently, the entire genes for the hM2 and hM3 receptors were mapped (Zhou et al., 
2001; Forsythe et al., 2002).  
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1.1.1 Signal transduction 
Muscarinic receptors were shown to belong to the superfamily of G-protein-coupled 
receptors (GPCRs) (for review see Wess, 1996) in contrast to nicotinic receptors 
which belong to the family of ligand-gated ion channels. Fig. 1.1 gives a cartoon of a 
nicotinic and a muscarinic receptor.  
 
Fig. 1.1 Model of a nicotinic and muscarinic receptor. Taken from Felder et al., 2000. 
 
Hydrophobicity analysis and comparison to the identified GPCR structure of 
rhodopsin (Lu et al., 2002) suggests, that each muscarinic receptor displays seven α-
helical membrane-spanning domains (TM1-7), an external N-terminus and an internal 
C-terminus. M1-5 receptors possess a high degree of sequence homology, especially 
within the TM domains (Bonner, 1989). Heterogeneity between M1-5 receptor proteins 
was observed within the large (approximately 240 amino acids long) third intracellular 
loop (i3), the N- and C-terminus. The most critical receptor domains involved in G-
protein-coupling are located at the i2-, i3-loop and C-terminus (Brann et al., 1993; 
Burstein et al., 1998). For this regions sequence similarity was observed between the 
odd-numbered and even-numbered subtypes, sharing the same signal transduction 
pathways (for review see Hulme et al., 1990; Felder et al., 2000). M1, M3, and M5 
were shown to couple preferentially via Gq (Fig. 1.2), leading to an activation of 
phospholipase Cβ (PLCβ) resulting in an enzymatic breakdown of 
phosphatidylinositol-4,5-bisphosphate (PIP2), thus providing the second messengers 
inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 leads to Ca
2+ liberation  
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from intracellular stores, inreasing [Ca
2+]i which is a cellular trigger for several 
downstream effects. DAG activates proteinkinase Cβ (PKCβ) initiating a variety of 
cellular effects. M2 and M4 receptors preferably couple to Gi (Fig. 1.2). Thus, 
activation leads to inhibition of adenylate cyclase (AC) resulting in decreased 
intracellular cAMP levels.  
 
Fig. 1.2 Preferential second messenger pathways for M1-5 receptors. Cartoon taken 
from Felder et al., 2000. 
 
Unfortunately, a vast amount of additional pathways was reported, thus making 
signal transduction within the muscarinic system a highly complex network 
(Nathanson, 2000). One should notice, that multiplicity was not only detected within 
the subunits of  G-proteins (17α-, 5β-, and 12γ-subunits were cloned), but also for AC 
and PLC, with 9 and 11 identified isoenzymes each, respectively (for review see 
Ulloa-Aguirre et al., 1999; Hur and Kim, 2002). M2 and M4 receptors may (when 
expressed at high levels) couple to PLC (isoenzymes β2 and β3) via their Gβγ 
subunit, in contrast to the Gq coupled receptors which stimulate PLC (isoenzymes 
β1-4) via their Gα subunit. The Gβγ subunit was shown to activate K
+ channels in the 
heart, too. For M1, M3, and M5 receptors stimulation of phospholipase A2, 
phospholipase D and tyrosine kinases was shown, but it remains yet to be elucidated 
whether this is a result of a direct G-protein interaction or a downstream effect of 
PLC. Regulation of cAMP level via muscarinic receptors is even more complex. Gq-, 
as well as Gi-coupled subtypes can increase cAMP levels via interaction with Gs 
(when expressed at high levels). Additionally, cAMP level can be regulated in a cell-
type specific manner via second messenger effects on phosphodiesterases. 
Oligomerization (for review see Rios et al., 2001; Dean et al., 2001) further 
complicating the signal transduction was shown for many GPCRs, including 
muscarinic receptors (Maggio et al., 1999; Park et al., 2001).  
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1.1.2 Receptor desensitization and sequestration  
An interesting feature observed for all muscarinic receptor subtypes is constitutive 
activity that could be reduced with atropine acting as an inverse agonist. Distinct 
amino acids within TM3, TM6 and the i2 loop were pinpointed to be involved in the 
level of constitutive activity (Spalding and Burstein, 2001; Ford et al., 2002). 
Internalization of muscarinic receptors following agonist stimulation was observed at 
all subtypes. However, rate and extent of sequestration were depending on the 
examined subtype and the used cell system (Koenig and Edwardson, 1996). Rapid 
uncoupling from G-proteins and desensitization was shown in the case of M2 
receptors to be regulated by phosphorylation through G-protein-coupled receptor 
kinases (GRK) within the i3 loop and arrestins (Hosey et al., 1999). Different 
mechanisms involved in M2 receptor sequestration were determined depending on 
the examined cell type. In JEG-3 cells, but not in HEK293 cells, arrestins were 
involved in receptor trafficking (Schlador and Nathanson, 1997; Roseberry and 
Hosey, 1999). The underlying mechanism involved in HEK-293 cells remains yet 
unclear. In PC12 cells, involvement of the small GTPase Rab11a was demonstrated 
in M4 sequestration from the cell surface to endosomes (Volpicelli et al., 2002). 
Further studies are needed to clarify the mechanisms involved in internalization of 
muscarinic receptors. 
 
1.1.3 Receptor distribution in the periphery 
In the following paragraphs a brief summary of the most important features of 
muscarinic receptors in peripheral tissues is given. 
 
1.1.3.1 M1 receptors 
This subtype was detected in sympathetic and parasympathetic ganglia where they 
facilitate ganglionic neurotransmission (Hammer and Giachetti, 1982). Studies with 
M1-KO mice showed the increase in heart rate and blood pressure following the 
application of McN-A-343 (presumably due to catecholamine release from 
sympathetic ganglia) to be abolished (Hamilton et al., 2001; Hardouin et al., 2002). 
M1 receptors were found at neurons within the gastrointestinal tract (GIT). 
Immunological studies detected this subtype in salivary glands (Levey, 1993), where  
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they play a minor role in salivation (Bymaster et al., 2003). In rabbit vas deferens M1 
receptors were detected to mediate inhibition of neurogenic contractions (Eltze et al., 
1988). Recently, it was shown that M1 receptors in stomach smooth muscles of 
M3-KO mice mediate an NO driven relaxation that is normally masked by a direct 
M3-mediated contraction (Stengel and Cohen, 2003). 
 
1.1.3.2 M2 receptors 
M2 receptors are widely distributed within periphery. In heart tissue, M2 receptors are 
the most important subtype, mediating negative chronotropic, inotropic and 
dromotropic effects (Caulfield, 1993). In studies with M2-KO mice, these effects were 
abolished, confirming the predominant role of this subtype in heart tissue (Stengel et 
al., 2000; Bymaster et al., 2001). Great amounts of M2 receptors were detected in a 
variety of smooth muscle preparations (for review see Eglen et al., 1994, 1996) 
where they are located pre- and postjunctionally. M2 receptors clearly outnumber M3 
receptors in most smooth muscle tissues. Studies with M2-KO mice demonstrated a 
reduced potency of muscarinic agonists to contract smooth muscle preparations 
(Stengel et al., 2000; Bymaster et al., 2001). However, the role of postjunctional 
receptors is not fully understood. Prejunctionally located M2 receptors represent the 
major subtype among muscarinic autoreceptors (Caulfield, 1993; Langer, 1997). 
 
1.1.3.3 M3 receptors 
This subtype was shown to be located in many smooth muscle preparations including 
GIT, urinary tract and airways (Fetscher et al., 2002). M3 receptors were shown to be 
the most important subtype involved in smooth muscle contraction. In studies wit M3-
KO mice contractile response of smooth muscle was massively impaired in tissue 
preparations of GIT and urinary bladder (Matsui et al., 2000; Stengel et al., 2002). 
Additionally, M3-KO mice (but not M1,2,4,5-KO mice) had enlarged pupils, confirming a 
role for M3 receptors on the tone of pupillary sphincter muscles (Matsui et al., 2000). 
M3 receptors were detected in salivary glands. Studies with M3-KO mice showed a 
pronounced decrease in salivation being more important than M1 and M4 receptors 
(Bymaster et al., 2003). Activation of M3 (and possibly M1) receptors on pancreatic B-
cells resulted in an increased insulin secretion (Verspohl et al., 1990).  
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1.1.3.4 M4 receptors 
M4 receptors are located in several peripheral human and animal tissues. However, 
the physiological role of M4 receptors often remains unclear. In human detrusor 
muscle, M4 receptors serve as inhibitory autoreceptors (D'Agostino et al., 2000). A 
minor role in salivation could be confirmed in M4-KO mice (Bymaster et al., 2003). 
Somadendritically located M4 receptors mediate NANC relaxation in the rabbit 
anococcygeus muscle. This preparation is therefore used as a functional M4 model 
(Gross et al., 1997). Involvement in autoreceptor function, next to M2 receptor, was 
suggested in postganglionic sympathetic axons in mouse bladder (Trendelenburg et 
al., 2003). 
 
1.1.3.5 M5 receptors 
Apart from its localisation in blood vessels in brain and the periphery, this subtype 
was not detected in other peripheral tissues (Phillips et al., 1997; Elhusseiny et al., 
1999). 
 
1.1.4 Receptor distribution in the CNS 
All known subtypes of muscarinic receptors were found to be widely distributed within 
human brains using different experimental approaches. Radioligand binding studies 
(Waelbroeck et al., 1989; Ferrari-Dileo et al., 1994), autoradiographic experiments 
(Rodriguez-Puertas et al., 1997) and immunological studies in rats (Yasuda et al., 
1992; Levey, 1993) and humans (Flynn et al., 1995) were carried out. Taken 
together, highest levels of M1 receptors were detected in cortex and hippocampus, 
whereas in the striatum even higher levels of M4 receptors were identified. In 
midbrain, pons, cerebellum and brainstem the M2 subtype was the most frequently 
expressed receptor. Interestingly, M3 receptors were detected in low, M5 receptors in 
very low levels within the examined brain areas. Because highly selective, brain 
penetrating ligands for muscarinic receptor subtypes are not commonly available, it is 
difficult to assign single subtypes to special behavioural and cognitive functions. With 
the generation of genetically modified mice, lacking one or more muscarinic receptor 
subtypes (knock-out, KO mice), some central functions could be elucidated and 
clearly attributed to a single subtype (for review see Bymaster et al., 2003).  
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1.1.4.1 M1 receptors 
With high density in cortex and hippocampus a role of M1 receptors in cognition and 
memory was suggested. Studies with M1-KO mice showed cognitive dysfunctions in 
some tasks, confirming a role of this subtype (Anagnostaras et al., 2003). M1-KO 
mice displayed hyperactivity with increased locomotor activity and had increased 
dopaminergic transmissions in the striatum (Gerber et al., 2001). Participation of M1 
receptors located in the hypothalamic suprachiasmatic nucleus (SCN) in the 
regulation of circadian rhythm was shown in rats (Gillette et al., 2001). In a study 
using antisense inhibition of the M1 subtype an involvement in central antinociception 
was detected (Ghelardini et al., 2000). 
 
1.1.4.2 M2 receptors 
Several aspects concerning the physiological role of this subtype were elucidated. 
Muscarinic agonists penetrating into the CNS elicit a potent analgesic response. 
Several studies with M2-KO, M4-KO and M2/M4-KO mice addressed this aspect and 
found the M2 subtype to be most important for the analgesic effects (Gomeza et al., 
2001; Duttaroy et al., 2002). Additionally, a minor role of M4 receptors was 
determined in analgesic effects. Taken together, M2 and M4 receptors mediate 
muscarinic agonist evoked analgesic effects on spinal and supraspinal levels (for 
review see Wess et al., 2003). Further studies revealed the M2 subtype to be critically 
involved in mediating central muscarinic effects such as tremor and hypothermia 
following application of a muscarinic agonist (Bymaster et al., 2001; Gomeza et al., 
2001). A role within the hypothalamic-pituitary-adrenocortical axis was detected in 
M2-KO mice (Hemrick-Luecke et al., 2002). The increase of serum corticosterone 
levels following the application of a muscarinic agonist was abolished in mice lacking 
M2 receptors. One of the perhaps most important physiological M2 functions in the 
CNS is participation in release control of ACh as an autoreceptor. The critical role of 
M2 was confirmed in several studies using human and rat brains (Feuerstein et al., 
1992; Kitaichi et al., 1999; Zhang et al., 2002a). Within cortex and hippocampus, the 
ACh release is controlled mainly via the M2 subtype, whereas in the striatum the M4 
subtype plays the predominant role. 
  
Introduction 
 
 
9 
1.1.4.3 M3 receptors 
Only little is known about the function of this comparably small receptor fraction. 
Studies with M3-KO mice showed a role for M3 receptors in food intake and control of 
whole body weight (Yamada et al., 2001b). Mice lacking this subtype were 
hypophagic and lean with pronounced decreases in leptin and insulin levels. An 
indirect inhibitory effect on striatal dopamine (DA) release was reported for this 
subtype (Zhang et al., 2002b). 
 
1.1.4.4 M4 receptors 
Studies revealed a participation in analgesic effects mediated through the muscarinic 
system next to the M2 subtype (Duttaroy et al., 2002). A major role in autoinhibitory 
release control of ACh in the striatum was demonstrated (Zhang et al., 2002a). 
Further on, the involvement of this subtype in dopaminergic transmission was 
investigated. M4-KO mice had increased basal locomotor activity and increased D1 
receptor sensitivity (Gomeza et al., 1999). M4 receptors facilitate dopamine release in 
the striatum (Zhang et al., 2002b). An interesting report was given about the 
influence of steroids on M4 density in some brain regions. Density of M4 receptors in 
hippocampus and hypothalamus were reduced in rats by application of estrogens but 
not gestagens (El Bakri et al., 2002). 
 
1.1.4.5 M5 receptors 
The years following the discovery of M5 receptors gave only little insight in the role of 
this subtype. Reviews summarising the fragmented knowledge were published 
recently (Reever et al., 1997; Eglen and Nahorski, 2000). It was more than ten years 
after discovery of this subtype when first M5-KO studies showed influence on 
dopaminergic transmission (Yeomans et al., 2001; Forster et al., 2001). M5 receptors 
were shown to facilitate a prolonged dopamine release in some brain regions. Mice 
lacking M5 receptors showed increased drinking, suggesting a role in fluid intake for 
this subtype (Takeuchi et al., 2002). Finally, this subtype was shown to be involved in 
the ACh driven dilation in cerebral, but not peripheral blood vessels via NO (Yamada 
et al., 2001a). 
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1.1.5 Non-neuronal ACh 
Apart from neuronal cells, ACh and the synthesising enzyme, choline 
acetyltransferase  (ChAT), have been detected in a variety of e.g. epithelial cells, 
endothelial cells and immune cells (for review see Wessler et al., 2003). It is 
important to notice, that non-neuronal ACh acts as a local signalling molecule 
involved in the regulation of cellular functions, whereas neuronal ACh acts as a 
neurotransmitter, rapidly mediating communication between neurons and effector 
cells. Table 1.1 gives the most prominent differences between the neuronal and non-
neuronal cholinergic systems.  
 
Table 1.1 Differences between the neuronal and non-neuronal cholinergic systems. 
Modified from Wessler et al. (2003). 
Neuronal     Non-neuronal 
nerve terminal  SYNTHESIS  whole cell 
vesicles  STORAGE  cytosol (?) 
exocytosis /  RELEASE  transporter / 
on demand    continously 
hot spots  RECEPTORS  uniformly expressed 
short lasting  ACTION  continously 
rapid  ELIMINATION  slow 
 
In contrast to neuronal transmission, ACh in non-neuronal cells is synthesised in the 
whole cells and not stored in special compartments. A constant release was shown 
to be mediated by organic cation transporters, whereas a complex exocytosis 
mechanism takes place during neuronal ACh release. 
Comparatively many studies were undertaken with regard to the cholinergic system 
in lymphocytes (for review see Kawashima and Fujii, 2000). M4 and M5 receptors 
were detected in all studies, whereas expression of M1-3 receptors was not detected 
in all examined persons. There is an increasing body of evidence, that ACh from T-
lymphocytes acts as an autocrine and/or paracrine factor regulating immune 
functions next to the cytokine system. Recently, the involvement of autocrine 
cholinergic mechanisms on expression of both, IL-2 and its receptor in T-cells was 
demonstrated (Nomura et al., 2003). Changes in muscarinic receptor density in  
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lymphocytes were detected in patients suffering from Alzheimer’s disease or asthma, 
giving hope to derive new clinical markers or therapeutic options (Tayebati et al., 
2001; Ricci et al., 2002). Increased M5 mRNA levels were detected in lymphocytes 
during immunological responses (Fujii et al., 2003). Additionally, all muscarinic 
receptor subtypes were located in human skin melanocytes (Buchli et al., 2001), but 
the physiological role remains unclear. Expression of ChAT in human ovary was 
detected in endocrine cells expressing M1 and M5 receptors. A role in cell 
proliferation was suggested (for review see Mayerhofer et al., 2003). Finally, an 
important role of the non-neuronal cholinergic system was detected in the eye (for 
review see Duncan and Collison, 2003), where involvement in tear fluid production 
(mediated exclusively via M3) and form-deprived myopia was shown (mediated 
perhaps via M1 and M3).  
 
1.1.6 Muscarinic ligands 
A brief overview of muscarinic agonists and antagonists is given in the following 
paragraphs. Muscarinic ligands have been extensively reviewed elsewhere (Eglen 
and Watson, 1996; Eglen et al., 1999; Broadley and Kelly, 2001). The development 
of selective muscarinic ligands turned out to be a difficult task and only in the last 
years progress was reported. 
 
1.1.6.1 Muscarinic  agonists 
Several non-selective agonists next to the endogenous ligand ACh are known, 
including the closely related compounds carbachol and oxotremorine (Fig. 1.3). As 
hope came up to obtain potent drugs for Alzheimer’s disease (AD) therapy with the 
development of M1-selective agonists, a rush in pharmaceutical industry started in 
the search for CNS penetrating, M1-selective agonists. Several compounds were 
tested in clinical trials. However, all tested compounds had only little selectivity for M1 
receptors. Additionally, most drugs had a poor bioavailability and were metabolically 
unstable. Thus, studies with xanomeline, milameline, sabcomeline, talsaclidine and 
alvameline in AD patients were discontinued due to side effects or little efficacy (for 
review see Sheardown, 2002). Only one so called “M1-selective” agonist, cevimeline 
(Fig. 1.3), was approved to the market but not for use in AD therapy. It was approved  
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next to the non-specific agonist pilocarpine (Fig. 1.3) for therapy of the autoimmune 
disease Sjögren’s syndrome (for review see Fox et al., 2001; Fox, 2003). This 
disease leads to dysfunction of salivary and lacrimal glands resulting in dry mouth 
and eyes (xerostomia). Stimulation of M1 and M3 receptors within glandular tissue 
ameliorates these symptoms. Although most companies stopped their programs for 
M1-selective molecules, there is still some research carried out in order to develop 
second generation compounds with better selectivity, increased bioavailability and 
metabolic stability (for review see Fisher et al., 2002). One newer M1-selective 
compound is AF-150(S) with somewhat improved characteristics (Fig. 1.3). Synthesis 
of dimeric muscarinic ligands led to the discovery of M1/M4 selective compounds 
(Christopoulos et al., 2001). The idea of using M1 agonists in AD therapy is not buried 
yet and improved drug candidates might lead to better results in clinical trials. 
 
N
N
O
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+
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Fig. 1.3 Chemical structures of selected muscarinic agonists. The asterisks  denote 
the centres of chirality.  
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1.1.6.2 Non-selective  antagonists 
The most prominent representatives within this group are undoubtedly the well 
known alkaloids atropine and its derivative scopolamine (Fig. 1.4), both highly potent 
antagonists without any subtype selectivity. The quaternary N-methyl congener of the 
latter was and is widely used as the radioligand N-methyl-scopolamine (NMS).  The 
formerly considered M3-selective reference compound 4-DAMP (Fig. 1.4) turned out 
to be a non-selective compound in binding studies (Dörje et al., 1991). 
 
1.1.6.3 M1-selective antagonists 
With the introduction of pirenzepine (Fig. 1.4; Hammer et al., 1980) the first potent 
M1-selective antagonist was described. This compound has low selectivity versus M4 
and good selectivity versus the other subtypes. The derivative guanylpirenzepine 
(Micheletti et al., 1990) has slightly improved selectivity but decreased affinity. With 
PD150714, a compound with good selectivity profile (at least 19-fold versus the other 
subtypes) was developed (Augelli-Szafran et al., 1999). Interesting M1-selective 
compounds related to phenglutarimide displaying high stereoselectivity were 
synthesised (Waelbroeck et al., 1996). Molecular properties of M1-selective 
compounds were reviewed (Widzowski et al., 1997). 
 
1.1.6.4 M2-selective antagonists 
With the discovery of the M4 subtype many formerly considered M2-selective 
compounds, e.g. himbacine (Fig. 1.4), were shown to be unable to discriminate 
between these subtypes which is also true for AF-DX116  (Fig. 1.4) and its congener 
AF-DX384  (Dörje et al., 1991). Tripitramine was the first truly M2-selective antagonist 
with high affinity to M2 receptors and good selectivity (Melchiorre et al., 1993; Maggio 
et al., 1994) but displayed non-competitive behaviour in some functional assays. 
M2-selective compounds derived from dimethindene were part of this work and are 
described in detail later. A brain-penetrating M2 antagonist was reported with BIBN99 
(Fig. 1.4) showing low selectivity versus M4 and good selectivity to the other subtypes 
(Doods et al., 1993). Recently, a series of reports were given concerning M2-selective 
compounds developed by Schering-Plough with high affinity and good or excellent 
selectivity (Lachowicz et al., 1999; Kozlowski et al., 2000, 2002; Wang et al., 2001,  
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2002a, b; McCombie et al., 2002; Boyle et al., 2002; Boyle and Lachowicz, 2002), 
e.g. SCH57790 (Fig. 1.4) and a congener (named “Schering compound” in Fig. 1.4). 
 
1.1.6.5 M3-selective antagonists 
With darifenacin (Fig. 1.5) a compound with M3-selectivity was developed (Wallis and 
Napier, 1999). In the last years novel, highly potent compounds with superior 
selectivity were reported from Banyu Pharm (Banyu Pharm Co Ltd: WO0107406, 
2001; Sagara et al., 2002). In an approach using combinatory chemistry, more than 
1000 compounds were evaluated regarding their affinity at muscarinic subtypes. An 
example for a new compound with affinity to M3 receptors in the subnanomolar range 
and high selectivity is given in Fig. 1.5 named “Banyu compound”. In recently 
published studies, follow-up compounds with comparable affinities were presented 
(Sagara et al., 2003; Ogino et al., 2003). 
 
1.1.6.6 M4-selective antagonists 
The first compound displaying M4-selectivity was PD102807 (Fig. 1.5) with high 
affinity to M4 receptors (Augelli-Szafran et al., 1998). Selectivity was determined to be 
186-fold, 77-fold, 37-fold and 486-fold versus M1, M2, M3 and M5, respectively. 
Congeners with elongation of the aliphatic methyl group (marked with an arrow in 
Fig. 1.5) displayed increased affinity and a further improved selectivity profile 
(Schwarz et al., 2001; Böhme et al., 2002). The propyl-congener was determined to 
have 1000-fold, 550-fold, 35-fold, and 1000-fold selectivity versus M1, M2, M3 and M5, 
respectively. Snake toxins (peptides) taken from mamba venom possess selectivity 
for muscarinic receptor subtypes, for example  MT3 is M4-selective (for review see 
Bradley, 2000; Jerusalinsky et al., 2000). However, due to costs and non-competitive 
kinetics, non-peptide compounds are likely to completely displace these toxins from 
the laboratories. 
 
1.1.6.7 M5-selective antagonists 
Up to date, no compounds displaying selectivity for this subtype have been reported. 
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Fig. 1.4  Chemical structures of selected muscarinic antagonists. The asterisks 
denote the centres of chirality.  
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Fig. 1.5 Chemical structures of selected muscarinic antagonists. The asterisks 
denote the centres of chirality. The arrow marks the modification site leading to highly 
M4-selective compounds. 
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1.1.7 Therapeutic options 
A short summary about the most important therapeutic aspects of muscarinic ligands 
will be given in the following paragraphs (for review see Eglen et al., 2001; Felder et 
al., 2000). 
 
1.1.7.1 Peripheral  tissues 
It is long known, that non-selective, quaternary muscarinic antagonists like N-butyl-
scopolaminium bromide can be used as antispasmodics in GIT disorders. Further 
studies are needed to evaluate, whether M3-selective compounds like darifenacin are 
more effective for that purpose (Eglen, 2001). The role of pirenzepine in gastric ulcer 
therapy (Eglen and Watson, 1996) has decreased with newer, more potent drug 
classes reaching the market to reduce gastric acid secretion. Muscarinic agonist 
stimulating M1/M3 receptors in salivary glands were shown to be effective in 
xerostomia in Sjögren’s syndrome (see 1.1.6.1). Pilocarpine as a non-selective 
muscarinic agonist is used in glaucoma therapy to reduce intraocular pressure (IOP) 
but elicited blurred vision and night blindness as unwanted side effects (both 
mediated via M3 receptors). M3-sparing muscarinic agonists might be better tolerated 
and highly effective in decreasing IOP since cholinomimetics are the only class of 
glaucoma drugs facilitating trabecular meshwork outflow (Gil et al., 2001). The use of 
pirenzepine to reduce development of myopia was suggested and is under 
investigation (for review see Duncan and Collison, 2003). Ocular application to 
children was well tolerated (Bartlett et al., 2003). Therapeutic options targeting 
muscarinic receptors in smooth muscle tissues in the airways and bladder are well 
known. The use of drugs with prolonged blockade of M3 receptors in human airways 
with little effect on M2 receptors were found to be highly effective bronchodilators, 
especially in chronic obstrucive pulmonary diseases (COPD). Drug properties 
important for efficacy in COPD therapy were part of this work and will be discussed 
later in detail. Anticholingergic drugs are widely used in therapy of unstable bladder 
to relieve urge incontinence, nocturia and enuresis. The non-selective drugs 
trospium, oxybutynin and tolterodine are commonly used in therapy (for review see 
Doggrell, 2001; Yoshimura and Chancellor, 2002), inducing dry mouth as the most 
important side effect. This side effect was markedly reduced with the introduction of  
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an once-daily formulation of oxybutynin and tolterodine resulting in lower plasma 
peak levels (Appell, 2002; Sussman and Garely, 2002). As drug effect within the 
bladder and side effects in salivary glands are both mediated via M3 receptors it is of 
interest to find tissue-specific compounds. Finally, the use of M2-selective ligands in 
therapy of arrhythmias was suggested. The M2-selective antagonist AF-DX116 was 
used in clinical trials as a chemical pace maker (Schulte et al., 1991), but was 
discontinued due to retention of cardiologists. M2-selective agonists were suggested 
in therapy of tachyarrhythmia (Goyal, 1989). However, up to date this idea has only 
little relevance. 
 
1.1.7.2  Central nervous system 
Studies with KO mice revealed an important role of M2 and M4 receptors in mediation 
of spinal and supraspinal nociceptive processing. M4-selective muscarinic agonists 
were suggested to be potential analgesic compounds (Duttaroy et al., 2002) with 
fewer side effects than it would be expected from the use of M2 agonists. An 
interesting approach was reported in a study with mice, using non-selective brain-
penetrating muscarinic agonists for analgesia in combination with a quaternary 
antagonist to block peripheral muscarinic side effects (Tekol and Eminel, 2002). 
 
Influence on dopamine release was detected in KO mice for M4 and M5 receptors. In 
Parkinson’s disease (PD) a proceeding loss of dopaminergic neurons within the 
substantia nigra and a reciprocal increase in cholinergic transmission in the striatum 
was detected (for review see Centonze et al., 1999) leading to disorders of the 
extrapyramidal system. At present, muscarinic antagonists with high affinity for M1 
and M4 receptors, like biperiden, are in therapeutic use (Grimm et al., 1994). 
Selective, brain-penetrating M4 antagonists (see also 1.1.6.6) were suggested to be a 
novel therapeutic approach in PD therapy (Salamone et al., 2001; Mayorga et al., 
1999). M1/M4 agonists were suggested to be helpful in therapy of psychosis (Felder 
et al., 2001). Additionally, an involvement in dopaminergic transmission in rewarding 
effects following drug abuse was determined for M5 receptors (Forster et al., 2001). 
Mice lacking this subtype had attenuated morphine withdrawal symptoms but 
unchanged analgesia (Basile et al., 2002). In Asian countries good results were 
achieved in detoxification of heroin addiction with scopolamine. Hence, it was  
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suggested that this was possibly a M5-mediated effect and M5 antagonists might 
serve as a new approach in the treatment of opiate addiction (Yang, 2002). 
 
Handling of Alzheimer’s disease (AD) (see also 1.1.6.1 and 1.1.6.4) is one of the 
most difficult tasks to public health in our times. The histopathologic hallmarks of AD 
are neurofibrillary tangles consisting of hyperphosphorylated tau protein and β-
amyloid plaques (for review see Selkoe, 2001). Early reports on decreased activity of 
cholinergic markers in the brains of AD patients (Davies and Maloney, 1976) and the 
finding that scopolamine reduced perfomance in memory tasks (Drachman and 
Leavitt, 1974) led to the cholinergic hypothesis in AD (Bartus et al., 1982). This 
hypothesis was supported with the therapeutic success of  currently used AChE 
inhibitors. However, AChE inhibitors provide a merely symptomatic therapy with little 
efficacy. Several new therapeutic aspects were and still are under investigations (for 
review see Kumari and Ram, 2001; Dominguez and De Strooper, 2002; Yamada and 
Toshitaka, 2002) but in the following focus is laid on the muscarinic system. Two 
approaches are currently examined. Firstly, the application of M1-selective agonists 
(see also 1.1.6.1) as disease modifying drugs with influence on β-amyloid 
metabolism and tau hyperphosphorylation (for review see Fisher, 2000, 2002). 
However, up to now, all clinical studies with so-called “M1 agonists” showed little or 
no positive effects in clinical trials, perhaps due to low selectivity or inappropriate 
kinetic properties of the tested drugs. There is a strong need for M1-selective 
agonists with improved drug characteristics to clarify the utility of M1 agonists in AD. 
The second approach is, like AChE inhibitors, a non disease modifying approach. 
Inhibitory M2 autoreceptors were shown to control ACh release in several brain 
regions (Feuerstein et al., 1992). Therefore, it was suggested that M2 antagonists 
might improve cognition. Indeed, blocking these autoreceptors with selective M2 
antagonists was shown to facilitate ACh release and improve cognitive performance 
(Packard et al., 1990; Quirion et al., 1995). However, the use of M2 antagonists in AD 
might be limited because the number of cholinergic neurons decreases over time in 
AD, reducing the amount of available prejunctionally located target sites (Sheardown, 
2002). Further clinical studies with brain-penetrating, highly selective M2 antagonists 
are needed to clarify this issue. 
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1.1.8 Diagnostic potential 
With positron emission tomography (PET) a medical imaging technique with high 
potential is becoming more and more popular. PET studies can provide in vivo 
information about receptor density and blood flow in a special tissue (Bartenstein, 
2002). PET ligands for receptor imaging should provide a high affinity to the target 
site, high selectivity and specificity. At present, diagnosis in AD is made post-mortem. 
With PET tracers selective for M2 receptors (which decrease in AD) the evaluation of 
new disease modifying drug therapies could be imaged in vivo. Further, a diagnosis 
could be posed before AD becomes clinically relevant (Volkow et al., 2001; 
Silverman and Small, 2002; Petrella et al., 2003). 
 
1.2 Histamine receptors 
Already before world war I, first reports on the physiological actions of histamine 
were reported (Dale and Laidlaw, 1910). In the following decades pharmacologically 
different histamine receptor subtypes were identified. In 1997 the IUPHAR 
differentiated three different GPCR belonging to the histaminergic family, named H1, 
H2 and H3 receptors (Hill et al., 1997). First cloning of the H2 subtype positively 
coupled to adenylyl cyclase (AC) via Gs was reported in the early 1990’s (Bakker et 
al., 2000). At that time, bovine and later human H1 receptors were cloned, too 
(Yamashita et al., 1991; De Backer et al., 1993). Stable expression of this subtype in 
CHO cells clearly demonstrated its coupling with Gq, increasing intracellular Ca
2+ 
level (Moguilevsky et al., 1994; Smit et al., 1996). The hH1 receptor gene was cloned 
and completely mapped to chromosome 3, identified as an intronless gene (Fukui et 
al., 1994; Bakker et al., 2000). In the late 1990’s the hH3 receptor was cloned for the 
first time and later on the gene was mapped (Lovenberg et al., 1999; Wiedemann et 
al., 2002). This subtype is negatively coupled to AC via Gi/o. In the years 2000 and 
2001, several groups published in close succession the cloning and characterisation 
of a previously unknown histamine receptor, denominated H4 (Nakamura et al., 2000; 
Oda and Matsumoto, 2001; Morse et al., 2001; Nguyen et al., 2001; Zhu et al., 2001). 
This newly identified subtype is closely related to the H3 subtype and couples via Gi/o 
to AC. Recently, a histamine-gated chloride channel was identified in Drosophila 
(Lopez, 2002). Thus, the search for previously undetected ligand-gated ion channels  
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sensitive to histamine started in humans. Fig. 1.6 gives a phylogenetic tree between 
some members of the GPCR family. A close relationship between H1 and muscarinic 
receptor subtypes can be seen. Greatest amounts of histamine within the human 
body are located in tissue mast cells and enterochromaffin-like cells in the GIT. To a 
smaller extend histamine is stored in basophil leukocytes and platelets.  
 
In the following paragraphs a brief summary of the most important findings 
concerning the H1 receptor is given. 
 
Fig. 1.6 Phylogenetic tree of homology between members of the GPCR family of 
amine transmitter systems. Taken from Leurs et al., 2000. 
 
1.2.1 H1-receptor distribution and function 
H1 receptors are widely distributed within the human body (for review see Hill et al., 
1997). In vascular endothelial cells, H1 receptor stimulation leads to increased 
vascular permeability as a result of endothelial cell contraction. A variety of 
transmitter molecules and proteins can be released from endothelial cells, including 
the vasodilator NO. Influence of histamine on the cardiovascular system is complex 
and dose-dependent. Application of histamine results in a decrease in blood pressure 
as a result of endothelial NO liberation. Several smooth muscles, especially in human 
airways and GIT, contract as a result of H1 stimulation. In the adrenal medulla, H1 
receptor stimulation facilitates the release of adrenaline and noradrenaline. H1 
receptors are also widely distributed within the brain of humans and other species.  
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1.2.2 Ligands at H1 receptors 
In this paragraph focus is laid on antagonists. The molecular properties of agonists 
and antagonists at H1 receptors were extensively reviewed (Leurs et al., 1991, 1995; 
Hill et al., 1997). So-called “first generation” H1 antagonist like diphenhyramine (Fig. 
1.7) were penetrating into the CNS where they elicited sedation as a side effect. This 
effect was clearly confirmed as an H1 effect in human studies using dimethindene 
(Nicholson et al., 1991). As a consequence, new molecules were designed with less 
lipophilic structures. Introduction of hydrophilic moieties in the molecular structures of 
already known H1 antagonists resulted in less lipophilic drugs with comparably low 
brain penetration, e.g. hydroxyzine  cetirizine (Fig. 1.7) or azatidine  loratadine 
(Fig. 1.7) (Leurs et al., 1995). These compounds are generally considered as non-
sedating “second generation” H1 antihistaminergic drugs with fewer CNS side effects. 
Some tricyclic antidepressant drugs like doxepin (Fig. 1.7) display high affinity to this 
receptor next to many other receptor sites (Figge et al., 1979). Chemical diversity 
within the vast amount of known H1 antagonists is large, especially within the newer 
compounds. Up to now, no model exists that is capable of fitting all of them to an 
interaction with the H1 subtype. Mepyramine (= pyrilamine; Fig. 1.7) was discovered 
almost half a century ago and is still the most popular radioligand for affinity 
determinations at H1 receptors (Marshall, 1955). It is also noteworthy, that many 
previously described H1 antagonists were found to be inverse agonists (Leurs et al., 
2002). Compounds derived of the well known H1 antagonist dimethindene were part 
of this work. Therefore more details about dimethindene are reported later in the 
Aims chapter (see 2.7). 
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Fig. 1.7 Chemical structure of selected H1 antagonists. The asterisk denotes the 
centre of chirality. 
 
1.2.3 Therapeutic implications 
The most important therapeutic use of H1 antagonists are allergic diseases, such as 
rhinoconjunctivitis, urticaria and atopic dermatitis (Baroody and Naclerio, 2000). 
“Second generation” H1-antihistamines are widely used for that purpose with good 
efficacy and little side effects. However, studies concerning the use of this class of 
drugs in asthma were disappointing (Mincarini et al., 2001). The use of 
antihistamines as analgesic drugs provided conflicting data and needs further 
evaluation (Raffa, 2001). “First generation” H1 antagonists are still in use as mild 
sedatives and for prevention of motion-sickness.  
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1.3 Serotonin receptors 
Serotonin (5-hydroxytryptamine, 5-HT) has a long history as an endogenous 
signalling molecule in humans and animals mediating a great variety of physiological 
effects. Early studies were carried out in guinea-pig ileum (GPI) to clarify the role of 
this newly described agent (Rocha e Silva et al., 1953). In the late 1950’s two 
different receptors for 5-HT were identified in GPI (Gaddum and Picarelli, 1957). 
They were named M- and D-receptor, because the responses at these subtypes 
could be blocked with morphine and dibenzyline. It was in the late 1980’s and the 
begin of the 1990’s when a burst in serotonin receptor pharmacology took place with 
cloning techniques coming up. An almost incredible amount of 5-HT receptor 
subtypes were cloned in humans and several animals. NC-IUPHAR for serotonergic 
receptors confirmed already seven different receptor families for serotonin in 1994 
(Hoyer et al., 1994). At this time, it seems as if 5-HT plays a unique role in the 
monoamine neurotransmitter family with regard to receptor diversity. With 
posttranslational modifications, alternative splicing, oligomerization and 
heteromerization an almost endless complexity among this receptor class seems 
possible. The former D-receptor is now called 5-HT2, the M-type 5-HT3 receptor. Fig. 
1.8 gives an overview of the actual findings on serotonergic receptors. It is important 
to note that all identified subtypes belong to the class of 7-TM GPCR-family with 
exception of the 5-HT3 receptor which was identified as an ligand-gated ion channel.  
Serotonergic receptors are widely distributed throughout the periphery and the 
central nervous system of the human body. The vast amount of existing data 
concerning all known subtypes was extensively reviewed during the last years (Hoyer 
et al., 1994, 2002; Barnes and Sharp, 1999). As it is impossible to address all 
subtypes in this work, focus was laid on the 5-HT3 and 5-HT4 receptor subtypes 
which were subjects of research in this dissertation. It is interesting to notice, that 
95% of the total 5-HT in the human body is found in the GIT. 90% of that amount are 
located in enterochromaffin cells and 10% in enteric neurons. The remainder of 5-HT 
(5%) is found in the brain. Serontonergic neurons constitute about 2% of all 
myenteric neurons in the GIT. Virtually all of the 5-HT in blood is derived from GIT, 
where it is released from the bowel following stimulation. 5-HT is additionally a 
constituent of platelets and is participating in aggregation and coagulation of blood 
(Kim and Camilleri, 2000).  
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Fig. 1.8 Summary of the current classification of 5-HT receptors (modified from Hoyer 
et al., 2002). Subtypes for which up to now no physiological function was 
demonstrated are given in uncapitalised letters. 
 
1.3.1 5-HT3 receptors 
5-HT3 receptors were identified as ligand-gated ion channels. First reports were given 
in tissue preparations of guinea-pig submucosus plexus with patch clamp 
experiments (Derkach et al., 1989). This finding was supported with the first cloning 
of a 5-HT3 receptor from NCB20 cells (mouse neuroblastoma x chinese hamster 
embryonic brain cells) and expression in xenopus oocytes resulting in a serotonin  
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sensitive increase in conductance (Maricq et al., 1991). The formed ion channel was 
found to be non-selective, as opening resulted in Na
+, Ca
2+ influx and K
+ efflux 
(Davies et al., 1999). The ion-channel was suggested to be composed of five 
subunits with regard to the related nACh receptor family. The ultrastructure of 5-HT3 
receptors could be elucidated with purified receptors derived from NG108-15 cells 
(mouse neuroblastoma x rat glioma cells) and mouse tissue (Boess et al., 1995; 
Green et al., 1995). Fig. 1.9 gives a computer filtered picture of purified 5-HT3 
receptors. The pentameric structure was confirmed in these studies. Receptors were 
modelled as cylinders 11 nm in length,  8nm in diameter and with a central cavity of 3 
nm in diameter. For each of these five subunits a 4TM structure was proposed based 
on hydropathy profiles and homology to nACh receptors (Hovius et al., 1998). Direct 
evidence confirming this theory was derived with a set of antibodies recognising 
different structural domains of 5-HT3 receptors. (Spier and Lummis, 2002). With the 
mapping of the h5-HT3A gene (located on chromosome 11) a detailed topological 
model of the receptor, given in Fig. 1.10, was possible (Brüss et al., 2000b). The 
coding region of the h5-HT3A gene consists of 9 small exons separated by relatively 
large introns and stretches over a total of 15 kilobases. Evidence was given that the 
TM2 domains of all subunits account for the formation of the ion pore (Panicker et al., 
2002) and that the large second intracellular loop (i2) is in parts responsible for the 
single channel conductance (Kelley et al., 2003). Receptor purification studies 
(McKernan et al., 1990) and electrophysiological studies (Hussy et al., 1994) gave 
strong evidence that additional subunits next to 5-HT3A were abundant. Additional 
5-HT3B (Dubin et al., 1999; Davies et al., 1999), 5-HT3C, 5-HT3D and 5-HT3E subunits 
were found after extensive search, recently (Dubin et al., 2001; Niesler et al., 2003). 
Apart from heteroassembly between the 5-HT3A and 5-HT3B subunits to functional 
channels (in contrast to 5-HT3B alone) at the cell surface, little is known about the 
functional importance of these subunits (Boyd et al., 2002). 
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Fig. 1.9 Computer filtered image of purified 5-HT3 receptors from NG108-15 cells. 
Bar = 5 nm. Taken from Boess et al., 1995.  
 
 
Fig. 1.10 Topological model of the h5-HT3A receptor protein with respect to particular 
exons. TM domains were localised with hydrophobicity analysis. The particular exons 
are alternatively shown in grey and black. The numbers indicate the amino acid 
residues at exon-intron boundaries. The black box (N-terminus) shows the 23 
residues long signal sequence. Taken from Brüss et al., 2000b. 
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1.3.2 5-HT3-receptor distribution 
5-HT3 receptors are exclusively located on neurons of central and peripheral origin 
mediating rapid depolarisation. The response following activation desensitises and 
resensitises quickly (Hoyer et al., 1994). CNS distribution of 5-HT3 receptors in 
several species was extensively examined in binding studies (Kilpatrick et al., 1987; 
Fletcher and Barnes, 1999; Miller et al., 1992). Considerable concentrations of 5-HT3 
binding sites were detected in the raphe nuclei (located in midbrain, pons and 
medulla oblongata), where the major part of serotonergic cell bodies is located 
(Molderings, 2002). These neurons project in various other brain regions. Lower 
concentrations were detected in other brain regions. Interestingly, highest amounts of 
5-HT3 sites were identified in the area postrema of all examined species including 
humans. However, apart from this region, amount and distribution pattern differ 
between species (Marazziti et al., 2001; Kilpatrick et al., 1989). In the periphery, 5-
HT3 receptors are located on pre- and postganglionic autonomic neurons, on neurons 
of the sensory nervous system, and on intrinsic neurons of the GIT (Hoyer et al., 
2002).  
 
1.3.3 Ligands at 5-HT3 receptors 
Based on early findings in 1953 that cocaine (Fig. 1.11) acted as a M-type (later 
named 5-HT3) antagonist  (Gaddum and Picarelli, 1957), J. R. Fozard started a 
screening for novel 5-HT3 antagonists. Based on variation of the local anaesthetic 
molecule procaine, metoclopramide (MCP) (Fig. 1.11) was identified as a potent but 
non-selective compound (Fozard and Mobarok Ali, 1978). In a series of tropane 
esters, MDL72222 (Fig. 1.11) was found as the first potent and selective compound 
(Fozard et al., 1979; Fozard, 1984). At that time, tropisetron (Fig. 1.12) was 
synthesised in the laboratories of Sandoz (Richardson et al., 1985) and Glaxo 
published first data on ondansetron (Stables et al., 1987; Butler et al., 1988), both 
compounds being highly potent 5-HT3 antagonists with good subtype selectivity, later 
approved to the market. In the following years GR65630 (Fig. 1.11) was identified. 
This compound was not a milestone as a therapeutic drug but its tritiated form served 
and still serves as an important tool in radioligand binding studies (Kilpatrick et al., 
1987).   
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Fig. 1.11 Chemical structures of important ligands at 5-HT3 receptors.  
 
Later on, granisetron (Sanger and Nelson, 1989), dolasetron (Boeijinga et al., 1992) 
and finally alosetron (Clayton et al., 1999) were approved to the market (Fig. 1.12). 
Alosetron was removed from the market (Charatan, 2000) because several deaths 
were reported due to ischaemic colitis as a severe side effect. Recently, this drug 
was reintroduced with stern obligation for therapy of diarrhoea predominating irritable 
bowel syndrome in women. It is obvious that all approved 5-HT3 antagonists (Fig. 
1.12) are closely related to the physiological ligand serotonin. 
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Fig. 1.12 Approved 5-HT3 antagonists with their brand names currently used in 
Germany in comparison to the endogenous receptor ligand serotonin.  
 
Comparably little has been reported about 5-HT3 agonists. The non-selective and 
metabolic unstable derivative 2-methyl-5-HT (Fig. 1.11) was identified as an agonist. 
Actually the most potent available partial agonist at 5-HT3 receptors is 1-(m-
chlorophenyl)-biguanide with good subtype selectivity, displayed in Fig. 1.11 
(Kilpatrick et al., 1990b). 
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1.3.4 Functional models 
In GPI contraction is elicided by 5-HT via stimulation of cholinergic neurons in the 
plexus myentericus. In rabbit isolated heart, 5-HT can modulate input to the heart via 
sympathetic and parasympathetic neurons. In the presence of muscarinic 
antagonists positive chronotropic and intropic effects are elicited by 5-HT (indirectly 
via noradrenaline). Negative chronotropic and intropic effects are seen in the 
presence of ß-blockade (via acetylcholine). However, these two models provide only 
indirect 5-HT3 effects. As a direct effect of 5-HT at 5-HT3 receptors the depolarisation 
of rat vagus nerve (RVN) can be measured (Kilpatrick et al., 1990a; Oxford et al., 
1992). 
The most important in vivo model is the vagally mediated reflexive fall in heart rate 
and blood pressure (von Bezold-Jarisch reflex) following an i.v. bolus application of 
5-HT, usually measured in anaesthetised cat or rat, believed to be mediated through 
depolarisation of afferent nerve endings in the right ventricle (Fozard, 1984).  
 
1.3.5 Therapeutic options 
A brief overview concerning the therapeutic potential of 5-HT3 ligands is given in the 
following paragraphs. The use in GIT disorders will be presented in the 5-HT4 chapter 
(see 1.3.10.4). 
 
1.3.5.1 Antiemetic  properties 
Cancer therapy was revolutionised with the introduction of 5-HT3 antagonists. These 
drugs potently inhibit acute emesis (onset during the first 3 h) following chemo- and 
radiotherapy (Günther, 2002). These quite aggressive therapy regimen trigger the 
liberation of 5-HT from enterochromaffin cells in the GIT. 5-HT activates 5-HT3 
receptors located on afferent vagal fibres and in the area postrema resulting in 
nausea and vomiting. The area postrema was identified as an important area for 
control of nausea and emesis. However, little efficacy was achieved with 5-HT3 
antagonists in therapy of delayed emesis (persisting 3-5 days). Actually steroids in 
combination with MCP are in use to prevent delayed emesis. Recently, good results 
were obtained with additional application of NK1 antagonists (de Wit et al., 2003). 
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1.3.5.2  Use in mental disorders 
The use of drugs with affinity to 5-HT3 receptors in mental disorders was extensively 
reviewed (Silverstone and Greenshaw, 1996; Greenshaw and Silverstone, 1997; 
Barnes and Sharp, 1999). The potential use of 5-HT3 antagonists in anxiety and 
psychotic disorders was investigated in several animal models. Some studies yielded 
good preclinical data, even though sometimes conflicting results were obtained. 
However, up to now, no double-blind clinical study showed positive results in 
humans, making an effective use of this drug class in anxiety and psychotic disorders 
unlikely. As findings came up that noradrenaline release was facilitated by 5-HT3 
receptors, the question of a potential use of 5-HT3 agonists as antidepressant drugs 
came up. With SR57227A (Bachy et al., 1993) a potent, brain-penetrating agonist 
was described. This compound showed positive effects in some animal models. 
Further studies are needed to confirm the utility of 5-HT3 agonists as antidepressant 
drugs in humans. Conflicting results were also reported in several studies concerning 
the use of 5-HT3 antagonist in drug abuse, depending on the investigated drug. 
Slightly reduced ethanol intake was, for example, seen in animals and humans, but 
up to now no convincing study reports on the utility of 5-HT3 antagonists in drug 
abuse syndromes were published. With the discovery that 5-HT3 receptors influence 
ACh release in several brain regions, interest came up for a use in AD. First studies 
with alosetron in healthy humans gave positive results (Preston et al., 1991), together 
with the encouraging finding that 5-HT3 receptor density is unchanged in the brains of 
AD patients (Barnes et al., 1990). Further studies are needed to confirm the efficacy 
of 5-HT3 antagonists in AD. 
In summary, most clinical trials following the extensive research in animal models for 
new therapeutic indications were disappointing. Little hope is left to find an effective 
use for 5-HT3 ligands in the most mental disorders discussed above. In contrast to 
animal studies, which often gave rise to hope, the findings in human clinical trials 
lead to the question, whether some of the used animal models are suitable to mirror 
conditions found in humans.  
 
1.3.5.3 Antinociceptive  effects 
5-HT3 receptors involved in nociception were found on sensory afferent neurons and 
in the dorsal horn of the spinal cord (Hamon et al., 1989). Evidence for participation  
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in cardiac pain was given. The most interesting findings were reported for the use of 
tropisetron in rheumatic diseases. Local injections resulted in a pronounced 
analgesic effect in various diseases of the locomotor system (such as tendinopathies 
and peri-arthropathies) comparable to the effect achieved with injection of 
dexamethason plus lidocaine, but with prolonged time of  action (Stratz and Müller, 
2003; Müller and Stratz, 2003). Beside the antinociceptive effects, antiphlogistic 
actions contributed to the high efficacy in this study. The detailed mechanisms of 
action remain yet to be elucidated. 
 
1.3.6 5-HT4 receptors 
First reports on the 5-HT4 receptor subtype were given in the late 1980’s (Dumuis et 
al., 1988). Studies at mouse embryo colliculi neurons and guinea-pig brains revealed 
the existence of a previously unknown receptor subtype belonging to the 
serotonergic family. This subtype was the first 5-HT receptor to be identified with 
positive coupling to adenylate cyclase, elevating intracellular cAMP level. In the 
following decade different splice variants of this subtype were cloned from several 
species. Comparably late the human 5-HT4 receptor was cloned (Van den Wyngaert 
et al., 1997). Mapping of the human 5-HT4 receptor gene (Bender et al., 2000) 
pinpointed coding regions for all previously known splice variant. The coding 
sequence for the first nine amino acids of the 5-HT4 receptor protein was not 
allocated and is likely to be found on an additional exon located upstream exon 2. 
Fig. 1.13 gives a schematic graph of the human 5-HT4 receptor gene structure with 
the possible splicing sites, whereas Fig. 1.14 shows a model of the resulting receptor 
protein. All splice variants except 5-HT4(h) are identical up to amino acid 358 and 
differ only in the C-terminus. 5-HT4(h) displays an insertion of 14 amino acids in the 
second extracellular loop and can be combined with all possible splice variants in the 
C-terminus. The physiological role of the various splice variants is not completely 
understood and will be dealed with in the Discussion chapter. 
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Fig. 1.13 Alternative splicing possibilities among the different 5-HT4 receptor exons 
are indicated by connection lines. Boxes represent exons, whereas introns are 
shown as bold lines. The dotted line between exon 4 and 5 represents the splicing 
that will include exon h into the mRNA, whereas the splice event following the 
dashed lines omits exon h. Downstream exon 5 different splices are depicted by 
differently formatted lines. Modified from Bender et al., 2000. 
 
 
Fig. 1.14 Schematic model of the 5-HT4 receptor protein with 7TM domains. 
C-terminal amino acid sequences of the human splice variants (a-g, n). The arrow 
indicates the site for a 14 amino acid insertion in the second extracellular domain of 
the 5-HT4(h) splice variant. Modified from Langlois and Fischmeister, 2003. 
 
1.3.7 5-HT4-receptor distribution 
5-HT4 receptors were reported to be widely distributed in the CNS and periphery (for 
review see Eglen et al., 1995; Hegde and Eglen, 1996). Autoradiography studies in 
several species (Waeber et al., 1994; Reynolds et al., 1995; Patel et al., 1995) 
revealed within the CNS highest 5-HT4 concentrations on neuronal structures in the 
limbic system (that is, e.g., the frontal cortex, hippocampus and amygdala) and lower  
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concentrations in several other brain regions. With regard to the periphery, 5-HT4 
receptors were detected in various organs (Fig. 1.15). In hearts of human and pig 
5-HT4 receptors were detected on muscle cells of atria and sinu-atrial node 
(Kaumann, 1990). 5-HT4 density in human heart was low in comparison to 
ß-receptors. The calculated ratios were approximately 1 : 5 : 10 for 5-HT4 : ß2 : ß1 
receptors (Kaumann et al., 1996). The 5-HT4 subtype was detected in lower urinary 
tract of human and other species facilitating ACh release (Tonini and Candura, 
1996). Only little influence on vasculature was reported for 5-HT4 receptors, for 
example, in some blood vessels in sheep. Reports were given that the secretion of 
corticosteroids and aldosterone from the adrenal cortex in frogs and humans is 
promoted by 5-HT4 (Idres et al., 1991). Finally, 5-HT4 receptors were detected in the 
GIT (Craig and Clarke, 1990). The GIT is one of the most complex regions in the 
human body containing approximately 10
8 intrinsic neurons. At least 25 different 
neurotransmitter were detected within the enteric nervous system (Molderings, 
2002). This highly complex physiological network is currently far from being 
completely understood. 5-HT4 receptors are located on mucosal cells involved in 
secretory functions and on smooth muscle cells of the longitudinal and circular 
muscles. Additionally, 5-HT4 receptors are located on neuronal structures. 
Several other serotonergic receptor subtypes were identified in the GIT. Serotonin is 
considered to be a key player in GIT with major influence on peristaltic reflex, 
secretion and sensory fibres termed as “mediator of the brain-gut connection” (Kim 
and Camilleri, 2000).  
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Fig. 1.15 Location of 5-HT4 receptors in various peripheral organs. Modified from 
Hegde and Eglen, 1996. 
 
1.3.8 Ligands at 5-HT4 receptors 
MCP (Fig. 1.11) and tropisetron (Fig. 1.12) were used as starting points for the 
development of 5-HT4 ligands. Prokinetic properties of MCP were published decades 
before the identification of the 5-HT4 subtype (Jacoby and Brodie, 1967). Low affinity 
at this subtype was reported for tropisetron within the first characterisation of 5-HT4 
receptors (Dumuis et al., 1988). MCP had a low affinity and was neither a selective 
nor specific compound with comparable affinities to 5-HT4, 5-HT3 and D2 receptors. 
The benzamide MCP and its analogues cisapride and zacopride (both Fig. 1.17) 
were reported to be full agonists or partial agonists at 5-HT4 receptors with prokinetic 
actions (Buchheit and Buhl, 1991). With the ester congener SDZ205-557 (Fig. 1.16) 
of the benzamide MCP one of the first potent 5-HT4 antagonists was identified 
(Buchheit et al., 1991, 1992), however, with only little subtype selectivity versus  
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5-HT3. Better selectivity was achieved with the piperidine analogue RS23597 (Eglen 
et al., 1993b). The first highly potent compound with excellent selectivity was 
reported with SB204070 (Fig. 1.16) with an affinity in the picomolar range (Gaster et 
al., 1993). The big problem of all previously reported compounds was their ester 
moiety, making them not useful as drugs due to rapid degradation. One of the first 
orally active compounds lacking the ester group was RS36904  (Fig. 1.16) with high 
affinity and selectivity (Hegde et al., 1995). Starting from tropisetron the highly potent 
and selective indole amide GR113808 (Fig. 1.16) was identified (Gale et al., 1994; 
Langlois et al., 1994). The tritiated form emerged to the most frequently used 
radioligand in the field of 5-HT4 binding studies (Grossman et al., 1993). ML10302 
(Fig. 1.17) was one of the first selective compounds displaying intrinsic activity at 
5-HT4 receptors (Elz and Keller, 1995). The benzimidazolone BIMU1 (Fig. 1.17) was 
shown to possess agonistic properties, too (Lelong et al., 2003). Recently, the 
serotonin analogue tegaserod (Fig. 1.17) was approved to the market as a partial 
agonist at 5-HT4 receptors. 
 
1.3.9 Functional models 
Several in vitro models for 5-HT4 receptors were established. In guinea-pig ileum the 
ability of 5-HT agonists to enhance the contraction evoked by electrical field 
stimulation was measured. Antagonist affinity was determined as a function of the 
inhibition of 5-HT induced contraction (Buchheit et al., 1985; Tonini et al., 1992). The 
ability of 5-HT to relax rat oesophagus (ROS) tunica muscularis mucosae 
precontracted with carbachol was extensively used to determine 5-HT4 affinity 
(Baxter et al., 1991). Interestingly, this model was not adaptable to other species 
such as guinea-pig, rabbit and dog (Cohen et al., 1994). The most commonly used in 
vivo models are gastrointestinal motility models in rat and mouse (Banner et al., 
1993) in which 5-HT4 agonists elicit prokinetic responses. In the anaesthetised mini-
pig the effect of 5-HT4 ligands on heart rate was examined. Agonists induced 
tachycardia, whereas antagonist affinity could be determined as the inhibition of 
5-HT-induced tachycardia (Eglen et al., 1993a).  
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Fig. 1.16 Chemical structures of selected 5-HT4 antagonists.  
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Fig. 1.17 Chemical structures of selected 5-HT4 agonists. 
 
1.3.10 Therapeutic  options 
1.3.10.1 Cardiac  arrhythmia 
5-HT induces rate-dependent arrhythmic contractions in human and pig heart in vivo 
via 5-HT4 receptors located in the atria (not ventricles), that can be blocked with 
5-HT4 antagonists (Kaumann and Sanders, 1994). It was proposed that 5-HT4 
antagonists might become interesting new drugs to prevent atrial flutter and stroke 
(Kaumann, 1994) beside ß-blocker and Ca
2+ channel blocker, without effects on the 
ventricles.   
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1.3.10.2 Urinary  incontinence 
5-HT4 receptors were identified in the human bladder located on cholinergic fibres 
facilitating ACh release in human detrusor muscle (Tonini et al., 1994). As one could 
expect, activation of these receptors led to increased micturation frequency, reported 
as a side effect in patients treated with cisapride (Boyd and Rohan, 1994). It was 
proposed that 5-HT4 agonists might be suitable new drugs to enhance cholinergic 
tone in urinary voiding disorders associated with detrusor failure due to low 
cholinergic tone (Tonini and Candura, 1996). 
 
1.3.10.3 Cognition  enhancement 
With the discovery of a high amount of 5-HT4 receptors in hippocampal structures an 
important role in memory and cognition was suggested (Waeber et al., 1994). Many 
reports were given describing the influence of 5-HT4 receptors on the release of 
various neurotransmitters including ACh, 5-HT and DA in the brain (for review see 
Barnes and Sharp, 1999). Reports concerning 5-HT4 receptors in anxiety disorders 
were conflicting. More hopeful results were reported in memory disorders. It was 
demonstrated that 5-HT4 agonists ameliorated a scopolamine-induced memory 
impairment in rats (Matsumoto et al., 2001). Local application of a 5-HT4 agonist into 
distinct brain regions resulted in increased release of ACh. Therefore, future research 
on highly selective and potent 5-HT4 agonists and partial agonists is of great interest 
with regard to therapy of memory disorders such as AD. 
 
1.3.10.4 Gastrointestinal  disorders 
Several receptors belonging to the serotonergic family were detected in the GIT 
influencing secretion, sensation and peristalsis. Intestinal secretion is enhanced   
directly via 5-HT4 receptors located on enterocytes and indirectly via 5-HT3 receptors 
on secretory mucosal nerves and vagal afferents (Spiller, 2002). Visceral sensation is 
mediated through 5-HT3 receptors located on vagal afferents. A key role for control of 
peristalsis accounts to 5-HT release out of enterochromaffin cells transducing a 
luminal pressure signal in a nervous stimulus. Fig. 1.18 summarises the network 
involved in the peristaltic reflex and the role of 5-HT4 receptors. An ascending 
stimulus of circular muscle contraction together with a descending relaxation of  
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circular muscles results in a caudal propulsion. Prokinetic properties in human and 
animals were described for MCP long before the identification of 5-HT4 receptors.  
 
 
Fig. 1.18 Model of 5-HT effect on activation of intrinsic afferent neurons in the lamina 
propria after being released from enterochromaffin cells. Activation of CGRP neurons 
(calcitonin  gene  related  peptide) stimulates myenteric neurons to activate the 
“peristaltic reflex”. This involves an oral contraction mediated through ACh and 
substance P and an caudal relaxation mediated through NO, VIP (vasoactive 
intestinal  peptide) and PACAP (pituitary  adenylate  cyclase-associated  peptide). 
Adapted from Camilleri, 2001 and Langlois and Fischmeister, 2003. 
 
In the following a short focus is laid on the irritable bowel syndrom (IBS). IBS is the 
most common non-infectious diagnosis in GIT and secondly only to the common cold 
as a cause of work absenteeism. With 10 - 20 % of all individuals being affected from 
IBS, resulting in enormous costs to public health care, an enormous burst in research 
took place that was extensively reviewed (Thompson, 2002; Camilleri et al., 2002). 
IBS is defined as a group of functional bowel disorders in which abdominal 
discomfort or pain is associated with a change in bowel habit and with features of  
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disordered defecation. Diagnosis is made by exclusion of other organic diseases. 
Three subtypes of IBS are differentiated based on the predominant bowel habit: 
constipation, diarrhoea and alternating bowel movements abbreviated C-IBS, D-IBS 
and A-IBS, respectively. Currently available drug therapy is far from satisfying. 
Anticholinergics, low-dose antidepressants, dietary fibre and opioid agents are used 
with little efficacy next to more experimental approaches and psycho-therapy. With 
new insights in the role of the serotonergic systems in the GIT, 5-HT3 and 5-HT4 
receptors were identified as new target sites for IBS treatment. 
 
In summary, 5-HT4 agonists may potently increase motility and therefore might 
represent useful drugs in C-IBS, functional constipation, gastro-oesophageal reflux 
disease and dyspepsia (Spiller, 2002; Hansen, 2003). The lately approved 5-HT4 
partial agonist tegaserod showed increased gastric emptying, accelerated small and 
large bowel transit as a potent prokinetic agent in women, reduced pain associated 
with defecation and ameliorated hypersensitivity to rectal distension (Lacy and Yu, 
2002; Zimmermann, 2002). 5-HT3 antagonists are of interest for D-IBS as alosetron 
decreased abdominal pain, colon hypersensitivity and motility in D-IBS women. For 
some GIT disorders, such as dyspepsia and gastro-oesophageal reflux disease, it is 
still not clear whether 5-HT3 antagonists, 5-HT4 agonists, a combination or non of 
both is suitable for therapy. 
 
1.4 Radioligand binding studies 
Radioligand binding studies have become a more and more important tool within the 
drug discovery process as a robust and fast screening method, rapidly providing 
binding characteristics of compounds at several target sites (Williams, 1991). 
Identification and characterisation of receptor sites in tissue preparations is another 
suitable application for this method. Radioligand binding studies provide valid data 
when experimental conditions are chosen carefully. Incubation temperature, pH 
value, ionic strength and composition of incubation buffer are critical parameters 
within the testing procedure and strongly influence the result (Asselin et al., 1983; 
Pedder et al., 1991; Hou et al., 1996). Attention should also be paid to incubation 
time because it is important to reach an equilibrium state within the tests to assure  
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correct data analysis. However, binding studies merely provide an affinity estimate 
for a compound at a specific target site and give no direct information about potential 
intrinsic activity. Agonists often show shallow, sometimes biphasically shaped 
competition curves resulting from the existance of multiple agonist affinity states 
(Birdsall et al., 1978). The assessment of agonist affinity and efficacy in binding 
studies is difficult. There are some approaches to determine these properties that 
allow a comparison of agonist potencies in a semi-quanitative way (for review see 
Christopoulos and El Fakahany, 1999), but results may not totally reflect reality. In 
summary, binding studies provide a fast and robust method to determine affinity 
values for antagonists but are not favourable to determine agonist properties. 
 
1.5 Recombinant receptor systems 
In native tissues there is often a diversity of receptors expressed that belong to one 
neurotransmitter system. This makes it difficult to address affinity to a single receptor 
subtype in radioligand binding studies unless highly selective radioligands are 
available. This problem could be eliminated with the recombinant expression of a 
single receptor in suitable cell lines. Recombinant cell lines provide easy access to a 
constant, high receptor population without using laboratory animals. However, 
different expression systems provide a different cellular machinery for 
posttranslational modifications, resulting in differences to the receptors expressed in 
native tissues. Additionally, the receptor expression in recombinant systems is often 
very different from physiological density. An advantage of recombinant systems is 
that human receptors can be used instead of receptors of laboratory animals. This is 
important as huge species differences were reported for some receptor subtypes 
between humans and laboratory animals. 
 
1.6 Stereochemistry 
Enantiomers are composed of the same number and kinds of atoms bonded in an 
identical fashion, but differ in their three-dimensional orientation. Enantiomers share 
the same physical and chemical properties and behave identical in an achiral 
environment. Binding sites at receptors represent a chiral environment and form  
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diastereomeric complexes with chiral ligand molecules, most probably resulting in 
different binding properties for enantiomers. The difference in pharmacological 
activities of the stereoisomers of chiral compounds is called “stereoselectivity” 
(Lambrecht and Mutschler, 1986). Special terms were introduced to distinguish 
enantiomers with regard to their pharmacological properties at a special target site. 
The enantiomer with higher affinity is called “eutomer”, the one with lower affinity 
“distomer” (Lehmann, 1986).  
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2.1 General considerations 
In this work structure-activity relationship (SAR) research in the field of several 
receptor families was carried out, including the serotonergic, histaminergic and 
muscarinic systems. Each receptor family is associated with different therapeutic 
implications and problems in drug development. Thus, it is of general interest to 
obtain more information about the relevance of molecular modifications at a chosen 
lead structure concerning affinity, subtype selectivity and specificity to design new 
drug candidates providing an appropriate binding profile. Improved binding 
characteristics may open new therapeutic options, improve patient compliance and 
drug efficacy or decrease side effects. Modification of kinetic properties may result in 
a prolonged time of action or kinetic selectivity. One important feature of this work 
was to highlight the influence of stereochemistry on absolute binding affinities as well 
as on kinetic binding properties.  
Compounds listed with “(±)” were tested as racemic mixtures, compounds with “(+/-)” 
or “(R/S)” as pure enantiomers. In some series “(±)” was omitted to keep 
nomenclature less complicated. 
 
2.2 Analogues of ondansetron 
The 1-imidazolylmethyl substituted tetrahydrocarbazolone ondansetron (1) can be 
considered as a prototypic 5-HT3 antagonist displaying high affinity to this subtype. It 
is widely used in therapy to prevent nausea and vomiting induced by chemo- and 
radiotherapy. Ondansetron was characterised already in 1987 (Kilpatrick et al., 1987) 
in binding studies using a rat brain tissue preparation confirming its high affinity to 
native 5-HT3 receptors. Since then, extensive research efforts were undertaken to 
find derivatives with even higher affinity and increased subtype selectivity. SAR work 
led to the discovery of alosetron (Fig. 1.12), a closely related molecule of 1, 
possessing the highest affinity of all approved 5-HT3 antagonists. As patents for older 
drugs are running out, there is still a major demand for new therapeutic options (e.g. 
in IBS). Therefore, new compounds displaying high 5-HT3 affinity are still of interest. 
In our study a series of 23 analogues (compounds 2A/B - 6A/B and 7  -  18) of 
ondansetron were evaluated for their binding affinities at cloned h5-HT3A receptors  
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stably expressed in HEK293 cells. Several of these molecules were previously 
shown to possess up to subnanomolar affinities at 5-HT2A receptors in functional 
studies using a rat tail artery model (Elz and Heil, 1995). All compounds were already 
tested at functional 5-HT3 receptors in guinea-pig ileum by in the group of Prof. Dr. S. 
Elz, Regensburg, Germany, displaying affinities up to pA2 = 7.4. We wanted to 
confirm these data and performed a comparative study at functional, native gp5-HT3 
and recombinantly expressed h5-HT3A receptors. Ondansetron (1) as starting point 
served as a reference drug.  
 
In Table 2.1 the formula of ondansetron is given with arrows indicating the general 
sites of modifications. All modifications left the tetrahydrocarbazolone structure 
unchanged and took place in the side chain and / or imidazole ring.  
 
Table 2.1 Structure of ondansetron (1) and general sites of structural variations. The 
asterisk denotes the centre of chirality. 
N
N
N
O
2
4 5
A
C
D
B
E
*
 
A  Introduction of substituents at position 4 / 5 
B  Modifications of substituent at position 2 
C  Condensing an aromatic ring or exchange of imidazole   piperidine 
D  Quaternization of nitrogen 
E  Changes in side chain and / or imidazole moiety 
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Compounds with the following modifications were tested in this study: 
 
   Compounds with changed substitution pattern in the imidazole structure. The 
proton in position 4 or 5 of the imidazole structure was replaced by 
substituents of increasing size - ranging from methyl (2A/B) up to a 
ethylphthalimide moiety (6A/B) - to find out which site is preferred for 
substitution. Compounds carrying substituents in position 4 are termed with 
“A”, those with substituents in position 5 with “B”. Table 2.2 gives the formula 
of compounds 2A/B - 6A/B. 
 
   Modifications of the substituent in position 2 of the imidazole structure. 
Introduction of a basic nitrogen with modification in alkylation pattern were 
tested in compounds 7 - 10 shown in Table 2.3. 
 
   N-Methylation of the nitrogen atom in position 3 of the imidazole moiety lead to 
the quaternary molecule 11 and enlargement of the basic imidazole structure 
by condensing of a phenyl ring to compound 12. Exchange of the imidazole 
structure by a piperidine ring led to compound 13, and the p-substituted 
compounds  (+)-14 and (-)-14, which were tested as pure enantiomers. 15 
displayed a sterically fixed, bulky substituent attached in position 4 of the 
piperidine ring. Structures  of compounds 11 - 17 are summarised in Table 
2.4. 
 
   Changes in the connecting side chain and / or the imidazolyl structure led to 
compounds 16 - 18 (Table 2.5). 
 
All compounds with exception of (+)-14 and (-)-14 were tested as racemates.  
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Table 2.2 Compounds with substituents in position 4 or 5 of the imidazole structure. 
Compounds were monosubstituted each with a hydrogen at the non-substituted 
atom. The asterisks denote the centres of chirality. 
N
N
N
O
R
4 5
*
N
H
O
N
O
O
CH3
CH2OH
R No.
2A / 2B
3A / 3B
4A / 4B
A
B
R No.
5A / 5B
6A / 6B
C2H4NH2
N
N
N
O
R
4 5
*
  
Table 2.3 Analogues with modifiction in position 2 of the imidazole moiety. The 
asterisk denotes the centre of chirality. 
N
N
N
O R
2
*
N
O
O
NHCH3
N(CH3)2
R No.
7 
8 
 
R No.
9
10
CH2NH2
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Table 2.4 Derivatives with a quarternary nitrogen, condensed aromatic ring or 
piperidine ring. The asterisks denote the centres of chirality. 
R 1
No.
11
 
12 
 
No.
13
15
N
N
+
N
N
NH2
F
F
R 2
N
O
R 1 *
* N
N
O
R 2
H
F
O
(+/-)-14
 
Table 2.5 Analogues with modifications in the side chain and imidazole structure. 
The asterisk denotes the centre of chirality. 
R No.
16
 
17
18
N
O
R *
N
H
N
N
H
NH
N
N
H
N
N
H
N
O
O  
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2.3 Analogues of metoclopramide 
Metoclopramide (MCP), which can be considered as the starting point in research for 
compounds with prokinetic activity, displayed only low affinity to 5-HT4 receptors in 
several test models and insufficient subtype selectivity. A vast amount of research 
was done in the last 40 years to obtain new compounds related to MCP with 
improved characteristics. One step forward was made by exchanging the amide 
group of MCP into an ester group (Buchheit et al., 1991) leading to SDZ205-557 (19), 
showing increased affinity and improved subtype selectivity at 5-HT4 receptors in 
functional tests at guinea-pig ileum. Currently, several 5-HT4 receptor ligands are 
under investigation in clinical trials as new drug candidates for different indications. 
Most drugs in clinical trials displayed partial agonism at the 5-HT4 subtype. Even 
though many partial agonists were under investigation, only tegaserod as a newer 
compound with affinity to 5-HT4 receptors was approved in some countries for use in 
gastrointestinal disorders. In contrast, up to now, no 5-HT4 antagonist has reached 
the market. Since the withdrawal of cisapride due to cardiac side effects only MCP 
and domperidone are left on the market as synthetic prokinetic drugs.  
In this study we examined the binding affinities of SDZ205-557 (19) and its 
analogues 20 - 30 at cloned h5-HT4(b) receptors in a SAR study. All compounds were 
previously tested in functional studies at 5-HT4 receptors in guinea-pig ileum and 
some in rat oesophagus in the group of Prof. Dr. S. Elz, Regensburg, Germany. The 
values obtained at native gp5-HT4 and r5-HT4 receptors in functional studies were 
compared with binding affinities obtained in experiments with recombinantly 
expressed h5-HT4(b) receptors. 
 
Table 2.6 shows the formula of SDZ205-557 (19) which served as a starting point in 
this SAR study. Arrows indicate the general sites of modifications. All compounds 
had an unchanged 4-amino-5-chloro-2-methoxybenzoic acid structure and were ester 
analogues of MCP with different amino alcohols.  
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Table 2.6 Structure of SDZ205-557 (19) and general sites of structural variations. 
Cl
N H2 O
O
N
O
A
B
C
 
A  Methylation of the side chain creating centres of chirality 
B  Modification of side chain length 
C  Changing the structure of the amino group   piperidine or piperazine 
 
The following molecule variations were tested in our study: 
 
   Compounds with methylation in the side chain, (±)-20 and (±)-21. These 
compounds possess a centre of chirality in contrast to the unsubstituted 
mother compound 19. The structures are given in Table 2.7. 
 
   Insertion of the basic, tertiary nitrogen in a piperidine ring system and 
modification in the side chain delivered compounds 22 - 26 shown in Table 
2.8. 
 
   Insertion of the basic, tertiary nitrogen in a piperazine ring system, 
modification of side chain length and different substituents at the p-nitrogen of 
the piperazine ring lead to structures 27 - 30 displayed in Table 2.9. 
 
Chiral compounds (±)-20, (±)-21 and (±)-26 were tested as racemates, (+)-23 and (-)-
23 as pure enantiomers. 
 
  
Aims 
 
 
53 
Table 2.7 Compounds with a methyl group in the side chain. The asterisks denote 
the centres of chirality. 
Cl
N H2 O
O
N
O R1
R2
CH3
R1 No.
(±)-20
(±)-21
R2
CH3 H
H
H H
*
*
19
 
 
Table 2.8 Compounds with a piperidine ring system, modifications in the side chain 
length and methylation pattern. The asterisk denotes the centre of chirality. 
Cl
N H2 O
O
N
O
R 1
R 2
n
 
CH3
R 1 No.
22
24
25
R 2
H
H H
*
n
1
1
2
3
1
H H
H H
H
F
O
(±)-26
(+/-)-23
 
Table 2.9 Compounds with a piperazine ring and modifications of side chain length.  
Cl
N H2 O
O
N
O N
R
n
 
R No.
27
28
29
30
n
1
2
3
1 Phenyl
Benzyl
Benzyl
Benzyl
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2.4 Analogues of McN-A-343 
McN-A-343 (31) has a long history as a compound showing affinity to muscarinic 
ACh receptors since the 1960s of the last century (Roszkowski, 1961). Several 
publications on SAR concerning functional and binding characteristics at muscarinic 
receptors were published (Nilsson et al., 1992; Lambrecht et al., 1993, 1995). 
However, comparably little is known about binding affinities of 31 and its derivatives 
at other target sites such as histamine H1 and serotonin 5-HT3 and 5-HT4 receptors. 
31 was reported to display affinities to 5-HT3 and 5-HT4 receptors in binding studies 
as an atypical chemical structure in this pharmacological class (Sagrada et al., 1994). 
We wanted to confirm these results and provide new SAR information at these 
subtypes for some related compounds. It is well known that muscarinic ACh 
receptors are closely related to histamine H1 receptors. In our laboratory, former tests 
revealed affinity values at M1-5 receptors spanning 5 orders of magnitude for 
derivatives of 31 up to picomolar concentrations. We investigated binding affinities at 
histamine H1 receptors with a special focus on stereochemistry. McN-A-343 (31) and 
its derivatives 32  -  42 were examined in binding studies at hH1, h5-HT3A and 
h5-HT4(b) receptors. 
 
Table 2.10 shows the formula of McN-A-343 (31) which served as a starting point in 
this SAR study. Arrows indicate the general sites of modifications. All compounds 
were tested as tertiary amines and their corresponding N-methylated compounds 
generally marked with "
+". 
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Table 2.10 Structure of McN-A-343 (31) and general sites of structural variations. 
A
C D
B E
F N
+
N
H
Cl
C O
O
C C C
H
H
CH2
 
A  Changes in substitution pattern 
B  Exchange of the aromatic ring 
C  Removal of NH: carbamate   carboxylic acid ester 
D  Exchange of H atom   chiral compounds 
E N-Methylation    quaternary compounds 
F  Changing the amino group   pyrrolidine ring 
 
The following molecule variations were tested in our studies: 
 
   Compounds with an acyclic amino group and 4-F-substitution (32). Chiral 
derivatives with a phenyl ring attached to the carbon atom next to the 
carbamate structure in the chain, (R/S)-33, (±)-34, were tested. Structures are 
given in Table 2.11. 
 
   Compounds containing a pyrrolidine ring system with increasing size of 
substituents in the chain (Table 2.12), ranging from a simple methyl group in 
(R/S)-35 to a bulky naphthyl substituent in  (±)-39. 
 
   Compounds with exchanged aromatic moieties, (±)-40 and (±)-41, and an 
ester congener,  (±)-42, with replaced carbamate group (Table 2.13). 
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Table 2.11 Derivatives with acyclic amino group and changes in substituents at the 
aromatic ring and chain. The asterisk denotes the centre of chirality. 
N
+
N
H
R 2
C O
O
C C C
H
R 4
CH2
R 3
R
1
R 5
H
F
R 1
No.
 
(±)-34
(±)-34+
R 2 R 3 R 4 R 5
H
H
H
F
H
Cl
H
H
H
H
H
H
H
H
H
H
Phenyl
Phenyl
H Phenyl
Phenyl
Phenyl
Phenyl
H
H
H
CH3
H
CH3
H
CH3
H
CH3
(R/S)-33
(R/S)-33+
31 
32
32+
*
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Table 2.12 Derivatives with a pyrrolidine structure and changes in substituents at the 
aromatic ring and chain. The asterisk denotes the centre of chirality. 
F
F
R 1
No.
(±)-38 
(±)-38+
(±)-39
(±)-39+
R 2 R 3
F
H
H
F
F
Phenyl
Phenyl
-F-Phenyl
Phenyl
CH3
CH3
Phenyl
H
CH3
H
CH3
H
CH3
(R/S)-35
(R/S)-35+
(R/S)-36
(R/S)-36+
(R/S)-37
(R/S)-37+
N
+
N
H
C O
O
C C C
H
R 2
CH2 R
1
R 3
H
CH3
H
CH3
F
F
F -Naphthyl
-F-Phenyl
4
4
1
-Naphthyl 1
R 1
No. R 2 R 3
*
 
Table 2.13 Compounds with a pyrrolidine ring system, exchanged aromatic moieties 
and variation in the carbamate structure. The asterisk denotes the centre of chirality. 
R 1
No. R 2 R 3
-
NH
-
NH
NH
NH
H
CH3
H
CH3
H
CH3
(±)-40
(±)-40+
(±)-41
(±)-41+
(±)-42
(±)-42+
R
2
R
1
N
+
CO
O
C C C
H
CH2
R 3
-F-Phenyl 4
-F-Phenyl 4
-Naphthyl 1
-Naphthyl 1
(Phenyl)2-CH
(Phenyl)2-CH
*
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2.5 Analogues of glycopyrronium 
Since many years glycopyrronium (43) is used in therapy as premedication prior to 
surgical operations as a parasympatholytic drug and rarely as a spasmolytic drug, 
too (Mirakhur and Dundee, 1983). Some investigations were made in topical use of 
43 to reduce excessive sweating (Atkin and Brown, 1996). Glycopyrronium is a 
quaternary compound sold as a bromide salt. The glycopyrronium molecule displays 
two centres of chirality resulting in four stereoisomers (Table 2.14). Actually, a 
mixture of the enantiomers (3S, 2’R)- and (3R, 2’S)-glycopyrronium, named 
glycopyrrolate, is approved and in therapeutic use. The 2’-centre is located in the 
acid part of the molecule, the 3-centre in the basic amino-alcohol. In former tests in 
our laboratories SAR research in the field of glycopyrronium and its derivatives was 
carried out by K. Kreutzmann. He showed the (2’R)-configurated isomers of 43 to be 
more potent than the (2’S)-configurated congeners and only little influence on binding 
affinity at muscarinic subtypes of the absolute configuration at the second centre of 
chirality (personal communication). All tested compounds were non-selective at 
muscarinic receptor subtypes. Even more interesting was his finding that the (3R, 
2’R)-configurated isomer of 43 displayed a long dissociation half-life at the M3 
subtype compared to the other subtypes, resulting in kinetic selectivity. This 
characteristic was also described for the drug tiotropium, recently approved for 
COPD, resulting in a superior once-daily dosing regimen and prolonged action of this 
new drug compared to older drugs currently in use e.g. ipratropium and oxitropium 
(Barnes, 2001). Compounds corresponding to 43 with two centres of chirality have 
the letters A-D attached to the compound number, describing the absolute 
configuration of derivatives as follows: A: (3S, 2’S); B: (3R, 2’S); C: (3S, 2’R); D: (3R, 
2’R). Table 2.14 gives the structures of the four stereoisomers of 43. The letters “R” 
and “S” in the tables standing next to an asterisk describe the absolute configuration 
of that centre of chirality. 
 
Table 2.15 gives the structure of glycopyrronium (43) which served as a starting point 
in this SAR. Arrows indicate the general sites of modifications. 
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Table 2.14 Structures of the four possible stereoisomers of 43. 
O
O
N
+
O H
3 2'
* *
S S
O
O
N
+
O H
3 2'
* *
S R
A: 3S, 2'S
C: 3S, 2'R
O
O
N
+
O H
3 2'
* *
R S
O
O
N
+
O H
3 2'
* *
R R
B: 3R, 2'S
D: 3R, 2'R  
 
Table 2.15 Structure of glycopyrronium and general sites of structural variations. The 
asterisks denote the centres of chirality. 
A
C
D B
E
O
O
N
+
O H
3 2'
* *
 
A  Changing the absolute configuration of 2’-centre of chirality 
B  Changing the absolute configuration of 3-centre of chirality 
C  Exchange of amino-alcohol: pyrrolidine   chinuclidine 
D N-Alkylation    chiral compounds with an asymmetric nitrogen 
E  Exchanging the aromatic and/or aliphatic rings 
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All tested compounds were quaternary molecules containing an ester group. The 
following molecule variations were tested in our studies: 
 
   Compounds with a pyrrolidine structure in the alcoholic part. Analogues 
Dia-44D - Dia-48D (Table 2.16) had a stereochemical configuration identical 
to  43D (3R, 2’R) with modifications in N-alkylation. These compounds are 
mixtures of cis-trans isomers at the nitrogen atom. It is important to note that 
these compounds possess one more centre of chirality, namely the quaternary 
nitrogen atom. This makes a total of 8 possible stereoisomers. Compounds 
Dia-44D - Dia-48D were tested as racemic mixtures at this new stereocentre. 
 
   Compounds with a chinuclidine structure as an amino alcohol. All 
stereoisomers of the methyl-substituted compounds 49A-D were tested. 50D 
and  51D had modifications in N-alkylation. Table 2.17 shows the 
corresponding structures. 
 
   Two molecules of 43D were attached together to a dimer (52D) with an 
alkylene spacer. This molecule was tested as a mixture of four stereoisomers 
resulting from the chiral nitrogen atoms. Two synthesis precursors, Dia-53 and 
(R)-54, were tested for affinity, in order to find out whether a smaller acid part 
of the molecule was sufficient for high affinities at muscarinic subtypes. Dia-53 
is a mixture of the two (R, R)- and (R, S)-diastereomers. Structures are shown 
in Table 2.18. 
 
   Structural hybrids of tiotropium and glycopyrronium were tested. Compound 
(R)-55 consisted of the acid part of glycopyrronium and the alcohol part of 
tiotropium. Derivative (R)-56 possessed the acid part of tiotropium and a 
strucural variation to the amino alcohol of glycopyrronium. Both molecules 
were tested as pure (R)-configurated enantiomers. Structures are shown in 
Table 2.19. The structure of tiotropium is presented for reason of comparison. 
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Table 2.16 Compounds with pyrrolidine ring and modifications in N-alkylation. The 
asterisks denote the centres of chirality. 
O
O
N
+
O H
R
R No.
Dia-44D
Dia-45D
Dia-46D
R No.
3 2'
* *
*
R R
CF3
Dia-47D
Dia-48D
(CH2)2Phenyl
(CH2)3Phenyl
 
Table 2.17 Compounds with chinuclidine ring and modifications in N-alkylation. The 
asterisks denote the centres of chirality. 
R No.
49A-D
50D
51D
3 2'
* *
CH3
(CH2)2Phenyl
(CH2)3Phenyl
N
+
O
O
O H R
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Table 2.18 Dimerised structures and synthesis precursors. The asterisks denote the 
centres of chirality. 
3 2'
* *
*
R R
OH
O
O
N
+
3 2'
* *
R
O
O
O
N
+
3
*
R
2'
O
O
N
+
OH
O
O
N
+
O H
(CH2)4
3 2'
* *
R R
*
52 No.
No. Dia-53 (R)-54 No.  
 
Table 2.19 Hybrid molecules consisting of parts of tiotropium and glycopyrronium. 
The asterisks denote the centres of chirality. 
No.
*
R
3
*
R
S
S
N
+
O
O
O H
N
+
O
S
S O
O H O
N
+
O
O
O
O H
Tiotropium
(R)-55 No. (R)-56
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2.6 Characterisation of [
3H](3R, 2’R)-glycopyrronium 
Kinetic studies concerning the stereoisomers of glycopyrronium 43A-D were carried 
out in our laboratory by K. Kreutzmann. He investigated association- and dissociation 
rate constants (kon and koff) of 43A-D and of several analogues in experiments with 
cold, unlabelled compounds at muscarinic M2 and M3 receptors, using [
3H]NNMS as 
radioligand. He was able to show that dissociation half-lifes were very different for 
43A-D depending on the absolute configuration at the centres of chirality. 
Compounds with (2’R)-configuration showed much slower dissociation at the M3 
subtype compared to their (2’S)-configurated isomers. The longest t1/2 at M3 was 
found for the (3R, 2’R)-configurated stereoisomer 43D. Further on, dissociation at the 
M3 subtype was much slower compared to the M2 subtype for 43D (t1/2 = 134 and 18 
minutes, respectively, K. Kreutzmann, personal communication). This difference in 
dissociation half lives may lead to a kinetic selectivity as it was published for 
tiotropium (Disse et al., 1993). As it turned out to be difficult to find highly selective 
compounds at M1-5 receptors based on different affinities, the approach of kinetic 
selectivity is of particular interest. Tiotropium has already shown its superiority to 
older drugs on the market (ipratropium and oxitropium) concerning dosing regimen 
and efficacy in COPD therapy (Barnes, 2001). Structures of the quaternary 
compounds most commonly used in COPD therapy are given in Table 2.21. M1-3 
receptors were found in human lung tissue. The M3 subtype was found to be most 
important for direct bronchoconstriction in human airway smooth muscles (Bymaster 
et al., 2003). Therefore, antagonists with prolonged effect at M3 and possessing little 
influence on the other subtypes expressed in human airways, are of great interest. 
Cold-kinetic experiments carried out by K. Kreutzmann were an indirect way to obtain 
the kinetic constants of an unlabeled compound. For direct measurement of kinetic 
constants a labelled compound was necessary. Therefore, a cold precursor of the 
most interesting compound 43D (synthesised in the group of Prof. Dr. C. Noe, 
Vienna, Austria) was sent to Amersham (Buckinghamshire, UK) for radioactive 
labelling. Table 2.20 shows the structure of labelled [N-methyl-
3H](3R, 2’R)-
glycopyrronium used as trifluoroacetate, shortly [
3H]43D. In our studies we wanted 
to perform a complete characterisation of this compound. This implicated saturation-, 
competition-, and kinetic experiments. We wanted to confirm the kinetic constants  
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obtained in cold-kinetic experiments with the unlabelled drug and further on to 
determine the kinetic constants at all muscarinic receptor subtypes. 
 
Table 2.20 Structure of the labelled compound [
3H](3R, 2’R)-glycopyrronium 
([
3H]43D) used as trifluoroacetate. The asterisks denote the centres of chirality. 
O
O
N
+
O H
H
3
H
3
H
3
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R R
O
F
O
F
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Table 2.21 Structures of the most important approved drugs for use in COPD 
therapy. The asterisks denote the centres of chirality. 
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2.7 M2-selective antagonists related to dimethindene 
Considerable results were achieved at many pharmacological targets but up to now 
only little advance was made in the development of selective muscarinic antagonists. 
M2-selective antagonists are of great interest for several therapeutic indications, e.g. 
in therapy of AD. Even more promising than a therapeutic aspect in AD is the idea to 
develop a highly potent, M2-selective, brain-penetrating compound for PET-studies. A 
compound with this properties could be used as a diagnostic tool to verify AD 
diagnosis in vivo as the total number of M2 receptor decreases with proceeding of AD 
(Petrella et al., 2003). This would be a mile-stone, as only post-mortem studies can 
provide a 100% safe AD diagnosis to date. 
Dimethindene (57A) is used therapeutically since many years as a histamine H1 
receptor antagonist. It is well known that this drug is capable to cross the blood brain 
barrier causing sedation as a side effect in human therapy. 57A is currently used as 
a racemic mixture in therapy. In several functional models a 50 - 1000-fold higher 
affinity was found for the (R)-(-)-configurated enantiomer of dimethindene to H1 
receptors in comparison to the (S)-(+)-configurated enantiomer (Borchard et al., 
1985). These findings were confirmed in binding studies, too (Ter Laak et al., 1993). 
It was shown that drowsiness following application of one of the enantiomers to 
humans was related to the (R)-(-)-configurated isomer (Nicholson et al., 1991) as a 
result of its high H1 affinity. In functional studies in our laboratories at M1-3 receptors 
and in binding studies at native M1-4 subtypes the inverse effect was seen at 
muscarinic receptors where the (S)-(+)-configurated enantiomer showed higher 
affinities (Pfaff et al., 1995). These binding studies revealed that (+)-dimethindene 
had an at least 5-fold higher affinity at M2 versus M1,3,4. However, affinity to H1 
receptors was almost as high as affinity to M2. Taking 57A as a starting point, 
considerable efforts were made in our laboratory to improve absolute affinity and 
subtype selectivity at muscarinic M2 receptors and at the same time to reduce affinity 
to histamine H1 receptors. This extensively conducted research culminated in an 
analogue possessing two isopropyl substituents (75A) instead of two methyl groups 
at the basic nitrogen (Böhme et al., 2003). The (+)-enantiomer had an at least 36-fold 
selectivity for M2 versus the other subtypes and a 58-fold specificity to H1. However, 
one aim was still not reached - affinity at M2 was not increased (pKi = 7.37) in 
comparison to the parent compound.   
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Before synthesis for this study was started, a complete SAR study of the already 
existing dimethindene derivatives was done at hH1 receptors. After a thorough 
examination of binding data at M1-5 and H1, the hypothesis was postulated that 
reducing the side chain length connecting the amino moiety to the indene structure 
would increase affinity to muscarinic receptors and simultaneously decrease H1 
affinity. Synthesis was directed in a direction to prove this working thesis. All tested  
analogues were chiral compounds. Unless explicitly expressed, all drugs were tested  
as racemic mixtures. 
 
Table 2.22 shows the formula of dimethindene (57A) which served as a starting point 
in this SAR study with arrows indicating the general sites of modifications.  
 
Table 2.22 Structure of dimethindene (57A) and general sites of structural variations. 
The asterisk denotes the centre of chirality. 
N
N
*
A
B
 
A  Modification in side chain length 
B  Changes in substituents at the basic amino nitrogen 
 
The following molecule variations were testes in our studies: 
 
   Derivatives with modifications in N-alkylation pattern and modification in side 
chain length. Table 2.23 gives the structures. Compounds having the letter “A” 
affixed to the compound number possess a side chain equal to the parent 
compound 57A (n=2). Analogues with a “B” attached to the number have a 
shortened side chain (n=1). Derivatives 62 and 63 w e r e  o n l y  t e s t e d  w i t h  
reduced chain length (“B”).   
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   A series of compounds with either a benzyl or a phenylethyl substituent 
attached to the basic nitrogen with reduced side chain length, 65B - 74B, was 
tested. Table 2.24 displays the compounds. 
 
   Three compounds were separated in enantiomers. These were the parent 
compound (+/-)-57A, derivative (+/-)-72B and the diisopropyl analogue (+/-)-
75A. Structure of 75A is given in Table 2.25. 
 
   Analogues  76B and 77B with reduced chain length closely related to 72B 
were examined. Structures are given in Table 2.26. 
 
   Three sets of compounds with insertion of a para- or meta-substituent (78B - 
83B) in the phenylethyl substituent of 72B were tested. Structures are shown 
in Table 2.27. 
 
Table 2.23 Compounds with modifications in side chain length and N-alkylation. The 
asterisk denotes the centre of chirality. 
N
CH2 R
n
 
*
R No.
57A/B
58A/B
59A/B
60A/B
N
N
N
N
N
O
N
N
N
N
n = 2: A
n = 1: B
No.
61A/B
62B
63B
64A/B
R
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Table 2.24 Compounds with a benzyl or phenylethyl substituent at the basic nitrogen 
and reduced side chain length. The asterisk denotes the centre of chirality. 
R1
No.
65B
64B
  -
66B
67B
68B
  -
69B
n = 1: B
No. R2
N
N
R1
R2
*
Benzyl R1
Phenylethyl
70B
  -
71B
72B
  -
  -
73B
74B
H
CH3
C2H5
 
 
Table 2.25 Structure of compound 75A. The asterisk denotes the centre of chirality. 
N
N
*
No. (+/-)-75A
n = 2: A
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Table 2.26 Structure of compounds closely related to 72B. The asterisk denotes the 
centre of chirality. 
No.
76B
77B
n = 1: B
R2
*
R1
H
CH3
F
N
N
R1
R2
 
 
Table 2.27 Structure of compounds closely related to 72B with insertion of p- or m-
substituents at the phenyl ring. The asterisk denotes the centre of chirality. 
No.
78B
79B
80B
81B
82B
83B
n = 1: B
R2
*
R1
N
N
R1
R2
H
Cl
H
F
H
H
H
Cl
H
F
OCH3
OCH3
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3.1 Commercially available drugs 
3.1.1 Reference substances 
4-DAMP (Tocris, Bristol, UK) 
Astemizole (Promochem, Wesel, Germany) 
Atropine sulfate (E. Merck, Darmstadt, Germany) 
Cetirizine dihydrochloride (Promochem, Wesel, Germany) 
(R/S)-Chlorpheniramine maleate (Sigma / RBI, Deisenhofen, Germany) 
Diphenhydramine hydrochloride (Sigma / RBI, Deisenhofen, Germany) 
GR113808 (Tocris, Bristol, UK) 
McN-A-343 chloride (Sigma / RBI, Deisenhofen, Germany) 
MDL72222 (Bemesetron) (Sigma / RBI, Deisenhofen, Germany) 
Mepyramine maleate (Sigma / RBI, Deisenhofen, Germany) 
Metoclopramide hydrochloride (Sigma / RBI, Deisenhofen, Germany) 
RS23597-190 hydrochloride (Tocris, Bristol, UK) 
RS39604 hydrochloride (Tocris, Bristol, UK) 
SB203186 hydrochloride (Tocris, Bristol, UK) 
t-Triprolidin hydrochloride (Sigma / RBI, Deisenhofen, Germany) 
Tropisetron (Sigma / RBI, Deisenhofen, Germany) 
Terfenadine (Sigma / RBI, Deisenhofen, Germany) 
 
3.1.2 Radiochemicals 
Amersham, Buckinghamshire, England: 
1-[N-methyl-
3H]scopolamine methylchloride (SA 84.0 Ci/mmol) = [
3H]NMS 
[N-methyl-
3H]GR113808 (SA 83.0 Ci/mmol) 
[N-methyl-
3H](3R, 2’R)-glycopyrronium ([
3H]43D) (SA 84.0 Ci/mmol) was synthesised 
starting from a cold precursor provided by M. Walter, Vienna, Austria. 
[Pyridinyl-5-
3H]pyrilamine (SA 28.0 Ci/mmol) = [
3H]mepyramine 
 
Perkin Elmer / NEN, Bosten, MA, USA: 
1-[N-methyl-
3H]scopolamine methylchloride (SA 78.0 Ci/mmol) = [
3H]NMS 
[N-methyl-
3H]GR 65630 (SA 75.5 Ci/mmol)  
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3.1.3 Buffer compounds and solvents 
E. Merck, Darmstadt, Germany: 
N-2-Hydroxyethylpiperazine-N’-2-ethanesulphonic acid sodium salt (HEPES) 
Tris(hydroxymethyl)-aminomethane (Tris) 
MgCl2 x 6H20 
NaCl 
0.1 M-hydrochloric acid 
1 M-sodium hydroxide 
Dimethylsulfoxide (DMSO) 
Methanol 
 
3.1.4 Material for cell culture and protein assay 
Bovine serum albumine standard  (Sigma / RBI, Deisenhofen, Germany) 
Cell culture dishes (Nunc, Roskilde, Denmark) 
Dulbecco’s modified Eagle’s medium (BioWhitaker Inc., Walkersville, MD, USA) 
Fetal calf serum (Gibco, Grand Island, NY, USA) 
Glutamine (BioWhitaker Inc., Walkersville, MD, USA) 
Lowry - protein assay kit  (Bio-Rad, Richmond, USA) 
Non-essential amino acids (BioWhitaker Inc., Walkersville, MD, USA) 
Phosphate buffered saline (BioWhitaker Inc., Walkersville, MD, USA) 
Penicillin G / streptomycin mixture (BioWhitaker Inc., Walkersville, MD, USA) 
Trypsin-EDTA (BioWhitaker Inc., Walkersville, MD, USA) 
 
3.1.5 Material for radioligand binding assays 
Lumasafe Plus scintillation cocktail (Packard Bioscience, Dreieich, Germany) 
Polyethylene imine (50% in purified water) (Sigma / RBI, Deisenhofen, Germany) 
Whatman GF/B glas fibre filter (A. Hassel, München, Germany) 
Zinsser mini scintillation vials (Zinsser Analytik, Frankfurt, Germany) 
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3.2 Gifts 
3.2.1 Reference substances 
Alosetron hydrochloride (Prof. S. Elz, Regensburg, Germany) 
Dimethindene ((±)-maleate, (+/-)-tartrates) (Dr. D. Rehn, Zyma, München, Germany) 
Dolasetron mesylate (Prof. S. Elz, Regensburg, Germany) 
Fexofenadine hydrochloride (Prof. S. Elz, Regensburg, Germany) 
Granisetron hydrochloride (Prof. S. Elz, Regensburg, Germany) 
HHSiD hydrochloride (Prof. R. Tacke, Würzburg, Germany) 
Himbacine hydrochloride (Dr. W. C. Taylor, Sydney, Australia) 
Ipratropium bromide (Thomae, Biberach/Riss, Germany) 
Ondansetron hydrochloride (Prof. S. Elz, Regensburg, Germany) 
PD102807 (Dr. R. D. Schwarz, Parke-Davis, Ann Arbor, USA) 
Pirenzepine hydrochloride (Thomae, Biberach/Riss, Germany) 
 
3.2.2 Cells 
CHO-K1 cells stably expressing hH1 receptors (Prof. R. Leurs, Amsterdam, NL)  
CHO-K1 cells stably expressing hM1-5 receptors (Dr. J. Wess, NIDDK, National 
Institutes of Health, Bethesda, MD, USA) 
Membranes from HEK293 cells stably expressing h5-HT3A receptors (PD M. Brüss, 
Bonn, Germany) 
Membranes from HEK293 cells stably expressing h5-HT4(b) receptors (PD M. Brüss, 
Bonn, Germany) 
 
3.3 Synthesis 
   Analogues of ondansetron and metoclopramide were synthesised in the group 
of Prof. Dr. S. Elz, Institute of Pharmaceutical Chemistry, University of 
Regensburg, Germany. 
 
   Analogues of glycopyrrolate were synthesised in the group of Prof. Dr. C. Noe, 
Institute of Pharmaceutical Chemistry, University of Vienna, Austria.  
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   Analogues of dimethindene were synthesised in the group of Prof. Dr. G. 
Dannhardt, Institute of Pharmaceutical Chemistry, University of Mainz, 
Germany. 
 
   Analogues of McN-A-343 were synthesised in our laboratories by Dr. U. Moser 
and U. Hermanni.  
 
3.4 Anions of compounds 
Many compounds were obtained as free bases, those obtained as salts are listed 
below in Table 3.1 next to their corresponding anions. 
 
Table 3.1 Anions of compounds. 
 
chloride:  1 
bromide:  43-56 
iodide:  11, 31, 32
+, (R/S)-33
+, 34
+, (±)-38
+ - (±)-42
+ 
perchorate:  (R/S)-35
+ 
oxalate:  32, (R/S)-33, 34, (R/S)-35 - (R/S)-37, (±)-38 - (±)-42  
tosylate:  (R/S)-36
+, (R/S)-37
+, (±)-40
+, 65B, (±)-72B 
maleate:  17, (±)-57B, 58A - 61A 
 
3.5 Chirality 
Within the series of tested compounds were several chiral molecules. The pure 
enantiomers of compounds 72B and 75A were separated via HPLC by Dr. T. Böhme, 
Aventis, Frankfurt, Germany, and had no detectable impurities (for detailed method 
see Böhme et al., 2003). For compounds related to metoclopramide, ondansetron 
and McN-A-343, stereochemical purity was high according to pharmacological 
results. 
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3.6 Stock solutions 
To make 1 mM stock solutions small amounts of DMSO, methanol and 0.1 M 
hydrochloric acid were used to dissolve compounds when necessary, before filling up 
to the required volume with demineralised water. The radioligand dilution was 
prepared with demineralised water. 
 
3.7 Preparation of buffers 
Buffers were made of analytical grade purity chemicals: 
 
HEPES buffer:  HEPES  20 mM 
   M g C l 2   10 mM 
      NaCl             100 mM 
      NaOH            ad pH 7.4 
 
Tris  buffer:   Tris   5  mM 
      HCl             ad pH 7.4 
 
3.8 Methods 
3.8.1 Cell culture 
CHO-K1 cells stably transfected with hM1-5 or hH1 receptors were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf 
serum, 100 I.U./ml penicillin G, 100 µg/ml streptomycin, 2 mM glutamine and 0.1 mM 
non-essantial amino acids in a humidified atmosphere with 5-10% CO2 in monolayer 
culture. 1 ml-stocks were quickly thawed in a 37°C water bath and suspended in 
approximately 35 ml of warmed growth medium in a 175 cm
2 cell culture flask. The 
next day approximately two thirds of the medium were replaced. For passage (done 
at confluence three times weekly) the whole medium was removed, cells were 
washed with 37°C phosphate buffered saline (PBS), loosened with 2 ml trypsin-
EDTA and resuspended in fresh medium. According to cell density a splitting ratio of 
1:4 to 1:8 was used. To obtain stock aliquots, washed and trypsinised cells were  
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collected by centrifugation (10 min, approximately 300 g), resuspended in growth 
medium supplied with 10% DMSO and slowly frozen to -80°C before storage in liquid 
nitrogen. One 175 cm
2 cell culture bottle was used to obtain three stock aliquots. 
 
3.8.2 Membrane preparation 
Membranes of CHO-K1 cells were prepared four passages after thaw. For 
harvesting, cells were put in 525 cm
2 culture dishes after the last splitting. At 80-
100% confluence cells were washed with ice-cold PBS, scraped into ice-cold HEPES 
buffer and homogenised with ultrasonic waves using a Branson Cell Disruptor B15 
(duty cycle 20%, output control setting 3, 45 seconds) Danbury, CT, USA. 
Membranes were pelleted at 30.600g for 30 min at 4°C, resuspended in HEPES 
buffer using a hand potter, aliquoted and stored in liquid nitrogen. The protein 
concentration was determined as written below. The aliquots were stored in liquid 
nitrogen. During storage no change in binding parameters appeared. 
 
3.8.3 Protein assay 
Protein concentration was determined according to the method of Lowry (Lowry et 
al., 1951) using a  Bio-Rad protein assay kit in 5 mM Tris-buffer pH 7.4 and bovine 
serum albumin as standard. As HEPES disturbs this assay, membranes were 
pelleted and washed twice with Tris buffer before protein concentration was 
determined. 
 
3.8.4 Radioligand binding studies 
Radioligand binding assays were carried out according to literature (examples are 
given in Table 3.2) with the following modifications. All assays were carried out on 
96-well plates (maximum volume 1.2 ml) in a total volume of 1 ml in HEPES buffer 
pH 7.4. Final protein concentrations (in µg/ml) were: M1: 5; M2: 20; M3: 8; M4: 7; M5: 
13; H1: 27; 5-HT3: 5; 5-HT4: 23. These assay conditions were derived from the total 
number of receptors, the radioligand equilibrium dissociation constant (KD), which 
were both measured in saturation binding experiments, and the rule that receptor 
concentration should be less than 10% of the radioligand KD (Hulme, 1992).  
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Incubation was carried out at 25°C in a slowly stirred waterbath and terminated by 
vacuum filtration through a Brandell cell harvester (Brandell, Gaithersburgh, MD, 
USA) onto Whatman GF/B filters, presoaked in 0.5% polyethylene imine solution. 
Filters were washed three times with 1 ml ice-cold binding buffer and transferred into 
scintillation vials,  3 ml of scintillant were added and shaken for 2 hours. Samples 
were counted in a Wallac ß-counter (Wallac and Berthold, Milton Keynes, UK). The 
counting efficiency was approximately 53%. 
 
Table 3.2  Used radioligands and concentrations at corresponding receptors. Drugs 
and their final concentrations to determine non-specific binding (NSB). Literature 
examples concerning the assays are given in the last column. 
Receptor  Radioligand  c [nM]  NSB  c [µM]  Literature 
M1-5  [
3H]NMS 0.2  atropine    1 
Dörje et al., 1991    
Buckley et al., 1989
H1  [
3H]mepyramine 1.0 terfenadine 100 
Ter Laak et al., 1993  
Smit et al., 1996 
5-HT3  [
3H]GR65630 0.1  tropisetron 1 
Sharif et al., 1991    
Miyake et al., 1995 
5-HT4  [
3H]GR113808   0.1  RS39604  1 
Pindon et al., 2002   
Blondel et al., 1998 
M1-5  [
3H]43D 0.2  atropine  1  This work 
 
3.8.5 Saturation binding experiments 
To determine the total number of receptors (Bmax) in the membrane preparation and 
the equilibrium dissociation constant (KD) of the radioligand at the corresponding 
subtype, saturation binding experiment were carried out. Each new membrane batch 
was tested to make sure that the binding parameters did not change over time. 10 
increasing concentrations of radioligand (spanning approximately three orders of 
magnitude up to a maximum of 100 times KD where possible) were used to determine 
the KD. Incubation time was 2 h with exception for determination of the KD of [
3H]43D 
at M3 receptors where 4 h were chosen due to the slow dissociation of the 
radioligand at this subtype, to ensure that equilibrium was reached. Non-specific  
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binding (NSB) was determined according to Table 3.2. Each experiment was carried 
out in triplicate with the following sample conditions: 
   600 µl of HEPES buffer (to determine total binding) or 
500µl of buffer (to determine NSB) 
   100 µl of a suitable drug given in Table 3.2 (to determine NSB) 
   100 µl of radioligand dilution 
   300 µl of membrane suspension to initiate incubation. 
 
The data were analysed as written in 3.9.1. 
 
3.8.6 Competition binding experiments 
To determine the inhibition constant Ki, representing the binding affinity of unlabelled 
test compounds, competition experiments were carried out. A single concentration of 
radioligand  (given in Table 3.2) was used together with 7 - 9 different amounts of the 
test compound acting as a competitor. The radioligand concentration in competition 
experiments is recommended to be in range of the radioligand’s KD (Hulme, 1992). In 
combination with a reasonable concentration of binding sites, depletion of free 
radioligand can be avoided and low non-specific binding is achieved, resulting in a 
good “signal-to-noise-ratio”.  [
3H]43D was used at a concentration of 0.2 nM which is 
higher than KD. This was done in order to reach equilibrium at all subtypes in an 
incubation time of 4.5 h. Incubation time was 2 h for all other competition 
experiments. 
 
The competition binding experiments were carried out in duplicate with the following 
sample composition: 
   100 µl of test compound dilution (competition sample) or 
100 µl of a suitable drug dilution given in Table 3.2 (to determine NSB) 
   500 µl of HEPES buffer (competition samples and NSB) or 
   600 µl of HEPES buffer (to determine total binding) 
   100 µl of radioligand dilution 
   300 µl of membrane suspension to initiate incubation. 
 
The data were analysed as written in 3.9.2.  
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3.8.7 Kinetic binding experiments 
3.8.7.1 Association  binding  experiments 
To obtain the observed rate constant (kobs), association rate constant (kon) and the 
dissociation rate constant (koff), association curves with 12 points of time were 
recorded with 6 - 8 different concentrations of [
3H]43D (Motulsky, 1999). 
Concentrations were spanning approximately one order of magnitude (Table 3.3). 
Maximum incubation time was 2 h with exception of M3 receptor (4 h). 
 
Table 3.3 Concentrations of [
3H]43D in association binding experiments. 
Subtype [
3H]43D [nM] 
M1  0.10 0.20 0.30 0.40 0.50 0.60 0.80 1.00 
M2  0.05 0.10 0.20 0.30 0.40 0.60 0.80 1.00 
M3  0.08 0.12 0.16 0.20 0.25 0.30 0.35 0.45 
M4  0.08 0.12 0.16 0.20 0.25 0.30 0.35 0.45 
M5  0.10 0.15 0.20 0.25 0.30 0.40 0.50 0.60 
 
The association binding experiments were carried out in duplicate with the following 
sample composition: 
   600 µl of HEPES buffer (kinetic samples) or 
500 µl of HEPES buffer (to determine NSB) 
   100 µl of 10 µM atropine solution (to determine NSB) 
   100 µl of radioligand dilution 
   300 µl of membrane suspension to initiate incubation. 
 
The obtained data were analysed as described in 3.9.3. 
 
3.8.7.2 Dissociation  binding  experiments 
To separately determine the dissociation rate constant (koff) of [
3H]43D at the M1 and 
M2 receptor subtypes, off-kinetic experiments were carried out. The radioligand 
concentration was 0.2 nM and preincubation time with the membrane to reach 
equilibrium was 1 h. Then atropine was added at 24 points of time to block further  
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association. Maximum incubation time after adding atropine was 4 h in the case of M1 
and 2 h in the case of M2. 
 
3.9 Data analysis and statistics 
Data were analysed by curve fitting procedures using the GraphPad Prism program 
(GraphPad Software Inc., San Diego, CA, USA). Before fitting, specific binding was 
calculated for each point by subtracting the non-specific binding from the measured 
total binding.  
 
3.9.1 Saturation binding experiments 
3.9.1.1  One-site binding model 
Data from saturation binding experiments were fitted to the equation  
(1)  ) (
max
x K
x B
y
D +
⋅
=  
to determine the equilibrium dissociation constant (KD) of a radioligand and the total 
amount of binding sites (Bmax given in CPM). X is the concentration of radioligand and 
y is the amount of specific bound radioactivity (in CPM) calculated by subtraction of 
NSB from total binding. 
 
Measured CPM values were converted into real concentration values [nM] according 
to equation: 
(2)  SA V
e CPM
c
⋅ ⋅
⋅
=
2220
 
with e displaying the counting efficacy factor (1.883), V = assay volume and SA = 
specific activity of the radioligand [Ci/mmol] (depending on kind and batch of ligand). 
 
3.9.1.2  Two-site binding model 
Data from saturation binding experiments of [
3H]mepyramine were also fitted to a 
two-site binding model  
Material and Methods 
 
 
82 
(3)  ) ( ) ( 2
2 max
1
1 max
x K
x B
x K
x B
y
D D +
⋅
+
+
⋅
=  
The fits (1) and (3) were compared with an F-test. 
 
3.9.2 Competition binding experiments 
Data from competition binding experiments were fitted to the equation 
(4) 
H n x IC
B
y ⋅ − +
= ) (log
0
50 10 1
 
to compute Hill coefficient (nH), and to equation 
(5) 
50 log
0
10 1
IC x
B
y − +
=  
to calculate the IC50 value of a cold competitor. X is the logarithm of the competitor 
concentration and y is the specific bound radioactivity in CPM. B0 is the amount of 
specific radioligand binding in an experiment when no competitor is present (or its 
concentration is infinitesimal). 
 
Ki values of the test compounds were derived from IC50 values using the Cheng-
Prusoff equation (Cheng and Prusoff, 1973), 
(6) 
) 1 (
50
D
i
K
L
IC
K
+
=  
with L = concentration of radioligand, KD = equilibrium dissociation constant of the 
radioligand as the following conditions were provided: 
 
   No ligand depletion has occurred. 
   The experiment has reached equilibrium. 
   Binding was fully reversible and follows the law of mass action with a Hill 
coefficient not different from unity. 
   The receptors were homogenous and all binding sites had the same affinity for 
the ligand. 
   There was no cooperativity-binding, ligand-ligand interaction or chemical 
transformation.   
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3.9.2.1  Two-site binding model 
If the obtained Hill coefficient was significantly different from unity the competition 
curves were additionally fitted to a to two-site binding model. 
 
(7)  ) log (
0
) log (
0
2 _ 50 1 _ 50 10 1
) 1 1 (
10 1
1
IC x IC x
fraction B fraction B
y − − +
− ⋅
+
+
⋅
=  
 
This equation describes the competition of a ligand for two types of receptors. The 
radioligand has identical affinities for both receptors, but the competitor has a 
different affinity for each. Fraction1 is the fraction of the receptors that have an 
affinity described by logIC50_1. The remainder of the receptors have an affinity 
described by logIC50_2. If logIC50_1 is smaller than logIC50_2, then fraction_1 is the 
fraction of high affinity sites.  
The fits (5) and (7) were compared with an F-test. 
 
3.9.3 Kinetic binding experiments 
3.9.3.1 Association  binding  experiments 
To calculate the radioligand’s association rate constant (kon) and dissociation rate 
constant (koff) out of the observed rate constant (kobs) and the concentration of the 
radioligand (cRL) the following steps were performed (Motulsky, 1999): 
 
To calculate kobs from the association curves the following formula was used for a 
non-linear curve fitting procedure: 
(8)  ) 1 ( max
t kobs e y y
⋅ − − ⋅ =  
where ymax equals the maximum binding in CPM at equilibrium for a special 
concentration of radioligand (which is different from Bmax), t = time in minutes and kobs 
= observed rate constant [min
-1]. 
The rearrangement of formula 
(9) 
RL
off obs
on c
k k
k
−
=   
leads to   
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(10)  off RL on obs k c k k + ⋅ =  
 
which can be fitted as a straight line in a linear regression to 
 
(11)  c x m y + ⋅ =  
 
in which x = cRL [nM], y = kobs [min
-1], m = kon [nM
-1 min
-1] and c = koff [min
-1] (Anthes et 
al., 2002). 
 
The kinetic KD (kinKD) - in contrast to the saturation KD (satKD), which was assessed 
in saturation binding assays - was calculated by the formula  
(12) 
on
off
D k
k
kinK =  
using kon and koff values determined in the association experiments in the case of 
M3,4,5 receptors. For the M1 and M2  receptor the koff value to calculate the kinetic KD 
was taken from the separately done dissociation experiments (see below). For the M1 
receptor the kon value was computed as an average out of the kobs values from the 
association curves using the off-experiments koff and the used radioligand 
concentration. 
 
3.9.3.2 Dissociation  binding  experiments 
To ensure the validity of the data obtained in the association binding experiments, 
dissociation binding experiments were carried out at M1 and M2 receptor to directly 
assess koff. Non-linear curve fitting was used for the following formula displaying a 
classical first order decay process. 
 
(13) 
t koff e nding SpecificBi NSB ng TotalBindi
⋅ − ⋅ + =   
 
where t = time in minutes, koff = dissociation rate constant [min
-1]. Total binding was 
in CPM and NSB was fitted by non-linear regression.  
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The dissociation half life (t1/2) of [
3H]43D was calculated by 
 
(14) 
off k
t
2 ln
2 / 1 =  
 
where koff was used in [min
-1] and t1/2 was calculated in minutes. 
 
 
3.10 Statistics 
Unless stated otherwise, data are presented as means with standard deviation (±SD) 
of at least three independent experiments. Competition binding experiments and 
kinetic binding experiments were carried out in duplicate, saturation binding 
experiments in triplicate each. Statistical significance was assessed using Student’s 
t-test with p<0.05.  The F-Test was used to compare the non-linear regression fits for 
the one- and two-site binding models (see 3.9.1.2 and 3.9.2.1). 
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4.1 Validation of assays and general considerations 
4.1.1 Saturation binding experiments 
KD and Bmax values obtained were summarized in Table 4.1. In muscarinic and 
serotonergic saturation binding experiments specific binding was saturable and 
consistent with a one-site binding model. For all tested subtypes non-specific binding 
increased linearly within the range of the used concentrations of radioligand. 
Scatchard plots were linear indicating a one-site binding model without co-operativity. 
At H1 receptors, binding data fitted better to a two-site model. 
 
4.1.1.1 Muscarinic  M1-5 receptors 
Results obtained with [
3H]NMS at M1-5 receptors were in good agreement with data 
obtained previously in our laboratory and literature (Dörje et al., 1991). The mean KD 
values obtained in a huge number of experiments, carried out in our laboratory by Dr. 
C. Keim and K. Kreutzmann, were used for further calculations. As an example the 
binding isotherm for the M1 subtype is shown in Fig. 4.1. 
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Fig. 4.1 Saturation binding isotherms displaying total (boxes), specific (circles) and 
non-specific binding (triangles) of [
3H]NMS to cloned hM1-5 receptors stably 
expressed in CHO-K1 cells and the corresponding Scatchard plot. Data represent 
one typical experiment each.  
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4.1.1.2 Serotonin  5-HT3A receptors 
The saturation binding isotherm of [
3H]GR65630 at the 5-HT3A subtype is given in 
Fig. 4.2. The calculated KD value is close to several literature values. Our value is 
similar by a factor of 2 - 4 to data obtained in binding studies with rat tissue 
preparations (Kilpatrick et al., 1987, 1989). Similar results were reported for mouse 5-
HT3 receptors stably expressed in CHO cells (Hovius et al., 1998) and a study with 
bovine brain tissue (Miller et al., 1992). Great differences to other studies using 
HEK293 cells stably expressing h5-HT3A receptors (Brüss et al., 1999) exist. A 
discrepancy of approximately factor 20 between our value and this literature KD is 
surprising at the first glance. But when comparing the assays, major differences 
between the used assay conditions (buffer, pH, temperature and incubation time) are 
obvious, and may explain the differences in the resulting KD values. 
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Fig. 4.2 Saturation binding isotherms displaying total (boxes), specific (circles) and 
non-specific binding (triangles) of [
3H]GR65630 to cloned h5-HT3A receptors stably 
expressed in HEK293 cells and the corresponding Scatchard plot. Data represent 
one typical experiment each. 
 
4.1.1.3 Serotonin  5-HT4(b) receptors 
Fig. 4.3  displays the saturation binding isotherm of [
3H]GR113808 at the 5-HT4(b) 
subtype. The KD value given in Table 4.1 is in good agreement with literature results 
using [
3H]GR113808 as radioligand. Very good agreement exists to a study using 
HEK293 cells stably expressing h5-HT4(b) (Pindon et al., 2002) and a study using 
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human cortex preparations (Wong et al., 1996). However, a discrepancy of factor 8 
exists to a study using transiently expression of h5-HT4(b) in COS-7 cells (Blondel et 
al., 1998). As assay conditions were similar, it is likely that this difference results from 
the different expression systems. 
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Fig. 4.3 Saturation binding isotherms displaying total (boxes), specific (circles) and 
non-specific binding (triangles) of [
3H]GR113808 to cloned h5-HT4(b) receptors stably 
expressed in HEK293 cells and the corresponding Scatchard plot. Data represent 
one typical experiment each. 
 
4.1.1.4 Histamine  H1 receptors 
Saturation binding curves of [
3H]mepyramine at H1 receptors fitted significantly better 
to a two-site binding model. The second, low-affinity binding site, could not be fitted 
well (as the concentration of radioligand could not be increased further due to 
financial constraints), but was at least two orders of magnitude lower in affinity than 
the high-affinity site. In Fig. 4.4 the fits for a one- and a two-site binding model for 
[
3H]mepyramine are given. Scatchard plots were curve-linear, indicating a second 
binding site, too. For further competition studies the high-affinity site was assumed to 
be the H1 receptor. The obtained KD value for [
3H]mepyramine (Table 4.1) at the hH1 
receptor is in good agreement with literature. Data are similar to previous studies with 
CHO-K1 cells stably expressing hH1 receptors (Smit et al., 1996; Anthes et al., 2002). 
A difference of factor 4.5 exists to the KD reported by Moguilevsky et al. (1994). 
However, very different assay conditions were used in that publication. Good 
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agreement exists to saturation binding studies in GPI preparations (Ter Laak et al., 
1993), compared to our results. 
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Fig. 4.4 Saturation binding isotherms displaying the fit of specific binding (circles) to 
a two-site model (solid line), a one-site model (dashed line) and non-specific binding 
(triangles) of [
3H]mepyramine to cloned hH1 receptors stably expressed in CHO-K1 
cells and the corresponding Scatchard plot. Data represent one typical experiment 
each. 
 
Table 4.1 Equilibrium dissociation constants (KD) of the used radioligands (compare 
to Table 3.2) at their corresponding receptors and the total number of specific binding 
sites (Bmax) in membranes from stably transfected cells derived from saturation 
experiments. 
Receptor KD [nM]  pKD B max [fmol/µg protein]
M1  0.19 
a) 9.72  4.11  ±  0.50 
M2  0.33 
a) 9.48  0.56  ±  0.04 
M3  0.17 
a) 9.77  3.24  ±  0.06 
M4  0.10 
a) 10.00  1.25  ±  0.10 
M5  0.48 
a) 9.32  0.45  ±  0.03 
H1  0.84 ± 0.07     9.06 ± 0.03  0.73 ± 0.10 
5-HT3A  0.13 ± 0.05     9.91 ± 0.15  2.78 ± 0.57 
5-HT4(b)  0.078 ± 0.005   10.11 ± 0.03  0.39 ± 0.00 
a) The mean KD values at muscarinic subtypes were taken from former experiments 
carried out by Dr. C. Keim in our laboratory (Böhme et al., 2003). 
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4.1.2 Competition binding experiments 
At all receptor subtypes a variety of reference substances was tested in competition 
studies to demonstrate the validity of the binding assays in comparison to data 
reported in literature. Representative competition curves are given for each assay. 
Unless stated otherwise, all compounds behaved as pure competitive antagonists 
and the curves were consistent with a one-site binding model. Most Hill coefficients 
(nH) were not different from unity. Exceptions are given in grey italics in the 
corresponding tables. 
 
4.1.2.1 Muscarinic  M1-5 receptors 
The affinity values (pKi) of several reference drugs at muscarinic receptor subtypes 
are given in Table 4.2. The tested drugs spanned an affinity range of approximately 
three orders of magnitude and displayed different selectivity profiles. The obtained 
values are in good agreement with literature (Dörje et al., 1991; Böhme et al., 2003; 
K. Kreutzmann, personal communication). Examples of competition curves are 
shown in Fig. 4.5 displaying the curves of atropine, a highly potent, non-selective 
antagonist at M1-5 receptors. 
 
  
Results 
 
 
93 
Table 4.2 pKi values and Hill coefficients (in parentheses) of reference drugs at 
muscarinic subtypes determined in competition binding experiments with [
3H]NMS. 
Hill slopes significantly different from unity are given in grey italics. 
   M1 M 2 M 3 M 4 M 5 
Atropine 8.89 ± 0.03 8.59 ± 0.03 8.84 ± 0.08 8.94 ± 0.03 8.63 ± 0.03
   (0.97 ± 0.01)  (1.00 ± 0.05) (1.01 ± 0.07) (0.96 ± 0.02)  (0.93 ± 0.04)
4-DAMP 8.99 ± 0.05 8.03 ± 0.05 8.93 ± 0.02 8.52 ± 0.02 8.63  ± 0.03
   (0.90 ± 0.06)  (1.00 ± 0.05) (1.02 ± 0.06) (1.00 ± 0.02)  (0.96 ± 0.04)
(R)-Dimethindene 5.73 ± 0.03 5.91 ± 0.05 5.47 ± 0.04 5.41 ± 0.01 5.57 ± 0.03
   (1.01 ± 0.03)  (1.01 ± 0.04) (1.05 ± 0.07) (0.99 ± 0.09)  (0.99 ± 0.03)
(S)-Dimethindene 6.72 ± 0.05 7.52 ± 0.05 6.86 ± 0.01 6.53 ± 0.05 6.12 ± 0.03
   (0.93 ± 0.02)  (1.00 ± 0.04) (1.02 ± 0.01) (0.99 ± 0.03)  (1.02 ± 0.05)
Ipratropium 8.93 ± 0.07 9.14 ± 0.08 9.30 ± 0.05 9.18 ± 0.13 8.71 ± 0.05
   (0.92 ± 0.02)  (1.02 ± 0.08) (0.97 ± 0.02) (0.98 ± 0.04)  (1.01 ± 0.10)
Pirenzepine 7.93 ± 0.02 6.37 ± 0.01 6.70 ± 0.03 7.26 ± 0.01 6.86 ± 0.04
   (0.96 ± 0.03)  (1.01 ± 0.03) (0.95 ± 0.03) (0.94 ± 0.02)  (0.96 ± 0.11)
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Fig. 4.5  Competition curves of atropine at [
3H]NMS binding sites in membrane 
preparations from CHO-K1 cells stably expressing hM1-5 receptors. 
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4.1.2.2 Serotonin  5-HT3A receptor 
The affinity values (pKi) of several reference drugs at serotonin 5-HT3A receptor are 
given in Table 4.3. The tested drugs spanned an affinity range of approximately five 
orders of magnitude. The obtained values are in good agreement with literature data 
for binding studies in tissue preparations of rat brain (Kilpatrick et al., 1987, 1989) 
and bovine brain (Miller et al., 1992). Good agreement can be seen to binding 
studies using mouse and rat neuroblastoma cells (Boeijinga et al., 1992; Lummis et 
al., 1990; Sharif et al., 1991). Examples of competition curves are shown in Fig. 4.6.  
 
Table 4.3 pKi values and Hill coefficients (in parentheses) of reference drugs at 
serotonin h5-HT3A receptors determined in competition binding experiments with 
[
3H]GR65630. 
   5-HT3A       5-HT3A 
Alosetron  9.69 ± 0.04    MCP  6.29 ± 0.08 
   (1.06 ± 0.27)       (1.06 ± 0.09) 
Cocaine  5.40 ± 0.09    MDL72222  8.30 ± 0.08 
   (1.01 ± 0.12)       (1.10 ± 0.05) 
Dolasetron  7.11 ± 0.06    Ondansetron  8.83 ± 0.03 
   (1.06 ± 0.02)       (1.09 ± 0.12) 
Granisetron  9.10 ± 0.04    Tropisetron  8.87 ± 0.04 
   (1.05 ± 0.11)       (1.08 ± 0.09) 
McN-A-343  4.96 ± 0.07      
   (1.01 ± 0.14)      
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Fig. 4.6 Competition curves of reference drugs at [
3H]GR65630 binding sites in 
membrane preparations from HEK293 cells stably expressing h5-HT3A receptors. 
 
4.1.2.3 Serotonin  5-HT4(b) receptor 
Several reference drugs were tested with their affinity values spanning four orders of 
magnitude. Affinity data (pKi values) are given in Table 4.4. Due to financial 
constraints these experiments were carried out only twice in duplicate. Only little data 
is available in literature using recombinant expression systems to measure 5-HT4(b) 
affinity. Most data was derived using guinea-pig brain preparations with the resulting 
affinities lying close to our data for McN-A-343 (Sagrada et al., 1994), GR113808 and 
RS39604 (Hegde and Eglen, 1996) and functional data in rat oesophagus for 
SB203186 (Hegde and Eglen, 1996) and RS23597-190 (Eglen et al., 1993b). One 
study using the 5-HT4n subtype stably expressed in HeLa cells revealed data close to 
ours concerning tropisetron (Vilaro et al., 2002). In general, our results were close to 
literature values with differences ranging from 0.3 - 0.5 log units. Competition curves 
of some reference drugs are given in Fig. 4.7. 
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Table 4.4 pKi values and Hill coefficients (in parentheses) of reference drugs at 
serotonin h5-HT4(b) receptors determined in competition binding experiments with 
[
3H]GR113808. Hill slopes significantly different from unity are given in grey italics. 
   5-HT4B       5-HT4B 
GR113808  9.73 ± 0.08    SB203186  8.39 ± 0.05 
   (0.97 ± 0.00)       (1.00 ± 0.05) 
RS39604  8.83 ± 0.16    Tropisetron  6.41 ± 0.00 
   (1.00 ± 0.04)       (0.97 ± 0.01) 
RS23597-190  7.28 ± 0.08    McN-A-343  5.73 ± 0.13 
   (0.84 ± 0.01)       (1.03 ± 0.09) 
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Fig. 4.7 Competition curves of reference drugs at [
3H]GR113808 binding sites in 
membrane preparations from HEK293 cells stably expressing h5-HT4(b) receptors. 
 
4.1.2.4 Histamine  H1 receptor 
Affinity data (pKi values) of several reference drugs at H1 receptors are summarized 
in Table 4.5. The tested drugs spanned an affinity range of approximately 1.5 orders 
of magnitude. The obtained values are in good agreement with literature values for 
binding studies at hH1 receptors expressed in CHO-cells (Smit et al., 1996; Anthes et 
al., 2002). There is a striking consistence with binding data obtained in studies at H1  
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receptor in guinea-pig brain tissue preparation (Ter Laak et al., 1993). Examples for 
competition curves are given in Fig. 4.8.  
 
Table 4.5 pKi values and Hill coefficients (in parentheses) of reference drugs at 
histamine H1 receptors determined in competition binding experiments with 
[
3H]mepyramine. 
   H1       H1 
Astemizole  8.72 ± 0.15    Fexofenadine  7.28 ± 0.01 
   (1.19 ± 0.21)       (0.99 ± 0.10) 
Cetirizine  7.28 ± 0.22    Mepyramine  8.66 ± 0.07 
   (1.07 ± 0.13)       (1.08 ± 0.08) 
Chlorpheniramine 7.84 ± 0.01    Terfenadine  7.30 ± 0.07 
   (0.89 ± 0.10)       (1.31 ± 0.30) 
Diphenhydramine 7.54 ± 0.12    t-Triprolidine  8.48 ± 0.10 
   (0.98 ± 0.16)       (1.06 ± 0.08) 
 
 
-11 -10 -9 -8 -7 -6 -5
0
150
300
450
600
Mepyramine
t-Triprolidine
Diphenhydramine
Competitor [M]
s
p
e
c
i
f
i
c
 
b
i
n
d
i
n
g
 
[
C
P
M
]
 
Fig. 4.8 Competition curves of some reference drugs at [
3H]mepyramine binding sites 
in membrane preparations from CHO-K1 cells stably expressing hH1 receptors.  
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4.2 Analogues of ondansetron 
Affinities values (pKi) of the parent compound ondansetron (1) and derivatives 2A/B - 
6A/B and 7 - 18 are given in Table 4.6. Reference values (pA2) obtained in functional 
studies at 5-HT3  receptors in guinea-pig ileum by the group of Prof. Dr. S. Elz, 
Regensburg, Germany, are shown, too. Ratios of affinities (h5-HT3A/GPI) were 
calculated and added. One should notice that Hill coefficients of compounds 13 and 
(+)14 were significantly different from unity. For these competition curves a two-site 
binding model was calculated in addition to a one-site binding model and the fits 
were compared with an F-Test. As in both cases the one-site binding model resulted 
in a better fit, pKi values were derived from IC50 values although this is not permitted 
following the rules of Cheng-Prusoff in a strict sense. Those values should be 
handled with care. In later paragraphs pKi values were derived in the same way 
unless stated otherwise when Hill slopes were significantly different from unity. 
Calculated pKi values for derivatives of ondansetron (1) ranged from < 4.5 (10, 15) 
up to 9.05 (2A), and h5-HT3A/GPI ratios from < 0.03 (15) up to > 724 (13). 
 
Table 4.6 pKi values and Hill coefficients (in parentheses) of ondansetron (1) and its 
analogues 2A/B - 6A/B and 7 - 18 determined in radioligand binding studies at h-
5HT3A receptors. Hill slopes significantly different from unity are given in grey italics. 
Reference values (pA2) obtained in functional studies at 5-HT3 receptors in guinea-
pig ileum (GPI) and calculated ratios are shown in the last two columns. 
No. h5-HT3A n H Ref.  GPI  h5-HT3A / GPI 
1 8.83 ± 0.03  (1.09 ± 0.12)  7.00 68 
2A 9.05 ± 0.09  (0.96 ± 0.09)  7.37 48 
2B 8.32 ± 0.03  (1.06 ± 0.08)  6.13 155 
3A 7.97 ± 0.11  (0.95 ± 0.04)  6.30 47 
3B 7.84 ± 0.08  (0.99 ± 0.05)  5.60 174 
4A 7.13 ± 0.02  (0.99 ± 0.04)  5.80 21 
4B 5.42 ± 0.10  (1.00 ± 0.06)  < 4.30  > 13 
5A 7.10 ± 0.11  (1.12 ± 0.13)  6.75 2 
5B 6.06 ± 0.05  (1.09 ± 0.23)  5.85 2 
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Table 4.6 (Continued) 
No. h5-HT3A n H Ref.  GPI  h5-HT3A / GPI 
6A 6.97 ± 0.06  (1.03 ± 0.11)  7.15 0.7 
6B 6.06 ± 0.11  (1.04 ± 0.18)  6.16 0.8 
7 8.20 ± 0.07  (1.02 ± 0.14)  6.67 34 
8 7.87 ± 0.05  (1.01 ± 0.09)  5.91 91 
9 7.43 ± 0.03  (1.04 ± 0.04)  5.82 41 
10 <  4.5     4.88 <  0.4 
11 7.56 ± 0.04  (0.99 ± 0.07)  5.92 44 
12 7.75 ± 0.10  (0.93 ± 0.17)  6.72 11 
13 8.16 ± 0.16  (1.06 ± 0.02)  < 5.3  > 724 
(+)-14 5.00 ± 0.08  (1.10 ± 0.03)  - - 
(-)-14 6.41 ± 0.06  (1.15 ± 0.16)  - - 
15 <  4.5     6.08 <  0.03 
16 6.74± 0.05  (1.09 ± 0.21)  6.08 5 
17 6.77 ± 0.03  (1.14 ± 0.14)  4.84 85 
18 5.34 ± 0.10  (1.06 ± 0.10)  5.25 1 
 
4.2.1 Analogues with substituents in position 4 and 5 
Five pairs of regioisomers with substituents at position 4 (2A - 6A) and 5 (2B - 6B) of 
the imidazole ring were tested. pKi values are given in Table 4.6. It can be clearly 
seen that substitution in position 4 (“A” series) is preferred versus position 5 (“B” 
series). Higher affinity values for the “A“ series were found in binding and functional 
tests. Results are shown in Fig. 4.9. It is very interesting to notice, that the affinity 
values obtained at recombinant h5-HT3A receptors were higher than that obtained at 
native gp5-HT3 receptors in the case of 2A/B - 4A/B (up to 174-fold), almost identical 
in the case of 5A/B (2-fold higher) or even smaller in the case of 6A/B (factor 0.8 and 
0.7). The highest affinities of all tested substances - apart from compound 1 (pKi = 
8.83) - were found for the regioisomers 2A and 2B (pKi = 9.05 and 8.32, 
respectively), resulting in a 2-fold increase in  affinity in comparison to compound 1 in 
the case of 2A.  
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Fig. 4.9 Affinity values of regioisomers with substituents at position 4 (2A - 6A) or 5 
(2B - 6B) of the imidazole ring at h5-HT3A receptors (pKi) and functional data 
obtained in guinea-pig ileum (pA2). 
 
4.2.2 Analogues with modified substituents at position 2 
Four compounds with modification at position 2 of the imidazole ring (7 - 10) were 
investigated and affinity values are shown in Table 4.6. The methyl group of 1 was 
exchanged with groups possessing a basic nitrogen or a phtalimide moeity. Fig. 4.10 
(A) gives the affinity data for compounds 1 and 7 - 10. All compounds in this group 
showed reduced affinities in comparison to the parent compound 1. Changes in 
methylation pattern resulted only in minor affinity changes in compounds 7 and 8. An 
aminomethyl substitution in compound 9 slightly decreased affinity. However, 
insertion of the nitrogen atom into a bulky substituent led to a dramatic loss of affinity 
in substance 10 reducing the pKi almost 3 orders of magnitude. This reduction of 
affinity was less pronounced in guinea-pig ileum. For compounds 1 and 7  -  9 
pronounced higher affinities were found in binding studies than in functional studies 
(ratios ranging from 34 - 91), whereas the inverse was seen for compound 10 (ratio < 
0.4). 
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Fig. 4.10 Affinity values of ondansetron (1) and its derivatives 7 - 10 with changed 
substituents at position 2 of the imidazole ring (A) and with changes in side chain and 
/ or imidazole structure (16 - 18) (B) at h5-HT3A receptors (pKi) and functional data 
obtained in guinea-pig ileum (pA2). 
 
4.2.3 Quaternized congeners, compounds with condensed ring and 
substances with a piperidine structure 
N-Methylation of the nitrogen in position 3 of the imidazole ring of 1 led to the 
quaternary molecule 11 possessing comparable affinity to compound 12 with 
condensed aromatic ring. Affinity data is given in Table 4.6 and illustrated in Fig. 
4.11. Exchanging the imidazole ring to a piperidine ring (13) resulted in high affinity in 
the low nanomolar range (pKi = 8.16). However, for this compound the highest 
discrepancy between binding and functional studies was found. Affinity at h5-HT3A 
was > 724-fold higher than at native gp5-HT3 receptors. Introduction of a substituent 
in para-position of the piperidinyl moiety (14 and 15) led to a dramatic decrease in 
binding affinity. A considerable stereoselectivity ratio of 26 was seen for (+)-14 and 
(-)-14 even though absolute affinities were rather low (pKi = 5.0 and 6.4, 
respectively). Introducing a bulky and sterically fixed substituent in compound 13, led 
to a total loss of affinity at h5-HT3A (4571-fold decrease) in compound 15. The 
inverse effect was seen at native gp5-HT3 receptors, where an at least 6-fold 
increase in affinity was found. Thus, for 15 the smallest ratio, recombinant vs. native 
5-HT3 receptors, was calculated (< 0.03).  
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Fig. 4.11 Affinity values of quaternary (11), condensed compounds (12) and 
derivatives with a piperidine moiety (13 - 15) at h5-HT3A receptors (pKi) and 
functional data obtained in guinea-pig ileum (pA2). n. d. = not determined. 
 
4.2.4 Analogues with modifications in the side chain and / or 
imidazole ring 
Three compounds (16 - 18) were tested with insertion of a basic nitrogen in the side 
chain. Data is given in Table 4.6, and illustrated in Fig. 4.10 (B). This modification led 
to a reduction in affinity of 2 orders of magnitude in the case of 16 and 17, where the 
imidazole ring was conserved, and even more than 3 orders of magnitude in 18, 
where this part was exchanged, with regard to the parent compound 1. Compared to 
functional data, higher affinities were measured at h5-HT3A receptors for compounds 
16 and 17 (5-fold and 85-fold, respectively), whereas an almost identical affinity was 
found for substance 18. 
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4.3 Analogues of metoclopramide 
Affinities values (pKi) of compound SDZ205-557 (19) and derivatives 20 - 30  are 
given in Table 4.7. Reference values obtained at 5-HT4 receptors in guinea-pig ileum 
and rat oesophagus functional studies by the group of Prof. Dr. S. Elz, Regensburg, 
Germany, are shown, too. The obtained affinity values (pKi) at h5-HT4(b) were in the 
range of 6.08 up to 8.43, and functional pA2 values ranged from 5.7 to 8.5 in guinea-
pig ileum and 5.8 to 8.4 in rat oesophagus, respectively. 
 
Table 4.7 pKi values and Hill coefficients (in parentheses) of SDZ205-557 (19) and 
its analogues determined in radioligand binding studies at h5-HT4(b) receptors. Hill 
slopes significantly different from unity are given in grey italics. Reference values 
(pA2) obtained in functional studies at 5-HT4 receptors in guinea-pig ileum (GPI) and 
rat oesophagus (ROS) are shown in the last two columns. 
No. h5-HT4B n H Ref.  GPI  Ref.  ROS 
19 7.83 ± 0.05  (0.96 ± 0.05)  7.5 7.3 
(±)-20 6.08 ± 0.09  (0.84 ± 0.09)  5.7 5.8 
(±)-21 6.75 ± 0.04  (1.00 ± 0.02)  6.8 6.4 
22 8.37 ± 0.02  (1.03 ± 0.02)  8.5 8.4 
(+)-23 7.27 ± 0.05  (1.02 ± 0.04)  6.9 - 
(-)-23 6.37 ± 0.11  (0.86 ± 0.11)  6.6 - 
24 7.39 ± 0.05  (0.99 ± 0.04)  7.4 7.6 
25 6.51 ± 0.05  (1.08 ± 0.05)  7.1 7.4 
(±)-26 8.43 ± 0.15  (0.80 ± 0.03)  7.9 - 
27 6.65 ± 0.05  (1.02 ± 0.07)  6.8 - 
28 6.87 ± 0.02  (1.04 ± 0.01)  6.8 - 
29 6.99 ± 0.03  (1.02 ± 0.04)  7.3 - 
30 8.28 ± 0.06  (0.94 ± 0.05)  7.5 - 
 
4.3.1 Analogues with methylation in the side chain 
Introducing a methyl substituent into the side chain next to basic nitrogen atom led to 
a loss in affinity for h5-HT4(b) receptors of approximately one order of magnitude for  
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(±)-21 in comparison to the unsubstituted parent compound 19 (pKi values 6.75 and 
7.83, respectively). Moving the methyl group to the carbon atom next to the ester 
oxygen, (±)-21  (±)-20, resulted in even lower affinity (pKi = 6.08) (Table 4.7 and 
Fig. 4.12). The functional data obtained at native gp5-HT4 and r5-HT4 receptors were 
very similar to the binding affinities at recombinant h5-HT4(b) receptors. 
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Fig. 4.12 Affinity values of compounds with methyl groups in the side chain of 19 at 
h5-HT4(b) receptors (pKi) and functional data obtained in guinea-pig ileum (GPI) and 
rat oesophagus (ROS) (pA2). 
 
4.3.2 Analogues with a piperidine ring system 
Insertion of the basic nitrogen of 19 in a piperidine ring system led to compounds 22 - 
26. Affinity data is given in Table 4.7, and illustrated in Fig. 4.13. For the piperidine 
congener 22 of the parent compound 19 a 4-fold increase in affinity was found (pKi 
were 8.37 and 7.83, respectively). Compounds (+)-23 and (-)-23 were obtained by 
introduction of a methyl group in 22 next to the nitrogen atom. This resulted in 
decreased affinity (approximately one order of magnitude for the eutomer (+)-23). In 
contrast to functional studies in guinea-pig ileum, where almost no difference was 
seen for the enantiomers (+)-23 and (-)-23, a stereoselectivity ratio of factor 8 was 
found in binding studies at h5-HT4(b) receptors. Elongation of the side chain length of 
compound 22 from 2 carbon atoms up to 3 (24) and 4 (25) carbon atoms led to 
clearly decreased affinities with increasing chain length. Introduction of a bulky 
aromatic substituent in 4 position of the piperidine ring in compound 22, resulting in  
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(±)-26, was tolerated well without loss of affinity. This revealed this part of the 
molecule to be less critical than the side chain region with regard to binding affinity at 
5-HT4 receptors. With exception of compound 25, there was no difference between 
functional and binding data. In the case of 25, problems with solubility occurred when 
the substance was dissolved. Neither addition of methanol, DMSO nor hydrochloric 
acid led to complete dissolution. This may be the reason for the lower values found in 
our tests in comparison to functional tests. 
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Fig. 4.13 Affinity values of compounds with a piperidine ring system (22 - 26) and 
modifications in the side chain at h5-HT4(b) receptors (pKi) and functional data 
obtained in guinea-pig ileum (GPI) and rat oesophagus (ROS) (pA2). n. d. = not 
determined. 
 
4.3.3 Analogues with a piperazine ring system 
Insertion of the basic nitrogen of 19 in a piperazine ring system resulted in 
compounds 27 - 30. Affinity data is given in Table 4.7 and illustrated in Fig. 4.14. 
Compounds 27 - 29 have a benzyl-substituted piperazine ring with increasing side 
chain length (from 2 - 4 carbon atoms). Compared with the piperidine analogue 22 
the introduction of a benzyl substituted piperazine ring (27 - 29) resulted in 
decreased binding affinities with only minor changes resulting in modification of chain 
length (pKi values 8.37, 6.65, 6.87 and 6.99, respectively). Surprisingly, exchanging 
the benzyl substituent into a phenyl ring, 27    30, restored binding affinity to a 
comparable level compared to the potent piperidine analogue 22. For compounds 27  
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- 29, a good agreement was seen between functional and binding data, whereas a 
6-fold discrepancy was found for 30. 
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Fig. 4.14 Affinity values of compounds with a piperazine ring system (27 - 30) at 
h5-HT4(b) receptors (pKi) and functional data obtained in guinea-pig ileum (GPI) (pA2). 
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4.4 Analogues of McN-A-343 
Affinity values (pKi) of the parent compound McN-A-343 (31) and derivatives 32 - 42 
at 5-HT3A, 5-HT4(b) and H1 receptors are listed in Table 4.8. Reference values 
obtained in previous binding studies at muscarinic M1 receptors in our laboratories by 
Dr. C. Keim (2000) are added for the most interesting compounds discussed later on.  
 
Table 4.8 pKi values and Hill coefficients (in parentheses) of McN-A-343 (31) and its 
analogues (32 - 42) determined in radioligand binding studies at h5-HT3A, h5-HT4(b) 
and hH1 receptors. Hill slopes significantly different from unity are given in grey 
italics. Reference values (pKi) obtained in binding studies at M1 receptors are shown 
in the last column.  
No. 5-HT3A
a) 5-HT4(b) H 1 Ref.  M1
b) 
31 4.96 ± 0.07 5.73 ± 0.13 <  4.5   
   (1.01 ± 0.14)  (1.03 ± 0.09)       
32 16%  4.70 ± 0.06 <  4.5   
      (1.02 ± 0.03)       
32
+ 10%  4.75 ± 0.05 <  4.5   
      (1.11 ± 0.07)       
(R)-33 <  4.5 4.84 ± 0.04 5.43 ± 0.12 5.47 
      (1.23 ± 0.15)  (1.23 ± 0.42)    
(S)-33 6% 4.69 ± 0.05 4.93 ± 0.06 7.40 
      (1.75 ± 0.56)  (0.99 ± 0.26)    
(R)-33
+ 5.74 ± 0.19 4.75 ± 0.02 4.82 ± 0.11 5.90 
   (1.15 ± 0.19)  (0.96 ± 0.03)  (0.88 ± 0.11)   
(S)-33
+ 10%  4.60 ± 0.06 <  4.5  7.67 
      (1.17 ± 0.04)       
(±)-34 <  4.5  -  4.75 ± 0.09    
         (0.86 ± 0.30)    
(±)-34
+ 5.58 ± 0.02 -  <  4.5    
   (1.44 ± 0.17)          
(R)-35 15% 5.06 ± 0.08 5.09 ± 0.03   
      (0.99 ± 0.07)  (0.86 ± 0.15)    
(S)-35 13% 4.85 ± 0.05 4.82 ± 0.06    
      (1.09 ± 0.09)  (0.97 ± 0.03)    
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Table 4.8 (continued)
 
No. 5-HT3A
a) 5-HT4(b) H 1 Ref.  M1
b) 
(R)-35
+ 14%  5.26 ± 0.05 <  4.5    
      (1.01 ± 0.04)       
(S)-35
+ 4%  5.09 ± 0.09 <  4.5    
      (0.96 ± 0.07)       
(R)-36 21% 5.20 ± 0.07 6.71 ± 0.06 7.20 
      (1.23 ± 0.34)  (0.84 ± 0.10)    
(S)-36 28% 5.23 ± 0.09 5.78 ± 0.09 9.40 
      (1.15 ± 0.08)  (1.02 ± 0.08)    
(R)-36
+ 24%  5.23 ± 0.03 6.26 ± 0.06 6.66 
      (1.03 ± 0.07)  (1.00 ± 0.11)    
(S)-36
+ 31%  5.00 ± 0.08 4.71 ± 0.02 8.80 
      (0.98 ± 0.03)  (0.92 ± 0.15)    
(R)-37 4.65 ± 0.11 - 6.72 ± 0.08 6.18 
   (0.87 ± 0.12)     (0.92 ± 0.20)    
(S)-37 18%  -  5.68 ± 0.10 9.40 
         (0.98 ± 0.00)    
(R)-37
+ 18%  -  6.04 ± 0.02 6.87 
         (0.83 ± 0.04)    
(S)-37
+ 32%  -  <  4.5  8.76 
              
(±)-38 24%  -  6.98 ± 0.10    
         (0.86 ± 0.18)    
(±)-38
+ 18%  -  6.30 ± 0.11    
         (1.09 ± 0.16)    
(±)-39 5.25 ± 0.09 - 6.27  ± 0.09    
   (0.63 ± 0.19)     (1.37 ± 0.40)    
(±)-39
+ 5.22 ± 0.02 - 5.12 ± 0.15    
   (1.03 ± 0.09)     (0.68 ± 0.16)    
(±)-40 4.90 ± 0.09 - 6.12 ± 0.05   
   (0.74 ± 0.09)     (1.00 ± 0.02)    
(±)-40
+ 4.81 ± 0.04 - 5.86 ± 0.04    
   (1.11 ± 0.23)     (1.01 ± 0.04)    
(±)-41 5.45 ± 0.05 - 6.74 ± 0.05    
   (0.96 ± 0.05)     (1.05 ± 0.14)    
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Table 4.8 (continued)
 
No. 5-HT3A
a) 5-HT4(b) H 1 Ref.  M1
b) 
(±)-41
+ 24%  -  6.07 ± 0.11    
         (1.06 ± 0.26)    
(±)-42 5.08 ± 0.02 - 6.58 ± 0.06    
   (1.03 ± 0.02)     (1.23 ± 0.20)    
(±)-42
+ 32%  -  5.71 ± 0.08    
         (0.98 ± 0.05)    
a) Values given in percent were obtained in one point screening experiments using a 
concentration of 1 x 10
-5 M of cold competitor. Tests were carried out twice in 
duplicate. Values given are the means of inhibition of specific binding. 
b) Reference values of selected compounds at M1 receptors were measured in 
previous tests in our laboratory by Dr. C. Keim (2000) in binding experiments. 
 
4.4.1 Studies at 5-HT3A receptors 
Binding data for compounds tested at this subtype are shown in Table 4.8. All values 
given in percent equal a pKi value in the range of 4.5 - 5.0 or below. The affinity value 
determined for 31 was in good agreement with that reported in previous work 
(Sagrada et al., 1994). pKi values of tested derivatives culminated at 5.74 for 
compound  (R)-33
+ displaying a 6-fold increase in comparison to the parent 
compound. This was disappointing as all structural modifications led only to minor 
changes in affinity. For the quaternary compounds (R/S)-33
+ stereoselectivity was 
found. The (R)-configurated enantiomer displayed pronounced higher affinity than the 
(S)-configurated compound (pKi = 5.74 and < 4.5, respectively). It is astonishing that 
this fact was not found for the tertiary congeners (R/S)-33 which both did not display 
significant affinities. No preference for tertiary or quaternary compounds concerning 
binding affinity at this subtype was observed. 
 
4.4.2 Studies at 5-HT4(b) receptors 
Due to financial constraints only a comparably small number of compounds was 
tested at this subtype. Data are shown in Table 4.8. Binding data for the parent 
compound  31 were in good agreement with literature (Sagrada et al., 1994). 
Experiments with the tested 14 congeners revealed decreased affinities, ranging  
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from pKi = 4.60 to 5.26. No preference for tertiary or quaternary compounds could be 
detected. A very small stereoselectivity effect was found in favour of the (R)-
configurated compounds in the cases of (R/S)-33, (R/S)33
+, (R/S)-35, (R/S)-35
+ and 
(R/S)-36
+ (Fig. 4.15). All modifications introduced in 31 led to a decrease in affinity of 
at least factor 3 in the case of the most potent derivative (R)-35
+ (pKi = 5.26). 
Changing the substitution pattern in the aromatic aniline ring into a 4-fluoro 
substituent (32, 32
+) led to reduction in affinity by one order of magnitude. A phenyl 
substituent attached to the chain (36,  36
+) provided comparable affinities to the 
methyl substituted compounds (35, 35
+). Therefore, it can be concluded that this is a 
less critical point in the molecule compared to the substitution pattern of the aromatic 
aniline phenyl ring. 
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Fig. 4.15 Affinity values (pKi) of chiral compounds tested at h5-HT4(b). 
 
4.4.3 Studies at H1 receptors 
Since considerable efforts were made in our laboratory concerning the affinity of 
derivatives of McN-A-343 (31) at muscarinic receptor subtypes (see also chapter 
2.4), analogues listed in Table 4.8 (32 - 42) were tested at the closely related 
histamine H1 receptor. Obtained affinities were spanning a range from pKi < 4.5 - 
6.98.  
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4.4.3.1  Compounds with acyclic amino moiety 
The achiral 4-fluoro-substituted congeners 32, 32
+ as well as McN-A-343 (31) had no 
detectable affinity for this subtype in binding experiments. Chiral compounds (R/S)-
33 and (R/S)-33
+ with attached C1-phenyl substituent displayed only low affinities at 
the micromolar range. (±)-34 with an additional o-phenyl substituent had a low 
affinity, too. Taken together, derivatives with an acyclic amine moiety showed only 
low affinities with the highest affinity measured for (R)-33 (pKi = 5.4) being at least 9-
fold more potent than the parent compound 31. 
 
4.4.3.2  Derivatives with a pyrrolidine ring system 
Analogues with 4-fluoro-substituted aromatic aniline phenyl rings and different C1-
substituents attached to the chain starting from a simple methyl (R/S)-35, (R/S)-35
+ 
via phenyl (R/S)-36, (R/S)-36
+ and 4-F-phenyl (±)-38, (±)-38
+ to a bulky 1-naphthyl 
substituent  (±)-39,  (±)-39
+ were tested. In addition, the congeners of 36 without 
substituent in the aromatic ring 37, 37
+ were examined. Data are given in Table 4.8 
and are illustrated in Fig. 4.16. It could be seen that affinities increased with 
increasing size of the substituent starting at (R)-35 to (R)-36 reaching the highest 
affinity value for (±)-38 (pKi = 5.09, 6.71, 6.98, respectively). Exchanging the methyl 
group into a phenyl ring (35  36) increased affinity 42-fold. Only a small (2-fold) 
further gain in affinity was reached with a 4-F-phenyl substituent (36    38). 
Changing the phenyl ring into a bigger 1-naphthyl substituent (38  39) decreased 
affinity 5-fold. (±)-38 showed the highest H1 affinity of all tested compounds within 
this series and was > 302-fold more potent than the parent compound 31. 
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Fig. 4.16 Affinity values (pKi) of compounds with a pyrrolidine ring system and an C1-
substituent in the chain (35, 36, 38 and 39) at H1 receptor. The arrows mark the 
tertiary eutomers or racemates. 
 
In Fig. 4.17 the closely related compounds 36 and 37, differing only in a fluorine atom 
at the aromatic ring, were compared. This F  H exchange was bioisoster as binding 
data were almost identical, with non of the analogues displaying a difference in 
affinity above 2-fold at H1 receptor. 
(
R
)
-
3
6
 
 
(
R
)
-
3
7
 
 
(
S
)
-
3
6
 
 
(
S
)
-
3
7
 
 
(
R
)
-
3
6
+
(
R
)
-
3
7
+
(
S
)
-
3
6
+
(
S
)
-
3
7
+
5
6
7
8
36 at H1
37 at H1
<
 
4
.
5
p
K
i
 
N
+
N
H
C O
O
C C C
H
CH2 F
R
*
N
+
N
H
C O
O
C C C
H
CH2 H
R
*
36
37
 
Fig. 4.17 Affinity values (pKi) of tertiary and quaternary enantiomers of 36 and 37 at 
H1 receptors.  
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Compounds possessing a pyrrolidine ring instead of an acyclic amine moiety showed 
much higher affinities. This could be seen especially well in the analogues 33 and 37 
differing only in that part of the molecule. Data in Fig. 4.18 illustrate this pronounced, 
almost 20-fold increase in affinity in the case of the tertiary (R)-configurated 
compounds. 
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Fig. 4.18 Affinity values (pKi) of tertiary and quaternary enantiomers of 33 and 37 at 
H1 receptors. 
 
4.4.3.3  Compounds with exchange of the aniline or carbamate moiety 
Introducing a 1-naphthyl substituent (40) resulted in 4-fold lower affinity compared to 
the phenyl analogue eutomer (R)-37 (pKi = 6.12 and 6.72, respectively). Interestingly, 
exchange of the phenyl ring into a diphenyl-methyl moiety  (37  41) was tolerated 
without decrease in affinity (pKi = 6.72 and 6.74, respectively). Exchange of the 
carbamate structure into a carboxylic ester function (36  42) was tolerated. Data 
are illustrated in Fig. 4.19.  
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Fig. 4.19 Affinity values (pKi) of tertiary and quaternary compounds with exchanged 
aniline (40 and 41) or carbamate moiety (42) at H1 receptors. 
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4.5 Analogues of glycopyrronium 
Affinity values (pKi) of parent compound 43D and analogues 44 - 56 at muscarinic 
hM1-5 receptors are given in Table 4.9, being in the range of 5.53 - 10.70. 
 
Table 4.9 pKi values and Hill coefficients (in parentheses) of 43D and analogues 
44 - 56  determined in radioligand binding studies at hM1-5 receptors. Hill slopes 
significantly different from unity are given in grey italics. 
No. M1 M 2 M 3 M 4 M 5 
43D
a)  9.94 9.70 9.95 9.90 9.35 
                 
Dia-44D 9.60 ± 0.15 9.48 ± 0.03 9.69 ± 0.07 9.63 ± 0.07 9.23 ± 0.01 
   (1.02 ± 0.06)  (0.95 ± 0.06)  (1.00 ± 0.09)  (0.98 ± 0.05)  (0.99 ± 0.04) 
Dia-45D 9.80 ± 0.13 9.82 ± 0.10 9.78 ± 0.06 9.79 ± 0.05 9.36 ± 0.04 
   (1.08 ± 0.05)  (0.91 ± 0.10)  (1.04 ± 0.04)  (0.96 ± 0.15)  (0.94 ± 0.05) 
Dia-46D 9.53 ± 0.17 9.10 ± 0.06 9.54 ± 0.05 9.50 ± 0.05 8.97 ± 0.07 
   (1.01 ± 0.04)  (0.94 ± 0.04)  (1.15 ± 0.06)  (1.00 ± 0.02)  (1.10 ± 0.05) 
Dia-47D 9.59 ± 0.12 9.27 ± 0.23 9.53 ± 0.07 9.61 ± 0.07 9.27 ± 0.01 
   (1.28 ± 0.23)  (1.26 ± 0.07)  (1.30 ± 0.04)  (1.21 ± 0.13)  (1.26 ± 0.20) 
Dia-48D 9.74 ± 0.16 9.95 ± 0.17 9.61 ± 0.12 9.84 ± 0.13 9.44 ± 0.07 
   (0.92 ± 0.06)  (1.00 ± 0.08)  (0.93 ± 0.02)  (0.89 ± 0.06)  (1.01 ± 0.07) 
49A 7.88 ± 0.04 7.61 ± 0.11 6.85 ± 0.14 7.55 ± 0.14 7.69 ± 0.08 
   (0.63 ± 0.12)  (0.88 ± 0.05)  (0.76 ± 0.20)  (0.76 ± 0.43)  (0.78 ± 0.10) 
49B 8.27 ± 0.07 7.60 ± 0.12 7.63 ± 0.11 7.56 ± 0.07 7.85 ± 0.08 
   (0.93 ± 0.23)  (0.85 ± 0.09)  (0.92 ± 0.05)  (1.06 ± 0.18)  (1.02 ± 0.19) 
49C 9.76 ± 0.10 9.18 ± 0.09 9.44 ± 0.06 9.59 ± 0.06 8.83 ± 0.09 
   (1.36 ± 0.15)  (1.17 ± 0.09)  (1.31 ± 0.30)  (1.50 ± 0.36)  (1.31 ± 0.23) 
49D
a) 9.91  9.98  9.96  10.19  9.45 
                 
50D 9.96 ± 0.09 10.17 ± 0.07 9.87 ± 0.07 9.94 ± 0.11 9.52 ± 0.10 
   (1.08 ± 0.05)  (1.03 ± 0.04)  (1.28 ± 0.15)  (1.33 ± 0.31)  (1.36 ± 0.28) 
51D 10.33 ± 0.19 10.70 ± 0.06 10.17 ± 0.04 10.39 ± 0.16 9.61 ± 0.07 
   (0.90 ± 0.10)  (0.99 ± 0.09)  (0.68 ± 0.10)  (0.90 ± 0.08)  (1.02 ± 0.09) 
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Table 4.9 (continued) 
No. M1 M 2 M 3 M 4 M 5 
52 7.86 ± 0.17 7.89 ± 0.05 8.05 ± 0.08 7.95 ± 0.07 7.58 ± 0.08 
   (1.12 ± 0.09)  (1.24 ± 0.13)  (1.13 ± 0.05)  (1.07 ± 0.06)  (1.16 ± 0.07) 
Dia-53 6.36 ± 0.15 6.17 ± 0.20 6.41 ± 0.02 6.44 ± 0.02 6.33 ± 0.03 
   (1.03 ± 0.04)  (0.94 ± 0.06)  (1.08 ± 0.09)  (1.06 ± 0.08)  (1.05 ± 0.08) 
(R)-54 6.01 ± 0.12 5.99 ± 0.18 5.88 ± 0.10 6.01 ± 0.06 5.53 ± 0.08 
   (0.89 ± 0.20)  (1.01 ± 0.16)  (0.97 ± 0.01)  (0.95 ± 0.04)  (0.95 ± 0.10) 
(R)-55 9.47 ± 0.15 9.94 ± 0.10 9.24 ± 0.09 9.33 ± 0.05 8.79 ± 0.07 
   (1.01 ± 0.04)  (1.10 ± 0.06)  (0.96 ± 0.06)  (1.02 ± 0.05)  (1.05 ± 0.13) 
(R)-56 10.11 ± 0.10 10.19 ± 0.04 10.03 ± 0.07 9.82 ± 0.08 9.66 ± 0.02 
   (0.97 ± 0.17)  (0.82 ± 0.08)  (0.84 ± 0.19)  (0.95 ± 0.16)  (0.84 ± 0.28) 
a) Values were measured by K. Kreutzmann (personal communication). 
 
4.5.1 Analogues with a pyrrolidine ring system 
The exchange of a methyl group at the quaternary nitrogen of 43D resulted in the 
racemic compounds Dia-44D - Dia-48D. Neither introducing unsaturated moieties 
Dia-44D, Dia-45D nor saturated Dia-46D or aromatic substituents Dia-47D, Dia-48D 
at this position resulted in a significant change of binding affinities at muscarinic 
receptor subtypes. All compounds showed pKi values between 9.0 - 10.0 and 
displayed no selectivity for any subtype. Data are given in Table 4.9 and illustrated in 
Fig. 4.20 for Dia-44D - Dia-46D and Fig. 4.21 (A) for Dia-47D, Dia-48D.   
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Fig. 4.20 Affinity values (pKi) at M1-5 receptors of racemic compounds Dia-44D - 
Dia-46D containing a pyrrolidine ring and a chiral quaternary nitrogen. 
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Fig. 4.21 Affinity values (pKi) at M1-5 receptors of racemic compounds Dia-47D and 
Dia-48D containing a pyrrolidine ring and an aromatic substituent at the quaternary 
nitrogen (A) and  their chinuclidine congeners 50D and 51D (B). 
 
4.5.2 Compounds with a chinuclidine ring system 
Exchange of the pyrrolidine ring of the parent compound 43 into a chinuclidine ring 
led to the 4 stereoisomers of 49 (49A-D). Binding data are given in Table 4.9 and are 
illustrated in Fig. 4.22. It could be seen that none of the compounds had significant  
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subtype selectivity. The (2’S)-configurated compounds 49A and 49B had an 
approximately 100 - 300-fold decreased affinity in comparison to the (3R, 2’R)-
configurated compound 49D (K. Kreutzmann, personal communication). Only minor 
losses in affinities were found for the (3S, 2’R)-configurated isomer 49C with a 
maximum 6-fold decrease in the case of the M2 subtype. 
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Fig. 4.22 Affinity values (pKi) of 49A-D at M1-5 receptors. 
a) Values were measured by 
K. Kreutzmann (personal communication). 
 
Further on, compounds 50D and 51D were tested, both having an aromatic 
substituent at the quaternary nitrogen of the chinuclidine ring system. Graphs are 
shown in Fig. 4.21 (B) vis-à-vis its pyrrolidine congeners Dia-47D and Dia-48D (Fig. 
4.21 (A)). The highest affinity value in the whole series was measured at the M2 
subtype for 51D (pKi = 10.70). 51D showed slightly higher affinities than 50D at M1-4 
receptors. 50D had affinities comparable to the parent compound 43D, whereas 51D 
was even more potent at the M1,2,4 subtypes (up to 10-fold in case of the M2 subtype).  
 
4.5.3 Dimerised molecules and synthesis precursors 
Compound 52 consists of two molecules 43D linked with a aliphatic spacer. In  52 the 
quaternary nitrogen atoms are additional chiral centres, leading to a total of six 
centres of chirality in this molecule. In our tests a mixture of the resulting 
stereoisomers was used.  Dimerisation led to an approximately 100-fold decrease in 
affinity at all subtypes. Data are given in Table 4.9 and are illustrated in Fig. 4.23.  
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Further on, the affinity data of precursors Dia-53 and (R)-54 are shown. Affinities for 
these precursors were more than three orders of magnitude lower in comparison to 
the parent compound 43D. 
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Fig. 4.23 Affinity values (pKi) at M1-5 receptors of the parent compound 43D, the 
dimerised compound 52 and precursors Dia-53 and (R)-54. 
a) Values were measured 
by K. Kreutzmann (personal communication). 
 
4.5.4 Tiotropium / glycopyrronium hybrids 
The two hybrid molecules of tiotropium and glycopyrronium, (R)-55 and (R)-56, both 
displayed high affinities at muscarinic subtypes in the range of 43D. Data are given in 
Table 4.9 and illustrated in Fig. 4.24. 
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Fig. 4.24 Affinity values (pKi) of tiotropium / glycopyrronium hybrids (R)-55 and 
(R)-56 at M1-5 receptors.   
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4.6 Characterisation of [
3H](3R, 2’R)-glycopyrronium 
A complete characterisation of [
3H](3R, 2’R)-glycopyrronium ([
3H]43D) was 
performed at muscarinic M1-5 receptors. This included saturation, competition and 
kinetic binding experiments.  
 
4.6.1 Saturation binding experiments 
To determine the affinity (KD value) of the labelled compound at M1-5 receptors 
saturation binding experiments were carried out. The calculated KD values obtained 
are given in Table 4.10. Saturation binding isotherms and the corresponding 
Scatchard-plots are given in Fig. 4.25 for M1-3 and in Fig. 4.26 for M4+5. Very high 
affinities (KD) were measured ranging from 216 to 28 pM matching 9.67 - 10.55 as 
logarithmic values. No high selectivity for a special subtype was seen on the basis of 
affinity differences. For all tested subtypes non-specific binding increased linearly 
within the range of the used concentrations of radioligand and specific binding was 
saturable and consistent with a one-site binding model. In addition, Scatchard plots 
were linear  indicating a one-site binding model without co-operativity. 
 
Table 4.10 Equilibrium dissociation constants (KD) of [
3H]43D at hM1-5 receptors and 
the total number of specific binding sites (Bmax) in membranes from stably transfected 
CHO-K1 cells derived from saturation experiments. 
Receptor KD [nM]  pKD B max [fmol/µg protein]
M1  0.028 ± 0.001  10.55 ± 0.02  2.79 ± 0.22 
M2  0.067 ± 0.007  10.17 ± 0.04  0.18 ± 0.01 
M3  0.028 ± 0.003  10.55 ± 0.05  3.26 ± 0.09 
M4  0.033 ± 0.001  10.46 ± 0.01  0.69 ± 0.05 
M5  0.216 ± 0.041    9.67 ± 0.08  0.30 ± 0.02 
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Fig. 4.25 Saturation binding isotherms displaying total (boxes), specific (circles) and 
non-specific binding (triangles) of [
3H]43D to cloned hM1-3 receptors stably expressed 
in CHO-K1 cells and the corresponding Scatchard plots. Data represent one typical 
experiment each. 
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Fig. 4.26 Saturation binding isotherms displaying total (boxes), specific (circles) and 
non-specific binding (triangles) of [
3H]43D to cloned hM4+5 receptors stably 
expressed in CHO-K1 cells and the corresponding Scatchard plots. Data represent 
one typical experiment each. 
 
4.6.2 Competition binding experiments 
For further characterisation of [
3H]43D competition binding experiments were carried 
out. The affinity values (pKi) of examined drugs are given in Table 4.11. The tested 
drugs were spanning an affinity range of approximately four orders of magnitude and 
displayed different selectivity profiles. The obtained values are in good agreement 
with literature data obtained in competition experiments with [
3H]NMS (Dörje et al., 
1991; Böhme et al., 2003; and unpublished data from our laboratory). Examples of 
competition curves recorded with [
3H]43D are shown in Fig. 4.27.  
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Table 4.11 pKi values and Hill coefficients (in parentheses) of reference drugs at 
muscarinic receptor subtypes determined in competition binding experiments with 
[
3H]43D. Hill slopes significantly different from unity are given in grey italics. 
   M1 M 2 M 3 M 4 M 5 
Atropine 8.95 ± 0.08 8.75 ± 0.07 9.03 ± 0.05 9.14 ± 0.07 8.56 ± 0.02
   (0.92 ± 0.02)  (0.93 ± 0.05) (0.97 ± 0.09) (0.96 ± 0.05)  (0.83 ± 0.02)
Himbacine 6.81 ± 0.05 8.20 ± 0.05 6.95 ± 0.04 7.76 ± 0.04 6.08  ± 0.04
   (1.17 ± 0.14)  (0.94 ± 0.04) (1.07 ± 0.02) (1.06 ± 0.12)  (1.02 ± 0.03)
R-Dimethindene 5.94 ± 0.04 6.05 ± 0.04 5.70 ± 0.03 5.72 ± 0.01 5.51 ± 0.04
   (1.17 ± 0.10)  (1.17 ± 0.08) (1.24 ± 0.01) (1.23 ± 0.12)  (1.14 ± 0.01)
S-Dimethindene 6.94 ± 0.04 7.74 ± 0.04 7.10 ± 0.01 6.75 ± 0.06 6.06 ± 0.05
   (1.02 ± 0.05)  (1.08 ± 0.07) (1.10 ± 0.05) (1.10 ± 0.07)  (1.05 ± 0.08)
Pirenzepine 8.14 ± 0.05 6.67 ± 0.05 6.93 ± 0.05 7.57 ± 0.05 6.70 ± 0.04
   (0.82 ± 0.05)  (0.95 ± 0.01) (0.90 ± 0.04) (0.97 ± 0.05)  (0.86 ± 0.03)
HHSiD 7.81 ± 0.03 7.09 ± 0.04 7.99 ± 0.05 7.70 ± 0.03 6.86 ± 0.04
   (1.05 ± 0.01)  (0.90 ± 0.01) (0.90 ± 0.06) (0.96 ± 0.06)  (0.94 ± 0.03)
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Fig. 4.27 Competition curves of the M2 preferring antagonist himbacine at [
3H]43D 
binding sites in membrane preparations from CHO-K1 cells stably expressing hM1-5 
receptors. 
 
As an important experiment competition binding studies were carried out using “cold” 
43D as a competitor for the radiolabelled, “hot” compound [
3H]43D. Data are given in  
Results 
 
 
124 
Table 4.12 and competition curves are shown in Fig. 4.28. The obtained pKi values 
were 2-fold lower at all subtypes compared to the radioligands KD.  
 
Table 4.12 pKi values and Hill coefficients (in parentheses) of 43D at muscarinic 
receptor subtypes determined in competition binding experiments with [
3H]43D. 
   M1 M 2 M 3 M 4 M 5 
43D 10.24 ± 0.09 9.92 ± 0.10 10.25 ± 0.09 10.19 ± 0.08 9.46 ± 0.04
   (1.03 ± 0.10)  (1.03 ± 0.08) (0.99 ± 0.07) (0.97 ± 0.01)  (1.01 ± 0.08)
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Fig. 4.28 Competition curves of 43D versus [
3H]43D in membrane preparations from 
CHO-K1 cells stably expressing hM1-5 receptors. 
 
4.6.3 Kinetic binding experiments  
Association binding experiments were carried out to measure the observed rate 
constant (kobs) and to calculate the association and dissociation rate constant (kon 
and koff). A representative example of a set of association curves for the M5 subtype 
is given in Fig. 4.29. An increase in Bmax values (fitted as plateau of curves at 
equilibrium) can be seen with increasing concentration of radioligand.  One can 
notice that with an increase in radioligand concentration the time needed to reach an 
equilibrium state decreased.  
Results 
 
 
125 
0 20 40 60 80 100 120
0
200
400
600
800
0.07
0.97
0.77
0.58
0.39
0.30
0.21
0.12
[
3H]43D [nM]
time [min]
s
p
e
c
i
f
i
c
 
b
i
n
d
i
n
g
 
[
C
P
M
]
 
Fig. 4.29 Association curves recorded with [
3H]43D at muscarinic M5 receptor stably 
expressed in CHO-K1 cells. 
 
The fitted values for kobs were plotted versus radioligand concentration and a linear 
regression procedure was used to fit a straight line as described in material and 
methods. The slope of the fitted straight line equals the association rate constant 
(kon). The dissociation rate constant (koff) can be taken from the intersection with the 
y-axis. The values derived from Fig. 4.29 are given in Fig. 4.30 as an example. 
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Fig. 4.30 Linear regression of observed rate constant values (kobs) versus radioligand 
concentration recorded with [
3H]43D at muscarinic M5 receptor stably expressed in 
CHO-K1 cells.  
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To ensure validity of kinetic data, dissociation binding experiments were additionally 
conducted at the M1 and M2 subtype. Fig. 4.31 gives an example of a dissociation 
experiment carried out at the M2 subtype. 
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Fig. 4.31 Dissociation curve of [
3H]43D recorded at muscarinic M2 receptors stably 
expressed in CHO-K1 cells. Dissociation was initiated by addition of 1 µm atropine. 
 
A summary of all kinetic data is presented in Table 4.13. Association rate constant 
(kon), dissociation rate constant (koff) and the corresponding dissociation half lives 
(t1/2) are given. In addition the kinetic KD (kinKD) was calculated as described in 
materials and methods. 
  
Table 4.13 Kinetic constants (kon, koff), the derived dissociation half lives (t1/2) and 
kinetic KD values of [
3H]43D at muscarinic receptor subtypes determined in kinetic 
binding experiments in membrane preparations of CHO-K1 cells stably expressing 
hM1-5 receptors. 
   M1 M 2 M 3 M 4 M 5 
kon [nM
-1min
-1]  0.337 ± 0.099  0.464 ± 0.093 0.160 ± 0.012 0.229 ± 0.022  0.032 ± 0.009
koff [min
-1]  0.010 ± 0.001  0.030 ± 0.004 0.005 ± 0.002 0.009 ± 0.002  0.007 ± 0.002
t1/2 [min]  71  23 145 77 100 
kinKD [nM]  0.029 ± 0.003  0.065 ± 0.009 0.031 ± 0.013 0.040 ± 0.011  0.240 ± 0.137
- log(kinKD)  10.54 ± 0.05  10.19 ± 0.06  10.55 ± 0.22  10.41 ± 0.13  9.66 ± 0.24  
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Bar graphs showing the determined association rate constant (kon) at M1-5 are given 
in Fig. 4.32. Calculated dissociation rate constants (koff) are displayed in Fig. 4.33 
(A), the corresponding dissociation half lives in Fig. 4.33 (B). The shortest 
dissociation half live was obtained at the M2 subtype with 23 min and the longest t1/2 
at M3 with 145 min. This equals a more than 6-fold slower dissociation at M3 in 
comparison to M2. 
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Fig. 4.32 Association rate constants (kon) of [
3H]43D determined in kinetic binding 
experiments at hM1-5 receptors stably expressed in CHO-K1 cells. 
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Fig. 4.33 Dissociation rate constants (koff) of [
3H]43D (A) and corresponding 
dissociation half lives (t1/2) (B) determined in kinetic binding experiments at hM1-5 
receptors stably expressed in CHO-K1 cells.  
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4.7 M2-selective antagonists related to dimethinende 
 
Table 4.14 gives the affinity values (pKi) for compounds 57 - 83 at hM1-5 and hH1 
receptors. 
  
Table 4.14 pKi values and Hill coefficients (in parentheses) of dimethindene (57A) 
and its analogues 57B - 83 determined in radioligand binding studies at hM1-5 and 
hH1 receptors. Hill slopes significantly different from unity are given in grey italics. 
No. M1 M 2 M 3 M 4 M 5 H 1 
(±)-57A 6.43 ± 0.03 7.25 ± 0.03 6.58 ± 0.04 6.26 ± 0.05 5.98 ± 0.02 9.16 ± 0.12
   (1.04 ± 0.02) (0.98 ± 0.04)  (0.98 ± 0.07) (1.02 ± 0.05) (0.97 ± 0.06)  (1.07 ± 0.05)
(+)-57A 6.72 ± 0.05 7.52 ± 0.05 6.86 ± 0.01 6.53 ± 0.05 6.12 ± 0.03 7.16 ± 0.06
   (0.93 ± 0.02) (1.00 ± 0.04)  (1.02 ± 0.01) (0.99 ± 0.03) (1.02 ± 0.05)  (1.04 ± 0.15)
(-)-57A 5.73 ± 0.03 5.91 ± 0.05 5.47 ± 0.04 5.41 ± 0.01 5.57 ± 0.03 9.36 ± 0.14
   (1.01 ± 0.03) (1.01 ± 0.04)  (1.05 ± 0.07) (0.99 ± 0.09) (0.99 ± 0.03)  (1.14 ± 0.24)
57B
a)  7.46 7.91 7.50 7.01 7.06  7.54 ± 0.03
                  (0.84 ± 0.23)
58A
a)  6.06 6.84 5.74 6.00 5.66  8.35 ± 0.08
                  (0.96 ± 0.10)
58B
a)  6.64 7.29 6.13 6.22 5.95  7.90 ± 0.05
                  (1.00 ± 0.08)
59A
a)  6.35 7.35 6.02 6.34 5.68  7.67 ± 0.07
                  (1.04 ± 0.04)
59B 6.66 ± 0.03 8.00 ± 0.02 6.54 ± 0.01 6.95 ± 0.08 6.38 ± 0.01 8.20 ± 0.09
   (1.00 ± 0.07) (1.01 ± 0.08)  (1.01 ± 0.09) (1.00 ± 0.05) (0.96 ± 0.10)  (0.99 ± 0.12)
60A
a)  5.72 6.07 5.75 5.72 5.63  8.08 ± 0.06
                  (0.95 ± 0.03)
60B 5.88 ± 0.05 6.96 ± 0.06 5.50 ± 0.02 5.89 ± 0.05 5.44 ± 0.08 7.81 ± 0.06
   (0.98 ± 0.04) (1.06 ± 0.18)  (0.94 ± 0.02) (0.98 ± 0.01) (1.08 ± 0.10)  (0.91 ± 0.11)
61A
a)  5.36 5.84 5.56 5.38 5.57  7.91 ± 0.05
         (1.09  ±  0.04)
61B 5.08 ± 0.01 6.71 ± 0.09 5.24 ± 0.09 5.50 ± 0.02 < 4.5  6.31 ± 0.03
   (0.98 ± 0.03) (1.04 ± 0.03)  (1.14 ± 0.22) (1.04 ± 0.07)    (1.15 ± 0.12)
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Table 4.14 (continued) 
No. M1 M 2 M 3 M 4 M 5 H 1 
62B 5.01 ± 0.09 5.99 ± 0.04 4.88 ± 0.06 5.12 ± 0.05 5.37 ± 0.10 6.17 ± 0.03
   (0.80 ± 0.27) (0.98 ± 0.11)  (1.01 ± 0.05) (0.99 ± 0.05) (1.00 ± 0.06)  (1.21 ± 0.36)
63B 6.00 ± 0.52 5.97 ± 0.70 5.68 ± 0.61 5.71 ± 0.79 5.40 ± 0.49 6.49 ± 0.08
   (1.09 ± 0.28) (1.28 ± 0.25)  (1.18 ± 0.15) (1.16 ± 0.05) (1.04 ± 0.05)  (0.98 ± 0.04)
64A 5.61 ± 0.07 5.79 ± 0.08 5.26 ± 0.06 5.51 ± 0.09 5.25 ± 0.06 8.48 ± 0.10
   (0.92 ± 0.08) (0.68 ± 0.10)  (1.07 ± 0.13) (0.96 ± 0.03) (1.16 ± 0.09)  (0.98 ± 0.17)
64B 5.68 ± 0.09 6.80 ± 0.04 5.37 ± 0.04 5.74 ± 0.10 5.17 ± 0.05 6.36 ± 0.03
   (0.93 ± 0.04) (0.98 ± 0.02)  (1.00 ± 0.08) (1.02 ± 0.02) (1.12 ± 0.13)  (1.12 ± 0.17)
65B 5.20 ± 0.09 6.13 ± 0.06 5.23 ± 0.04 5.86 ± 0.06 5.10 ± 0.05 5.56 ± 0.10
   (0.83 ± 0.07) (0.68 ± 0.09)  (0.93 ± 0.31) (0.66 ± 0.05) (0.85 ± 0.07)  (0.93 ± 0.14)
66B 6.19 ± 0.06 7.11 ± 0.09 5.94 ± 0.01 6.39 ± 0.05 5.44 ± 0.06 5.63 ± 0.07
   (1.04 ± 0.02) (0.95 ± 0.04)  (1.11 ± 0.10) (1.15 ± 0.08) (1.05 ± 0.04)  (0.99 ± 0.09)
67B 5.89 ± 0.22 5.66 ± 0.11 5.50 ± 0.23 5.97 ± 0.14 5.22 ± 0.20 <  4.5 
   (0.83 ± 0.17) (0.67 ± 0.30)  (0.92 ± 0.03) (0.63 ± 0.26) (0.96 ± 0.01)    
68B 5.54 ± 0.21 5.77 ± 0.21 5.34 ± 0.27 5.44 ± 0.28 5.34 ± 0.29 <  4.5 
   (0.79 ± 0.23) (0.88 ± 0.23)  (1.10 ± 0.12) (1.02 ± 0.10) (1.22 ± 0.17)    
69B <  4.5  4.80 ± 0.37  < 4.5  < 4.5  < 4.5  < 4.5 
      (0.93 ± 0.12)             
70B 5.68 ± 0.13 6.14 ± 0.08 6.00 ± 0.05 5.80 ± 0.14 5.37 ± 0.08 6.46 ± 0.10
   (0.97 ± 0.06) (1.04 ± 0.07)  (1.10 ± 0.04) (0.86 ± 0.04) (1.05 ± 0.02)  (1.18 ± 0.06)
71B 6.27 ± 0.13 7.57 ± 0.02 6.36 ± 0.05 6.71 ± 0.05 6.05 ± 0.05 6.30 ± 0.04
   (1.01 ± 0.09) (0.95 ± 0.12)  (1.01 ± 0.07) (1.01 ± 0.02) (1.07 ± 0.05)  (1.05 ± 0.05)
(±)-72B 6.51 ± 0.08 8.47 ± 0.13 6.29 ± 0.03 6.77 ± 0.03 6.40 ± 0.05 5.30 ± 0.04
   (0.95 ± 0.03) (0.88 ± 0.08)  (1.05 ± 0.01) (1.19 ± 0.10) (1.03 ± 0.06)  (1.46 ± 0.08)
(+)-72B 6.69 ± 0.11 8.59 ± 0.10 6.58 ± 0.00 7.10 ± 0.10 6.51 ± 0.07 5.46 ± 0.02
   (1.08 ± 0.06) (0.78 ± 0.24)  (1.06 ± 0.02) (0.92 ± 0.04) (0.97 ± 0.04)  (1.03 ± 0.06)
(-)-72B 6.21 ± 0.10 7.33 ± 0.08 6.29 ± 0.09 6.34 ± 0.04 5.73 ± 0.07 6.13 ± 0.04
   (0.95 ± 0.06) (0.73 ± 0.29)  (1.03 ± 0.10) (1.03 ± 0.12) (1.15 ± 0.14)  (1.04 ± 0.04)
73B 6.34 ± 0.08 7.57 ± 0.16 6.34 ± 0.04 6.86 ± 0.08 5.92 ± 0.13 5.09 ± 0.09
   (1.03 ± 0.06) (1.00 ± 0.39)  (1.02 ± 0.05) (1.04 ± 0.06) (1.00 ± 0.03)  (0.89 ± 0.12)
74B <  4.5  5.22 ± 0.10 <  4.5 4.55 ± 0.04 < 4.5  < 4.5 
      (1.03 ± 0.22)     (1.09 ± 0.44)      
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Table 4.14 (continued) 
No. M1 M 2 M 3 M 4 M 5 H 1 
(±)-75A
a)  6.13 7.60 5.65 6.13 5.66  6.96 ± 0.04
                  (0.99 ± 0.02)
(+)-75A
a)  5.23 6.24 4.68 5.26 5.29  6.93 ± 0.07
                  (0.98 ± 0.05)
(-)-75A
a)  5.81 7.37 5.39 5.75 4.93  5.79 ± 0.03
                  (0.93 ± 0.09)
76B 5.84 ± 0.06 6.76 ± 0.05 5.65 ± 0.08 6.03 ± 0.08 5.20 ± 0.04 5.69 ± 0.04
   (1.05 ± 0.03) (1.04 ± 0.06)  (0.96 ± 0.20) (0.95 ± 0.14) (1.01 ± 0.05)  (0.93 ± 0.12)
77B 6.84 ± 0.07 7.82 ± 0.20 6.53 ± 0.03 7.14 ± 0.05 6.17 ± 0.10 5.85 ± 0.05
   (0.98 ± 0.06) (1.01 ± 0.09)  (0.99 ± 0.06) (1.01 ± 0.06) (1.02 ± 0.01)  (1.11 ± 0.07)
78B 6.42 ± 0.04 7.99 ± 0.13 6.10 ± 0.02 6.71 ± 0.05 6.12 ± 0.05 5.72 ± 0.09
   (1.02 ± 0.04) (0.87 ± 0.15)  (1.02 ± 0.07) (1.05 ± 0.07) (1.38 ± 0.12)  (1.30 ± 0.28)
79B 6.86 ± 0.10 8.22 ± 0.04 6.60 ± 0.10 7.24 ± 0.05 6.14 ± 0.11 5.35 ± 0.07
   (1.21 ± 0.16) (0.76 ± 0.18)  (1.08 ± 0.16) (1.00 ± 0.11) (1.00 ± 0.09)  (1.09 ± 0.11)
80B 6.63 ± 0.07 7.61± 0.06 6.29 ± 0.03 6.85 ± 0.06 6.07 ± 0.05 6.14 ± 0.06
   (1.33 ± 0.11) (1.05 ± 0.06)  (1.53 ± 0.22) (1.41 ± 0.05) (1.41 ± 0.14)  (1.18 ± 0.14)
81B 6.98 ± 0.04 7.68 ± 0.04 6.70 ± 0.06 7.27 ± 0.03 6.16 ± 0.09 5.66 ± 0.05
   (1.15 ± 0.09) (0.99 ± 0.06)  (0.99 ± 0.06) (1.04 ± 0.01) (1.10 ± 0.11)  (0.97 ± 0.06)
82B 6.67 ± 0.06 7.96 ± 0.14 6.49 ± 0.01 7.00 ± 0.07 6.52 ± 0.03 5.66 ± 0.01
   (1.01 ± 0.05) (0.98 ± 0.15)  (1.04 ± 0.00) (1.05 ± 0.02) (1.24 ± 0.12)  (1.00 ± 0.05)
83B 6.78 ± 0.05 7.53 ± 0.10 6.48 ± 0.03 7.08 ± 0.05 6.17 ± 0.03 5.70 ± 0.03
   (1.08 ± 0.03) (1.06 ± 0.39)  (1.03 ± 0.01) (1.03 ± 0.01) (1.03 ± 0.02)  (1.02 ± 0.02)
a) Data at muscarinic receptor subtypes measured by Dr. C. Keim and  K. 
Kreutzmann (Böhme et al., 2003).
 
 
4.7.1 Compounds with modifications in side chain length and amino 
moiety 
Several pairs of compounds were tested with reduced side chain length (n=1) in 
comparison to their congeners with a two carbon side chain (n=2). Compounds 
57A/B and 58A/B served as starting points. We saw increased affinities at 
muscarinic receptor subtypes and at the same time reduced affinty at H1 receptors 
for compounds with n=1. Data are given in Table 4.14. Bar graphs showing affinities  
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for compounds 57A/B - 59A/B are given in Fig. 4.34 (A + B). Changes resulting from 
reduction of chain length are shown in Fig. 4.34 (C). The most difficult problem in 
former studies was to increase absolute affinity at muscarinic M2 subtypes. To find 
out whether the findings with at 57A/B and 58A/B were a coincidence or a “rule”, we 
synthesised several other derivatives with reduced chain length (n=1). In the case of 
the parent compound 57A reduction of chain length to 57B led to an increase of 
approximately one order of magnitude at muscarinic receptor subtypes and to a 42-
fold reduced affinity at H1. A 3-fold increase was found for compounds 58A/B and 
also a less pronounced reduction at H1 (3-fold). For analogues 59A/B an increase in 
affinity at M1-5 and H1 was observed. For compounds 57A/B - 59A/B an increase in 
affinity at muscarinic receptors was found at all subtypes. 59B conserved the subtype 
selectivity found for 59A and displayed 11-fold selectivity for M2 but with higher 
affinity (pKi = 8.00 and 7.35, respectively). A problem was the even higher H1 affinity.  
 
Additional derivatives were examined. Fig. 4.35 gives the affinity data for 60A/B, 
61A/B, displaying cyclic amino moieties and 64A/B with an aromatic substituent. 
Interestingly, for these compounds a pronounced increase in affinity at muscarinic 
receptor subtypes was only found for M2 (8-, 7-, 10-fold, respectively). At the same 
time, H1 affinity was reduced for 60A/B (2-fold),  61A/B (40-fold) and drastically 
reduced for 64A/B (132-fold). Reducing side chain length resulted in compounds 
displaying good subtype selectivity (at least 12-, 16-, 11-fold) in favour for the M2 
subtype. However, absolute affinities were not sufficiently high (pKi = 6.96, 6.71 and 
6.80, respectively). For 61B and 64B, M2 affinity was a little higher than at H1. 
Compounds 62B and 63B showed low affinities (pKi < 6.0) at M1-5 and poor (4-fold) 
or no subtype selectivity. Additionally, H1 affinities were higher than at M2 (Fig. 4.36).  
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Fig. 4.34 Affinity values (pKi) of compounds with modifications in the amino moiety 
and with differing side chain length; compounds 57A - 59A with n=2 (A), 57B - 59B 
with n=1 (B) and comparison of resulting changes in affinities (C) at M1-5 and H1 
receptors. 
a) Data at muscarinic receptor subtypes taken from Böhme et al. (2003). 
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Fig. 4.35 Affinity values (pKi) of compounds with modifications in the amino moiety 
and with differing side chain length; compounds 60A, 61A and 64A with n=2 (A), 
60B, 61B and 64B with n=1 (B) and comparison of resulting changes in affinities (C) 
at M1-5 and H1 receptors. 
a) Data at muscarinic receptor subtypes taken from Böhme 
et al. (2003). 
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Fig. 4.36 Affinity values (pKi) of compounds 62B and 63B (n=1) and modifications in 
the amino moiety at M1-5 and H1 receptors. 
 
Taken together, it was shown that in all cases affinity to muscarinic receptor subtypes 
was improved by reducing side chain length (in cases of 60A/B, 61A/B and 64A/B, 
this gain in affinity was exclusively found at M2) and simultaneously (with exception of 
59A/B) a decrease in H1 affinity was achieved. Therefore, synthesis was 
concentrated on compounds with reduced side chain length. 
 
4.7.2 Compounds with a benzyl or phenylethyl substituent at the 
basic nitrogen 
Several analogues with reduced side chain length were synthesised with a benzyl or 
phenylethyl group affixed at the basic nitrogen. It was found that the phenylethyl- 
substituted compounds 70B, 72B, 74B had higher affinities at muscarinic receptor 
subtypes in comparison to their benzyl congeners 65B, 66B, 69B (see Fig. 4.37). 
The ispopropyl group in 72B was found as an optimum, as minor changes in this part 
of the molecule resulted in decreased affinity and selectivity (compared to 70B, 71B, 
73B, 74B; see Fig. 4.37 (B) and Fig. 4.38). 
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Fig. 4.37 Affinity values (pKi) of compounds with a benzyl substituent (65B, 66B, 69B 
(A)), or a phenylethyl substituent (70B,  72B,  74B ( B)) at the amino moiety and 
comparison of resulting changes in affinities (C) at M1-5 and H1 receptors.  
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Fig. 4.38 Affinity values (pKi) of compounds with a benzyl (68B) or a phenylethyl 
substituent (71B and 73B) in the amino moiety at M1-5 and H1 receptors. 
 
4.7.3 Pure enantiomers 
The parent compound 57A, the diisopropyl congener 75A and the most interesting 
compound of our new series, 72B, were isolated as pure enantiomers. Binding data 
of enantiomers are given in Table 4.14. Affinity data for (±)-57A and its enantiomers 
(Fig. 4.39) were in good agreement with those published (Böhme et al., 2003). For 
this and the following two figures the eutomer at muscarinic receptor subtypes is 
shown to the left of the racemic mixture (middle), the distomer on the right hand side. 
(±)-57A showed only little subtype selectivity for M2 (5-fold to 19-fold) and a 81-fold 
higher affinity to H1 (pKi = 9.16). As previously shown in literature (see also 5.4.3.5), 
inverse stereoselectivity was found concerning M1-5 and H1 subtypes, respectively. 
(+)-57A was the eutomer at muscarinic receptor subtypes with an approximately 2-
fold higher affinity at muscarinic receptor subtypes and a 100-fold lower affinity at H1 
receptors than the racemate. (-)-57A is the distomer at M1-5, but the eutomer at H1. 
Taken together, (+)-57A has a 5 - 25-fold selectivity for M2 receptors, but only a 2-
fold specificity, as far as H1 receptors are concerned. 
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Fig. 4.39 Affinity values (pKi) of (±)-57A and its enantiomers at M1-5 and H1 receptors.  
 
Previous SAR studies in our laboratory were done in order to increase selectivity,  
specifity and absolute affinity at M2 receptors. We found compound (±)-75A to 
possess better selectivity and specificity than the parent compound (±)-57A. The 
eutomer at M1-5,  (-)-75A, had good M2 selectivity (36 - 275-fold) and a 38-fold 
specificity versus H1 (Fig. 4.40). Racemic (±)-75A and both enantiomers were 
M2-selective compounds. However, the absolute affinity at M2 was not increased in 
comparison to (+)-57A (pKi = 7.37 and 7.52, respectively). 
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Fig. 4.40 Affinity values (pKi) of (±)-75A and its enantiomers at hM1-5 and hH1 
receptors. 
a) Data taken from Böhme et al. (2003).  
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As shown in Fig. 4.37, we found (±)-72B to possess high affinity at M2 (pKi = 8.47), 
comparable selectivity to (-)-75A and improved specificity. Fig. 4.41 summarizes the 
binding data for the tested enantiomers. (+)-72B was the eutomer at M1-5. It is a 
highly potent M2 antagonist displaying good selectivity M2/M1: 79-fold; M2/M3: 
102-fold; M2/M4: 31-fold; M2/M5: 120-fold and very high specificity M2/H1 1349-fold. 
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Fig. 4.41 Affinity values (pKi) of (±)-72B and its enantiomers at M1-5 and H1 receptors. 
 
4.7.4 Compounds related to 72B 
(+)-72B seems to have good binding characteristics to quantify M2 receptors in AD 
patients with PET. Additional derivatives of 72B were synthesised to find a congener 
displaying comparable binding data with an appropriate substituent for radioactive 
labelling. Usually an 
18F or 
11C atom is inserted into a molecule for PET-studies. 
Exchanging the isopropyl group of 72B by a fluoroethyl group led to 76B. Introducing 
a methyl group in para-position of the phenylethyl substituent of 72B resulted in 77B. 
Binding data for compounds 76B and 77B are given in Table 4.14, and are illustrated 
in Fig. 4.42. Even the minor changes from 72B    76B resulted in a dramatic 
decrease in affinity at muscarinic receptor subtypes (51-fold at M2). Insertion of a 
para-methyl group (72B  77B) led to a 4-fold decrease in affinity at M2 (pKi = 7.82). 
As the other subtypes showed a less pronounced decrease in affinity by methyl-
substitution, subtype selectivity was decreased (M2/M4: 5-fold).  
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Fig. 4.42 Affinity values (pKi) of 76B and 77B at M1-5 and H1 receptors. 
 
4.7.5 Compounds related to 72B with meta- or para-substituents at 
the phenylethyl group 
Additional derivatives closely related to 72B with a substituent in meta- or para-
position of the aromatic ring at the phenylethyl group were tested. 78B and 79B had 
a methoxy group, 80B and 81B a chlorine atom, 82B and 83B a fluorine atom. Data 
are given in Table 4.14. Fig. 4.43 (A) shows binding data for compounds with a meta-
substituent, Fig. 4.43 (C) for the para-congeners, and Fig. 4.43 (B) a comparison of 
these regioisomers. 78B showed good affinity at M2 (pKi = 7.99) and sufficient 
selectivity (at least 19-fold M2/M4) and specificity (186-fold M2/H1). The para-
substituted congener 79B had a 2-fold higher affinity at M2 (pKi = 8.22), but reduced 
selectivity (10-fold M2/M4), whereas specificity was increased (741-fold M2/H1). The 
chlorine derivatives 80B and 81B had lower affinities at M2 (pKi = 7.61 and 7.68, 
respectively), lower selectivity (6-fold and 3-fold M2/M4), but good specificity (30-fold 
and 105-fold M2/H1). Concerning 82B, a good M2 affinity was seen (pKi = 7.96), 9-fold 
selectivity M2/M4, and 200-fold specificity (M2/H1). The para-substituted congener 
83B had worse characteristics with 3-fold reduced affinity at M2 receptors (pKi = 
7.53), low selectivity (3-fold M2/M4) and lower specificity (68-fold M2/H1). Taken 
together, no clear relationship was observed for a preferred site of substitution 
concerning absolute affinity at M2 as the pKi value was increased (78B    79B), 
remained unchanged (80B  81B) or was diminished (82B  83B). Concerning  
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muscarinic receptor subtype selectivity, the meta-substituted derivatives showed 
better results. All compounds had sufficient specificity for M2 versus H1 receptors (at 
least 30-fold for 80B).  
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Fig. 4.43 Affinity values (pKi) of compounds related to 72B with substituents in meta-
position (78B, 80B, 82B (A)) or para-position (79B, 81B, 83B (B)) at the phenylethyl 
group and comparison of resulting changes in affinities (C) at M1-5 and H1 receptors. 
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5.1 General considerations 
As shown for all used assays in the Results chapter (4.1), obtained KD values for the 
various radioligands and pKi values of reference drugs were in good agreement with 
literature data. Hill coefficients of competition curves were in most cases not 
significantly different from unity, consistent with a pure competitive inhibition 
according to a one-site binding model and the law of mass action.  
 
5.2 Analogues of ondansetron at 5-HT3 receptors 
It was more than a decade ago when ondansetron (1) was characterised as an 
antiemetic drug in animal studies (Stables et al., 1987) and its pharmacological 
properties were described in various functional animal models at 5-HT3  receptors 
(Butler et al., 1988). Ondansetron was launched to the market in 1990 by Glaxo, 
followed by granisetron in 1991 by Smith Kline Beecham and tropisetron by Sandoz 
in 1992 (Gaster and King, 1997). Since then more than 30 compounds were and still 
are under clinical research. Many clinical trials were stopped because no effective 
therapeutic benefit was found next to anti-emesis, providing enough cashflow to 
compensate development costs. With irritable bowel syndrom as a new therapeutic 
aim, research got more interesting lately. 1 was extensively used in SAR research to 
find new 5-HT3 antagonists. This work led to alosetron which is closely related to 1 
(Fig. 1.12). Currently, ramosetron, which also is a congener of 1, is under clinical 
evaluation with affinity to 5-HT3 receptors in picomolar range (Rabasseda, 2002). The 
introduction of 5-HT3 antagonists can be considered as a mile stone in cancer 
therapy. With this new class of drugs new, more effective therapeutic options 
became possible in cancer therapy, which formerly were not tolerated in human 
patients due to severe side effects, especially massive vomiting and nausea. A good 
control of acute vomiting can be achieved using the 5-HT3 antagonists actually 
approved. However, these drugs are less effective in prevention of delayed sickness. 
Ramosetron was recently shown to have prolonged efficacy in prevention of 
vomiting. The question of side effects was lately raised for several 5-HT3 antagonists, 
which are in general believed to be a very save class of drugs (Keefe, 2002). As a 
matter of fact, latest analyses showed cardiac side effects (elongation of QT-interval)  
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to be more frequently in dolasetron therapy in comparison to granisetron and 
ondansetron. Ondansetron was reported to cause more CNS side effects (Goodin 
and Cunningham, 2002). As patents for the older drugs are running out in the next 
years and new therapeutic targets for 5-HT3 antagonists are under research, new 
compounds are still of interest. 
 
5.2.1 Influence of substitution pattern at the imidazole moiety 
In SAR research done at Glaxo it was found that the unsubstituted indole congener 
of ondansetron (1) had strong interactions with CYP450 enzymes (Oxford et al., 
1992). Introducing substituents at position 2 or 4 of the imidazole ring reduced this 
interaction and increased affinity to 5-HT3 receptors. Smaller substituents were found 
to result in higher affinities in a series of indole congeners with an optimum for a 
methyl substituent in position 2 ( ondansetron 1). Incorporating the side chain of 1 
into a tetrahydrocarbazolone system, led to increased oral activity. In our studies with 
analogues of 1 at 5-HT3A receptors we found the derivative 2A with a methyl group at 
position 4 to be slightly more potent than the parent compound with a methyl group in 
position 2 (pKi = 9.05 and 8.83, respectively). This is in contrast to the findings  with 
the indole congeners of Glaxo (Oxford et al., 1992), where findings were vice versa 
for the preferred substitution pattern (data at rat vagus nerve pA2 = 8.0 and 7.4 for 
substituents in 2 and 4 position, respectively). Compounds with substituents at 
position 5 (“B”-series; Table 4.6) were less potent than analogues with substitution at 
position 4 (“A”-series) up to 51-fold for 4A/B. Similar results were obtained in 
functional studies in guinea-pig ileum. With increasing size of substituent, affinity 
decreased exemplified for compounds 2A - 6A in Fig. 5.1 (A). It was very interesting 
to notice that the ratio of binding affinity at h5-HT3A and guinea-pig iIeum functional 
values decreased with increasing size of the substituent, shown in Fig. 5.1 (B). One 
can speculate that the substitution pattern at the imidazole moiety is more critical at 
h5-HT3A than at gp-5HT3 receptors, as bulky substituents were better tolerated in 
guinea-pig iIeum. Similar findings were obtained for compounds 7 - 10 with 
substituents at position 2. Increasing size of the substituents decreased affinities in 
agreement with the findings at Glaxo (Oxford et al., 1992). Fig. 5.2 (A) gives the 
affinities of compounds 1 and 7 - 10 next to the ratios of binding data and functional 
data (B). The methyl group of the parent compound was an optimum as affinities  
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decreased 4-fold, 9-fold, 25-fold and >  21380-fold 1    7 - 10, respectively. With 
increasing size of substituents ratios decreased, as seen already for compounds 
2A/B - 6A/B. 
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Fig. 5.1 Affinities of compounds 2A - 6A with different substituents at position 4 of 
the imidazole ring at h-5HT3A (A) and ratios of binding and functional data (B). 
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Fig. 5.2 Affinities of compounds 1 and 7 - 10 with different substituents at position 2 
of the imidazole ring at h-5HT3A (A) and ratios of binding and functional data (B). 
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5.2.2 Effect of quaternization 
N-Methylation of the unsubstituted imidazole ring at position 3 led to compound 11. A 
19-fold reduction in affinity was seen compared to 1. Almost the same affinities were 
found for 1 and its N-methylated derivative in tests at rat vagus nerve carried out at 
Glaxo with pA2 = 8.6 and 8.4 (Oxford et al., 1992), leading to the theory that the 
imidazole ring might be protonated in the binding interaction with the receptor. 
However, other studies showed different effects for N-methylation depending on the 
structure of the free base. Cases with no changes in affinities as well as 277-fold 
reduced affinities caused by N-methylation were reported (Cappelli et al., 2002). 
 
5.2.3 Stereochemical aspects 
In our series only one pair of enantiomers was tested (+/-)-14 and a stereoselectivity 
ratio of 26 was calculated. The influence of stereochemistry seems to be strictly 
related to the structure of the molecule. Almost identical values were measured for 
the enantiomers of 1 in functional (Butler et al., 1988) and binding studies (Kilpatrick 
et al., 1987). In another study, there was no difference in affinity for some pairs of 
enantiomers and for other compounds stereoselectivity ratios of 100 were found 
depending on size and shape of the basic centre (Cappelli et al., 2002). In one study 
inverse stereoselectivity was found at 5-HT3 and D2 receptors and compounds with 
high specificity for 5-HT3 and D2 receptors were obtained by investigating pure 
enantiomers (Hirokawa et al., 2002). 
 
5.2.4 Compounds related to ketanserin 
Compounds  13 - 15 were hybrids of ketanserin, a highly potent reference 5-HT2 
antagonist, and ondansetron. Compounds (+/-)-14 had the amino moiety of 
ketanserin and the tetrahydrocarbazolone moiety of ondansetron, whereas 13 lacked 
the substituent attached to the piperidine ring. Higher affinities at recombinant 5-HT3A 
receptors were found for 13 compared to functional 5-HT2 data at rat tail artery (pki = 
8.16 and pA2 = 5.98) (Elz and Heil, 1995). Interestingly, the complete ketanserin 
residue in (+)-14 and (-)-14 generated the inverse result (pKi = 5.00, 6.41 and pA2 = 
7.19 and 9.36) with much higher affinities at 5-HT2 receptors, showing this part of the  
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molecule to be of special interest to obtain compounds with high affinities to either 5-
HT2 or 5-HT3 receptors. Further increase of the substituent in 15 led to total loss of 
affinity at 5-HT3A in contrast to 5-HT2 receptors. 
 
5.2.5 Receptor diversity and species differences 
In an early stage of research for 5-HT3 antagonists, pronounced differences were 
found concerning the pharmacological properties of tested compounds in different 
functional animal models and binding studies. Some of the most prominent 
discrepancies were found in test at guinea-pig ileum in comparison to studies at rat 
vagus nerve (Butler et al., 1990), especially in agonist characteristics. Additionally, 
electrophysiological data revealed heterogeneity in different tissues with unequal 
electrophysiological properties of the measured single ion channels (Peters et al., 
1992). A lot of speculation about different subtypes and species variations were 
proposed. Facts were not clarified before cloning techniques came up to solve these 
questions. First cloning of a 5-HT3 receptor subunit was reported from NCB20 cells 
(mouse neuroblastoma x chinese hamster embryonic brain cells) (Maricq et al., 
1991). Since than, several splice variants and additional subtypes were identified in 
several species. 
 
5.2.5.1 5-HT3 splice variants 
For several laboratory animals 5-HT3 receptors were cloned in the last 10 years, e.g. 
mouse (Hope et al., 1993; Werner et al., 1994), rat (Miquel et al., 1995), and finally 
guinea-pig (Lankiewicz et al., 1998). Two splice variants were identified differing in 5 
or 6 amino acids, termed 5-HT3AS (short) and 5-HT3AL (long) for each species. The 
human 5-HT3 receptor cDNA was isolated and showed 85% and 84% identity to 
mouse and rat, respectively (Miyake et al., 1995). Two additional splice variants were 
reported for the h5-HT3A receptor (Brüss et al., 2000b), a truncated form 5-HT3AT and 
a longer variant 5-HT3AL. Splice variants of animals and humans do not correspond. 
This was clarified by mapping of the mouse and human 5-HT3A gene structures 
(Werner et al., 1994; Brüss et al., 2000b). Pharmacological characterisation of the 
human splice variants expressed in HEK293 cells showed that non of the splice 
isoforms formed a functional channel alone but modified channel properties when  
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they were coexpressed with h5-HT3A. Binding studies showed no differences for 
[
3H]GR65630 binding affinity at cells with additionally expressed splices variants. 
However, electrophysiological studies showed some parameters to be modified 
(Brüss et al., 2000a) when splice variants were coexpressed. 
Taken together, splice variants of 5-HT3 subunits were found in rodents and man, but 
they did not correspond to each other. Receptor diversity due to splice variants was 
only of minor relevance for pharmacological properties and not sufficient to explain 
former discrepancies (Fletcher and Barnes, 1998; Peters et al., 1992). As some 
findings were still not explainable, the search for further subunits continued. Good 
reasons for the existence of further subunits came from purification studies of pig 
5-HT3 receptors, finding other proteins attached to the receptor in addition to the 
5-HT3A subunit (Fletcher and Barnes, 1998). 
 
5.2.5.2 5-HT3 receptor subunits 
Another 5-HT3 receptor subunit, 5-HT3B, was identified in human (Davies et al., 1999; 
Dubin et al., 1999), mouse and rat tissue (Hanna et al., 2000). Studies showed that 
the 5-HT3B subunit was not able to assemble to functional channels alone but 
modified electrophysiological properties, when it was coexpressed with the 5-HT3A 
subunit. Distribution studies in rat showed both subunits in the peripheral nervous 
system (PNS) but only the 5-HT3A subunit in the CNS. In the PNS more neurons 
expressing the A than the B subunit were detected. 90% of cells containing the B 
subunit coexpressed the A subunit. In human tissues actually no direct prove for the 
abundance of the B subunit was shown. RT-PCR studies (Davies et al., 1999) and 
northern blot analysis detected the B subunit in several human tissues in CNS and 
PNS. However, PCR studies were shown to be critical, because the protein might not 
be produced even though PCR studies amplified the mRNA transcript (Stewart et al., 
2003). Up to now, one can not say for sure whether 5-HT3B is expressed in human 
brain (van Hooft and Yakel, 2003). With the identification of this second subunit some 
differences in channel conductance that were found between native neurons and cell 
lines (Hussy et al., 1994) could be explained (Hanna et al., 2000). In rodents and 
humans, heteromeric channels possess higher single channel conductances than 
homomeric channels. The question of physiological relevance remains still unclear, 
as in a lately published study the pharmacological profile for homomeric A and  
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heteromeric A/B channels was shown to be almost identical (Brady et al., 2001) and 
the proposal was made that rather the biophysical properties of the channels were 
changed. The relevance of assembly with subunits of other receptor families, e.g. 
subunits of nACh receptors (van Hooft and Yakel, 2003), needs further evaluation. 
Recently, h5-HT3C (Dubin et al., 2001), h5-HT3D and h5-HT3E subunits were cloned 
and the gene structures were identified (Niesler et al., 2003). Comparison of the 
distribution pattern of all known subtypes with RT-PCR technique showed the A, B 
and C subunit to be widely expressed, whereas the D subunit was only found in 
kidney, colon and liver. mRNA of the E subunit was even more restricted and only 
detected in colon and small intestine (Niesler et al., 2003). It is very likely that 
heteromeric receptors are built and contribute to receptor heterogeneity in humans. 
Further studies are needed providing direct evidence for distribution of the described 
subtypes. The physiological role of receptor diversity remains to be elucidated, too. 
 
5.2.6 Correlation of binding and functional data 
We observed marked differences between binding data at h5-HT3A and functional 
data at native gp5-HT3 in guinea-pig ileum. Fig. 5.3 gives a comparison of affinity 
data for some reference drugs obtained in the most important animal models (RVN, 
GPI) and in binding studies at cloned human, rat and guinea-pig 5-HT3A receptors. It 
can be clearly seen that binding data at rat and human receptors are identical to 
functional studies in rat vagus nerve. Functional data in guinea-pig ileum and binding 
affinity at cloned gp5-HT3 receptors were comparable, too, whereas pronounced 
differences were seen in comparison to human and rat data.  
 
In our series of compounds, no clear relationship was found between binding affinity 
to h5-HT3A and functional data at native gp5-HT3 receptors, as binding experiments 
resulted in higher, equal or lower affinities. Fig. 5.4 shows a correlation of binding 
and functional data. It can be concluded that data obtained in studies with gp5-HT3 
receptors are not suitable for the development of new drugs in humans (Lankiewicz 
et al., 1998) and are of little predictive power with regard to the relevance in human 
tissues. 5-HT3 receptors of human and guinea-pig can be considered as true species 
orthologues. 
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Fig. 5.3 Comparison of affinities of some reference drugs in various 5-HT3 models. 
Binding data at human, rat and guinea-pig receptors and functional data at rat vagus 
nerve (RVN) and guinea-pig ileum (GPI) are shown. 
a) Kilpatrick et al., 1987; 
b)Oxford 
et al., 1992; 
c)Kilpatrick et al., 1990a; 
d) Butler et al., 1988; 
e)Richardson et al., 1985; 
f) 
Sanger and Nelson, 1989; 
g) Lankiewicz et al., 1998. n.d. = not determined. 
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Fig. 5.4 Correlation of binding data at h5-HT3A and functional data obtained in 
guinea-pig ileum for analogues of ondansetron. When affinities lay below detection 
level, the detection minimum was used as given in Table 4.6.  
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5.3 Compounds related to metoclopramide at 5-HT4 
receptors 
Metoclopramide as a starting point in research for prokinetic drugs had only low 
affinity to 5-HT4 receptors (pKi = 6.0 in binding studies in rat brain) and displayed 
partial agonism. Additional studies at 5-HT3 and D2 receptors revealed comparable 
affinities at these subtypes (pKi = 6.4 and 6.5, respectively) (Yang et al., 1996). Many 
structural variations were carried out to find more potent derivatives with high 
specificity and selectivity in favour of the 5-HT4 subtype. In 1991, the ester-congener 
of metoclopramide, SDZ205-557 (19), was shown to be more potent at 5-HT4 
receptors with pA2 = 7.4 in guinea-pig ileum (Buchheit et al., 1991, 1992). However, 
only 3-fold selectivity was shown versus 5-HT3 in binding studies (pKi = 6.9) (Eglen et 
al., 1993a). With discovery of GR113808 as a highly potent and selective 5-HT4 
antagonist and radioactive labelling of this compound (Gale et al., 1994; Langlois et 
al., 1994) a new era started, using this newly available pharmacological tool for fast 
screenings (Grossman et al., 1993). In our study we evaluated the binding affinities 
of compounds related to 19 and compared the data with previously obtained data in 
functional 5-HT4 models in guinea-pig ileum and rat oesophagus. Several studies on 
esters derived from their benzamide congeners were carried out (Elz and Keller, 
1995; Yang et al., 1997). They confirmed the findings of metoclopramide and 19 that 
the esters had increased affinities at 5-HT4 receptors. For the benzamide congener of 
the carboxylic acid ester ML10302 (22), an approximately 100-fold lower affinity was 
found (Yang et al., 1997). 
 
5.3.1 Substitutions in the side chain 
In our studies, the introduction of methyl groups in the side chain resulted in 
dramatically decreased affinities in compounds with acyclic amino moieties (19  
(±)-20 (56-fold), 19  (±)-21 (12-fold) and 22  (+)-23 (13-fold)). The position next to 
the ester group seems to be more critical for substitution, as the decrease was more 
pronounced in (±)-20 in comparison to substitution at the next chain carbon atom at 
(±)-21 and (+)-23. This is in good agreement with literature in studies with 
conformationally fixed substituents in the side chain (Yang et al., 1996). 
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5.3.2 Influence of the piperidine ring 
Insertion of the basic nitrogen in a piperidine ring system (19    22 (ML10302)) 
resulted in a 3-fold increase in affinity (pKi = 7.83 and 8.37, respectively). The same 
affinity for 22 was found in other binding studies, too (Yang et al., 1997). This 
compound displayed good selectivity versus 5-HT3 (pA2 = 5.9 in guinea-pig ileum) 
and possessed partial agonism in 5-HT4 receptor studies in rat oesophagus and 
guinea-pig ileum (Elz and Keller, 1995). Studies (Yang et al., 1997) showed that 
introduction of substituents at the piperidine ring system was tolerated. Most of these 
analogues were partial agonists. Interestingly, the 3, 5-dimethyl derivatives behaved 
as full antagonists. Introduction of a bulky substituent (22    (±)-26) was well 
tolerated (pKi = 8.43). The congener missing the ketone oxygen of (±)-26 was found 
to have comparable affinity of pKi = 8.1 (Yang et al., 1997). Thus the ketone 
functionality was not relevant for binding. 
 
5.3.3 Modification of chain length 
We tested two series of compounds with modification of chain length (Fig. 4.13 and 
Fig. 4.14). Compounds 22,  24 and 25 had an unsubstituted piperidine ring and 
elongated side chain length with 2, 3 and 4 carbon atoms. Additionally, compounds 
27 - 29 with a benzyl substituted piperazine moiety were investigated. In the case of 
the analogues with a piperidine ring system elongation from 2 to 3 carbon atoms led 
to a decreased affinity (22  24 (10-fold)). Elongation to 4 atoms (24  25) resulted 
in a further 8-fold decrease in affinity. Comparable decreases in affinity were seen in 
guinea-pig ileum (13-fold and 2-fold). Functional data for the 5-HT4 antagonist 24 
(RS23597-190) were in agreement with literature data (Eglen et al., 1993b). 24 was 
shown to be highly selective versus 5-HT3 receptors in binding studies (pKi = 5.7; 
Eglen et al., 1993b). Interestingly, findings were very different for the piperazine 
derivatives. Elongation of the side chain from 2 to 3 carbon atoms (27  28) resulted 
in a 2-fold increase in affinity. Further elongation to 4 atoms (28  29) did not induce 
significant changes in affinity. It was surprising to find the phenyl congener 30 to be 
43-fold more potent than the benzyl analogue 27 (pKi = 8.28 and 6.65). Comparable 
affinities for 30 were found in literature (Curtet et al., 2000). Our findings indicate that 
the influence of side chain length on binding affinity depends on the structure of the  
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amino moiety, as different results were obtained for piperidine and piperazine 
derivatives. Different lengths of the spacer between the hydrogen bond acceptor (the 
carbonyl carbon atom) and the basic nitrogen atom are tolerated: Spacer with four 
bonds (e.g. in 19) up to 6 bonds (e.g. GR113808) resulted in potent compounds 
(Langlois and Fischmeister, 2003). In comparison to 30, analogues with heteroaryl 
substituents (pyrimidine, pyrazine, pyridazine and pyridine) were shown to be more 
potent with pKi values of approximately 9.0 (Curtet et al., 2000). Reduction of chain 
length to only one carbon atom was reported to result in decreased affinities in a set 
of pyrrolizidine analogues (Eglen, 1998). 
 
5.3.4 Stereochemical aspects 
We tested one pair of enantiomers ((+/-)-23) in this series. In functional studies, a 
stereoselectivity ratio of 2 was calculated, whereas a factor of 8 was calculated by 
using data obtained in binding experiments. For several other compounds related to 
metoclopramide low stereoselectivity was reported at 5-HT4 receptors. This includes 
rencapride (no stereoselectivity) and zacopride (factor 4) (Yang et al., 1997) with a 
centre of chirality in the basic amino moiety. These results indicate this molecule part 
to be not critical for binding affinity at 5-HT4 receptors. This hypothesis is supported 
as bulky substituents at the basic nitrogen moiety are tolerated and resulted in highly 
potent compounds (Langlois and Fischmeister, 2003). Taken together, the influence 
of stereochemistry depends strongly on the size and shape of the basic moiety. 
 
5.3.5 Comparison of pharmacophores at 5-HT3 and 5-HT4 receptors 
Both receptors share some general properties with regard of the pharmacophores of 
compounds of the benzoate type. An aromatic ring with a coplanar attached acceptor 
group for hydrogen bonding is necessary as well as a basic nitrogen moiety. At the 
5-HT4 receptor, an oxygen atom next to the hydrogen bond acceptor group is needed 
for most reported structures. A major difference was found for the size of the basic 
centre. Bulky substituents are not tolerated at the binding site of 5-HT3 receptors, 
whereas 5-HT4 receptors can fit voluminous groups. Usually benzoate compounds 
are antagonists at 5-HT3 receptors. At 5-HT4 receptors agonists, partial agonists and  
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antagonists were found. Minor changes were sometimes sufficient to convert a partial 
agonist into an antagonist. 
 
5.3.6 Receptor diversity and distribution pattern 
Cloning techniques brought up several splice variants of the 5-HT4 receptor. In the 
following chapter the current knowledge is summarised and the implications for 
receptor diversity are discussed. 
 
5.3.6.1 Splice  variants 
For h5-HT4 receptors several splice variants were cloned and characterised: 
h5-HT4(a) (Blondel et al., 1997; Claeysen et al., 1997), h5-HT4(b) (Van den Wyngaert 
et al., 1997), h5-HT4(c) (Blondel et al., 1998), h5-HT4(d) (Blondel et al., 1998; Mialet et 
al., 2000b) and h5-HT4(e) (Mialet et al., 2000a), which was later renamed h5-HT4(g) 
when the gene structure was discovered (Bender et al., 2000). All these splice 
variants are identical up to amino acid 358 and differ only in the intracellular 
C-terminus. Lately, another short splice variant lacking the C-terminus was cloned 
and named h5-HT4(n) because “non” of the known C-termini is expressed (Vilaro et 
al., 2002). In contrast to these splicing sites one splice variant resulting in an 
insertion in the second extracellular loop named h5-HT4(h) was reported, which can 
be combined with all the other splice variants at the C-terminus (Bender et al., 2000). 
This splice variant was cloned together with the C-terminus of h5-HT4(b) resulting in 
h5-HT4(hb). With regard to the h5-HT4 receptor gene structure, eight splice variants, 
h5-HT4(a-g) and h5-HT4(n), concerning the C-terminus were found and one additional 
splicing site at the extracellular domain 2, named h5-HT4(h), resulting in 16 possible 
splice variants. For rat, r5-HT4(a), r5-HT4(b) (Gerald et al., 1995) and r5-HT4(e) 
(Claeysen et al., 1999) were cloned. For mouse, m5-HT4(a), m5-HT4(b) (Claeysen et 
al., 1996), m5-HT4(e) and m5-HT4(f) were cloned (Claeysen et al., 1999). 
All splice variants display similar pharmacological profiles concerning binding 
affinities of most compounds (Curtet et al., 2000; Langlois and Fischmeister, 2003). 
This is not surprising, as most splice variants display exactly the same membrane 
topology differing only at the intracellular C-terminus. Differences were found for 
agonist potencies and constitutive activity. At h5-HT4(d) the reference antagonist  
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RS39604 behaved as a partial agonist and rencapride acted as full agonist instead of 
a partial agonist (Mialet et al., 2000b). For h5-HT4(n) (Vilaro et al., 2002) and 
h5-HT4(e), now termed h5-HT4(g) (Mialet et al., 2000a), the reference antagonist 
GR113808 was found to be an inverse agonist. At h5-HT4(hb) GR113808 was shown 
to possess partial agonism (Bender et al., 2000). The physiological relevance of 
these findings is doubtful as different cell lines were used and direct comparability is 
not possible. Further research showed some physiological implications of the 
different splice variants. It was shown that h-5HT4(b), but not h-5HT4(a), had the 
possibility to interact with Gi/o in addition to the well known interaction with Gs (Pindon 
et al., 2002). Studies showed that alternative splicing of the C-terminus results in 
modulation of constitutive activity. Regulation of basal activity was shown to be 
influenced by agonist-dependent receptor palmitoylation (Ponimaskin et al., 2002). In 
addition, an important role concerning receptor desensitisation was found for the C-
terminus and influence of PK-A was shown (Mialet et al., 2003). It is likely that 
receptor fine tuning is regulated by different expression of splice variants, resulting in 
subtle modifications of basal activity and desensitisation characteristics. 
 
5.3.6.2 Tissue  distribution 
Several studies were performed in the hope to find discrete expression for some 
splice variants of the 5-HT4 receptor in the CNS, peripheral nervous system (PNS) or 
a single organ. Hopes were disappointed when several studies showed a very 
complex expression pattern of subtypes with no subtype being exclusively expressed 
in a single region. On the other hand no tissue was found expressing only one 
subtype (Vilaro et al., 2002; Bach et al., 2001; Medhurst et al., 2001). It is important 
to note that all these studies were RT-PCR studies. Up to now no direct evidence 
concerning the expression pattern of the single subtypes is available. One study 
reported a quantitative mRNA analysis in several tissues for five splice isoforms 
(Medhurst et al., 2001). From mRNA analysis it was concluded that the most 
abundant receptor is  h5-HT4(b). This mRNA subtype was widely distributed in CNS 
and PNS. High mRNA levels were found in various regions of the CNS for the a, b, c 
and g splice variants. The h5-HT4(d) subtype was only found in the small intestine at 
low levels. This study provided indirect evidence for expression of 5-HT4 receptors at  
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higher levels in small intestine and uterus. Lower levels of mRNA were found in 
heart, testis, stomach and other tissues. 
 
5.3.7 Correlation of binding and functional data 
With the cloning of 5-HT4 receptors from rodents direct comparison to human 
receptors became possible. No pharmacological differences were seen between 
r5-HT4(a) and h5-HT4(a) receptors. Similar findings were reported for binding studies at 
h5-HT4(b), guinea-pig brain preparation and a subtype of rat (Van den Wyngaert et al., 
1997). Data obtained in functional 5-HT4 studies in guinea-pig ileum and rat 
oesophagus showed very good correlation (Elz and Keller, 1995). Fig. 5.5 gives a 
comparison of binding studies at h5-HT4(b) and guinea-pig brain and functional data 
at guinea-pig ileum and rat oesophagus for some reference compounds. Very good 
correlation can be seen for functional and binding data obtained at human, rat and 
guinea-pig receptors.  
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Fig. 5.5 Comparison of affinities of some reference drugs in various 5-HT4 models. 
Binding data at human and guinea-pig and functional data at guinea-pig ileum (GPI) 
and rat oesophagus (ROS) are shown. 
a) Gale et al., 1994 - functional data were 
obtained in guinea-pig colon; 
b) Grossman et al., 1993; 
c) Hegde et al., 1995; 
d) Elz 
and Keller, 1995; 
e) Van den Wyngaert et al., 1997. 
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Fig. 5.6 gives a correlation of binding data at h5-HT4(b) with functional data obtained 
in guinea-pig ileum. In contrast to 5-HT3 receptors (Fig. 5.4) a good correlation was 
seen between human and guinea-pig data. It can be concluded that 5-HT4 receptors 
of human, guinea-pig and rat are true species homologues and data obtained in one 
of these species, as well in binding studies as in functional studies, are of good 
predictive power for relevance in human clinical studies. 
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Fig. 5.6 Correlation of binding data obtained at h5-HT4(b) and functional data obtained 
in guinea-pig ileum (GPI) for analogues of metoclopramide. Values for 25 were 
omitted as the compound was not completely dissolved. 
 
5.3.8 Therapeutic implications 
Only tegaserod has reached the marked in the last years as a compound with partial 
agonism at 5-HT4 receptors for use in C-IBS. Studies on IBS led to a more precise 
understanding of the role of 5-HT receptors in human GIT. 5-HT3 and 5-HT4 
receptors were found on excitatory cholinergic neurons in the plexus myentericus. In 
addition, 5-HT4 receptors are located on inhibitory nitrergic neurons (Camilleri, 2001). 
Thus, serotonergic receptors are an interesting therapeutic target for therapy of 
gastrointestinal disorders, especially in IBS. In the last years an increasing body of 
evidence for the influence of 5-HT4 receptors in memory and cognitive performance 
came up. It was shown that 5-HT4 receptors are involved in cholinergic transmission  
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in the brain (Matsumoto et al., 2001) and enhance the release of non-amyloidogenic 
sAPPα  in CHO cells. Another report described 5-HT4 receptor density to be 
unchanged in cortex of AD patients (Lai et al., 2003). Good results were obtained in 
reversal of a scopolamine-induced cognitive deficit in rats with partial 5-HT4 agonists 
(Moser et al., 2002; Lelong et al., 2003). It is also noteworthy, that the combination of 
two per se ineffective doses of an AChE inhibitor and a 5-HT4 partial agonist resulted 
in enhanced cognitive performance in rats (Lamirault et al., 2003). This might be a 
new therapeutic approach in cognitive disorders with reduced side effects due to 
lower doses of the administered drugs. Further use for 5-HT4 partial agonists may be 
in voiding disorders associated with detrusor hypocontractility (Tonini and Candura, 
1996). 5-HT4 antagonists may be of interest as antiarrhythmic drugs inhibiting atrial 
flutter and fibrillation (Kaumann, 1994).  
 
Actually no information is available concerning the specific role of different isoforms 
of 5-HT4 receptors and their role in pathological conditions. Further direct prove for 
the distribution of the isoforms is needed. It will be a major future task to develop new 
compounds with selectivity for a single splice variant. 
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5.4 Analogues of McN-A-343 
McN-A-343 (31) and its derivatives were extensively investigated in SAR studies at 
muscarinic receptor subtypes (Lambrecht et al., 1986, 1993, 1995; Moser et al., 
1993, 1995; Keim, 2000) since first reports about 31 were given to act as a 
muscarinic ganglionic stimulant (Roszkowski, 1961). Studies showed 31 t o  b e  a  
functional selective agonist at muscarinic M1 receptors with antagonistic or low partial 
agonist properties at M2 and M3 subtypes (Lambrecht et al., 1993). Insertion of the 
basic nitrogen into a pyrrolidine ring system, introducing a C1-methyl substituent and 
changes in substitution pattern at the aromatic ring resulted in increased affinity at M1 
receptors (Lambrecht et al., 1995). Increasing the substituent at C1 via ethyl to 
phenyl resulted in increased affinities at M1. However, these compounds were no 
longer agonists but full antagonists. 
In comparison to the effects at muscarinic receptor subtypes only little is known 
about SAR at other receptors such as 5-HT3, 5-HT4 and H1. 31 was reported to be a 
weak antagonist at 5-HT3 and 5-HT4 receptors in the range of its affinity at muscarinic 
receptor subtypes (Sagrada et al., 1994). In our study we investigated several 
analogues of 31 at 5-HT3, 5-HT4 and H1 receptors. 
 
5.4.1 Studies at 5-HT3 receptors 
In functional studies at rat cervical ganglion and in binding studies with NG108-15 
cells, low affinities for 31 were reported  at 5-HT3 receptors (pA2 = 4.9, pKi = 5.3). 
Affinities in binding experiments at M1, M2 and M3 in tissue preparations were found to 
be in the same range with pKi = 5.3, 5.2, 4.9, respectively (Sagrada et al., 1994). Our 
studies confirmed these findings at h5-HT3A receptors (pKi = 4.96). In our screening 
experiments many compounds were tested in one point screening experiments with a 
concentration of the cold competitor of 10
-5 M. When no noteworthy inhibition was 
found (inhibition of specific binding < 40%, what is comparable to a pKi of 
approximately 5.0) no complete competition curves were recorded to reduce costs.  
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5.4.1.1  Modifications at the aromatic ring 
Changing the substitution pattern from m-Cl into p-F (31  32, 32
+) led to reduced 
affinities (16% and 10% inhibition, respectively). This is in contrast to muscarinic 
receptor subtypes where p-substitution with several halogens was shown to increase 
affinities (Moser et al., 1993). Further more, compounds with acyclic amino moieties 
and a phenyl substituent at C1 were tested. (R)-33
+ with no substituent at the 
aromatic ring was found to be the most potent compound in this series (pKi = 5.74) in 
contrast to its enantiomer (10% inhibition) and the related tertiary congeners (almost 
no inhibition). Introduction of an o-phenyl ring ((R/S)-33, (R/S)-33
+  (±)-34, (±)-34
+) 
resulted in comparable affinities. (±)-34
+ was equipotent in comparison to the 
eutomer  (R)-33
+ (pKi = 5.58 and 5.74, respectively), whereas (±)-34 had no 
detectable affinity. Insertion of the basic nitrogen in a pyrrolidine ring system and 
increase of the aromatic ring to a naphthyl moiety in (±)-40, (±)-40
+ led to affinities 
comparable to that of the parent compound (pKi = 4.90 and 4.81, respectively). 
Replacing the aromatic ring  with a diphenyl-methyl group ((±)-41, (±)-41
+) showed a 
3-fold increase in affinity for the tertiary compound (pKi = 5.45) and a slightly 
decreased affinity for the quaternary congener (32% inhibition). These findings at 5-
HT3 receptors are in contrast to those reported for muscarinic receptor subtypes, 
where introduction of bulky aromatic substituents resulted in pronounced losses in 
affinity (Keim, 2000 and K. Kreutzmann, personal communications). At the 5-HT3 
subtype, bulky substituents are tolerated in this position without pronounced losses in 
affinity. The exchange of a hydrogen into a fluorine atom  ((R/S)-37, (R/S)-37
+     
(R/S)-36, (R/S)-36
+) was found to be without effect on binding affinities (inhibition for 
all compounds between 18 - 32%). 
 
5.4.1.2  Compounds with a pyrrolidine ring and C1-substituents 
A series of compounds with the basic nitrogen inserted into a pyrrolidine ring system 
were evaluated. Compounds had C1-substituents of increasing size and a 4-F 
substitution at the aromatic ring. No change in binding affinities at 5-HT3A receptors 
could be seen for different C1-substituents in compounds (R/S)-35, (R/S)-35
+, (R/S)-
36, (R/S)-36
+,  (R/S)-37, (R/S)-37
+  (methyl, phenyl and 4-F-phenyl substituents, 
respectively). Non of these compounds inhibited more than 32% of specific binding. 
A 2-fold increase in affinity was measured for (±)-39 and (±)-39
+ (pKi = 5.25 and 5.22)  
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with a bulky 1-naphthyl substituent attached to the side chain. This clearly 
demonstrates this molecule part to be of little importance for 5-HT3 affinity in contrast 
to muscarinic receptor subtypes, where dramatic changes were observed through 
modification of the C1-substituent (Keim, 2000 and K. Kreuzmann, personal 
communication). A direct comparison of the compounds (R/S)-33, (R/S)-33
+ with an 
acyclic amino moiety with its pyrrolidine congeners, (R/S)-37 and (R/S)-37
+, showed 
a decrease of approximately one order of magnitude in affinity compared to the 
quaternary eutomer (R)-33
+. All compounds with a pyrrolidine ring were less potent 
than the parent compound 31 unless a bulky substituent was introduced at C1, in 
(±)-39 and (±)-39
+, or as the aromatic system at the carbamate nitrogen ((±)-40, (±)-
40
+ and (±)-41
+). 
 
5.4.1.3 Ester  analogues 
Compounds (±)-42 and (±)-42
+  showed slightly higher affinities than their carbamate 
congeners (±)-36 and (±)-36
+. Affinity of (±)-42 was comparable to that of the parent 
compound 31 (pKi = 4.96 and 5.08, respectively). Thus, exchange of the carbamate 
moiety into a carboxylic acid ester function was of little influence at 5-HT3 receptors. 
This is in contrast to findings at muscarinic receptor subtypes, where affinity was 
drastically reduced (Keim, 2000). 
 
5.4.1.4  Effects of quaternization 
No clear relationship concerning the effect of N-methylation was found at 5-HT3 
receptors. Quaternary compounds possess higher, equal or lower affinities compared 
to their tertiary congeners. (R)-33
+ and (±)-34
+  showed higher affinities than the 
tertiary congeners (>  17-fold and >  12-fold). Comparable affinities were found for 
most tertiary and quaternary molecules with exception of (±)-41, where the tertiary 
compound was more potent. No clear structural relationship was seen. At muscarinic 
receptor subtypes some quaternary analogues were reported to be more potent than 
their tertiary congeners (Lambrecht et al., 1993, Moser et al., 1995). As ACh, the 
endogenous ligand, is a permanently charged molecule this is not very surprising.   
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5.4.1.5 Stereochemical  aspects 
Within the examined compounds several were tested as pure enantiomers. Most 
compounds showed little or no affinity to 5-HT3 receptors. Only in the case of (R)-33
+ 
a stereoselectivity ratio of approximately 10 was found, whereas no stereoselectivity 
was found for the other compounds.  
 
5.4.2 Studies at 5-HT4 receptors 
Binding studies in pig brain tissue preparations and functional studies in rat 
oesophagus revealed considerable affinity of McN-A-343 (31) at 5-HT4 receptors (pKi 
= 5.9 and pA2 = 6.2) (Sagrada et al., 1994). We were able to confirm these results in 
binding studies at h5-HT4(b) receptors (pKi = 5.73). All tested analogues showed 
lower affinity at 5-HT4 receptors compared to the parent compound. 
 
5.4.2.1  Modifications of McN-A-343 
Exchanging the m-Cl into a p-F substituent (31  32) resulted in a 10-fold decrease 
in affinity (pKi = 5.73 and 4.70, respectively). This decrease was more pronounced 
than at h5-HT3A receptors. Removal of the fluorine substituent and attachment of a 
C1-phenyl-substituent (32  (R/S)-33 and (R/S)-33
+) did not result in a change in 
affinity in contrast to 5-HT3A receptors. Insertion of the basic nitrogen atom into a 
pyrrolidine ring and adding a C1-methyl-substituent (32  (R/S)-35 and (R/S)-35
+) 
resulted in slightly increased affinities. Exchanging the C1-methyl-substituent into a 
phenyl ring ((R/S)-35,  (R/S)-35
+    (R/S)-36,  (R/S)-36
+) was tolerated without 
changes in affinity. It is concluded that a C1-substituent is not critical for binding at 5-
HT4(b) what is in good agreement with our findings at 5-HT3A receptors. It is likely that 
the pyrrolidine ring is responsible for the observed small increase in affinity at 5-
HT4(b). This is in contrast to our findings at 5-HT3A receptors, where most pyrrolidine 
compounds possess lower affinity compared to the congengers with acyclic amino 
moieties. However, this is in good agreement with our findings with analogues of 
metoclopramide at 5-HT4 receptors (5.3.2). As no tested derivative reached the 
affinity of the parent compound 31 it is concluded that the substitution pattern at the 
aromatic ring is the most critical part of the molecule concerning 5-HT4 affinity.  
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5.4.2.2  Stereochemical aspects and influence of quaternization 
As already mentioned in the results chapter, only a very weak tendency could be 
observed concerning stereoselectivity in favour to the (R)-configurated enantiomers. 
No clear tendency to higher binding affinities for tertiary or quaternary compounds 
was found for the charged or the uncharged molecules. 
 
5.4.2.3  Proposal of a new 5-HT4 ligand related to McN-A-343 
Literature reports highly potent 5-HT4 antagonists with phenylcarbamate structures 
(Eglen, 1998). These molecules have substituents in ortho-position of the aromatic 
ring as an important structural feature (Soulier et al., 1997). SAR work on 
phenylcarbamate analogues of metoclopramide showed compounds with piperidine 
ring systems to be most potent. A substituent in position 2 of the aromatic ring is 
necessary, whereas substituents in position 4 and 5 were dispensible in two SAR 
studies (Soulier et al., 1997; Oxford, 1993). Based on our findings and on literature 
data we propose a hybrid molecule consisting of either parts of metoclopramide and 
McN-A-343 as a new lead structure. Attachment of a methoxy substituent in position 
2 might result in more potent compounds. Hybrid molecules consisting of a modified 
aromatic part of metoclopramide and the carbamate moiety attached to a butyne 
spacer of 31 (Fig. 5.7) might be a very unusual molecular structures for drugs with 
affinity at 5-HT3 and 5-HT4 receptors. For the basic amino group, a cis-3,5-dimethyl-
piperidinyl ring was shown to be an optimum in other series of phenylcarbamates 
(Soulier et al., 1997). Substituents next to the ester group were reducing binding 
affinities in our series of metoclopramide analogues. Hence a hybrid molecule 
without a C1-substituent is most likely to be a potent 5-HT4 ligand.  
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Fig. 5.7 Proposal of a new class of 5-HT4 ligands based on the molecular structures 
of metoclopramide (MCP) and McN-A-343. 
 
5.4.3 Studies at H1 receptors 
Compounds acting as antagonists at H1 receptors are known for a long time. Up to 
now many new drugs were developed making the class of H1 antagonists a complex 
mixture of chemical structures. However, analogues of McN-A-343 show a very 
unusual chemical structure for compounds of this pharmacological class and were 
therefore interesting to examine. 
 
5.4.3.1  Influence of the amino moiety 
For all tested compounds with acyclic amino moieties only low affinities were found 
with the highest values obtained for (R)-33 (pKi = 5.43). As shown in the results 
chapter, the direct comparison of compounds 33 and 37, differing only in the amino 
moiety, showed pronounced higher affinities for the congener with a pyrrolidine ring  
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system (37). Size and shape of the amino moiety was an important feature for affinity  
to H1 receptors. 
 
5.4.3.2  Influence of C1-substituents 
Modifications of size of the C1-substituent lead to a noticeable change in affinity. The 
optimum was found for a 4-F-phenyl substituent in (±)-38 (pKi = 6.98). Bulkier or 
smaller substituents led to lower affinities in comparison to (±)-38. Size and shape of 
the C1-substituent was a second important feature affecting affinity to H1 receptors in 
this series.  
 
5.4.3.3  Influence of the aromatic ring systems 
Several modifications concerning the aromatic ring were introduced in 31. Changing 
the substitution pattern from m-Cl to p-F (31  32, 32
+) led to no change in affinity. 
Both drugs had no detectable affinity to H1 receptors. Concerning the C1-phenyl 
substituted analogues one should notice that introduction of a comparable bulky o-
phenyl substituent at the aromatic ring ((±)-34) resulted in an only 5-fold decrease in 
affinity in comparison to the unsubstituted eutomer (R)-33 (pKi = 4.75 and 5.43, 
respectively). A comparable 5-fold decrease in affinity was found for the naphthyl 
analogue (±)-40 in comparison to its phenyl congener eutomer (R)-37 (pKi = 6.12 and 
6.72, respectively). It is noteworthy that the analogue (±)-41 with a diphenyl-methyl 
group as an aromatic residue displayed unchanged affinity (pKi  = 6.74). Size and 
shape of the aromatic ring was less critical for H1 affinity in our series of compounds 
compared to the amino moiety and the C1-substituent. Major changes at this part of 
the molecules resulted in only small changes in affinity. 
 
5.4.3.4  Ester analogues and quaternization 
Exchange of the carbamate moiety into an ester group (36    42) resulted in 
unchanged affinities. Thus, it is concluded that neither the carbamate structure was 
essential for H1 affinity in our series nor was this a critical part in the molecule 
concerning interactions with the H1 receptor. For all tested compounds, tertiary 
compounds displayed higher affinity values in comparison to their N-methylated,  
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quaternary congeners. This effect ranged from a 2-fold (in the case of (±)-34 and 
(±)-40) to a maximum of 15-fold (found for (S)-37 and (S)-37
+) higher affinities in 
favour to the tertiary compounds. 
 
5.4.3.5 Stereochemical  aspects 
The (R)-configurated analogues were more potent at H1 receptors than their (S)- 
configurated isomers. This was most prominent for (R/S)-36
+ and (R/S)-37
+ with a 
stereoselectivity ratio of factor 35. Previous binding studies at muscarinic receptor 
subtypes carried out in our laboratory by Dr. C. Keim (2000) had shown the inverse 
situation at mACh receptors. The (S)-configurated compounds were more potent 
than their enantiomers at M1-5 receptors. For the enantiomers of analogues 33, 33
+, 
36, 36
+, 37 and 37
+ a direct comparison was done between H1 and M1 affinities and 
stereoselectivity ratios were calculated (Table 5.1). High binding affinities, up to 
picomolar range (pKi = 9.4), were measured at M1 receptors (Keim, 2000). Fig. 5.8 
gives the affinities for the stereoisomers of 33 and 33
+ at H1 and M1 receptors. 
Inverse stereoselectivity concerning H1 and M1 receptors can be seen at 33 and 33
+. 
The (R)-configurated enantiomers were the eutomers at H1 receptors, whereas the 
(S)-configurated isomers were the eutomers at M1 receptors.  
 
Table 5.1 Stereoselectivity ratios for binding data of analogues of 31 at M1 and H1 
receptors. These values are the antilogs of the differences between respective pKi 
values (pKi-(S) minus pKi-(R)). 
Compound  stereoselectivity 
ratio M1 
stereoselectivity 
ratio H1 
(S) / (R)-33  85 0.3 
(S) / (R)-33
+  59 <  0.5 
(S) / (R)-36  158 0.1 
(S) / (R)-36
+  138 0.03 
(S) / (R)-37  1660 0.09 
(S) / (R)-37
+  78 <  0.03 
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Fig. 5.8 Binding affinities of the stereoisomers of 33 and 33
+ at H1 and M1 receptors. 
M1 binding data were measured by Dr. C. Keim in our laboratory (Keim, 2000). 
 
In Fig. 5.9 (A) and (B) the binding affinities of the closely related compounds 36 and 
37 are shown. Comparison of 36 and 37 showed the F  H exchange to be 
bioisoster at M1  and H1 subtypes as binding data were almost identical. Inverse 
stereoselectivity concerning H1 and M1 receptors can be seen for 36, 36
+, 37 and 
37
+, but even more pronounced in comparison to 33 and 33
+. The (R)-configurated 
enantiomers were the eutomers at H1 receptors, whereas the (S)-configurated 
isomers were the eutomers at M1 receptors. It is interesting to note, that (S)-37, 
which is the eutomer at M1 receptors, is a highly potent M1 antagonist with 5248-fold 
specificity versus the H1 subtype, whereas (R)-37, which is the eutomer at H1 
receptors, is a H1 antagonist with 3-fold specificity versus the M1 subtype. 
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Fig. 5.9 Binding affinities of the stereoisomers of 36, 36
+ (A) and 37, 37
+ (B) at H1 
and M1 receptors. M1 binding data were measured by Dr. C. Keim in our laboratory 
(Keim, 2000). 
 
Inverse stereoselectivity concerning H1 and M1 receptors has been reported in 
literature for several other compounds. In a series of compounds related to the H1 
antagonist ebastine, inverse stereoselectivity was shown, although to a much lesser 
extend as in our series (Zhang et al., 1994). Comparable findings were accounted for 
3-methoxy-cyproheptadine in in vivo experiments (Remy et al., 1977). 
Stereoselectivity ratios comparable to those found for our compounds were 
described for a congener of diphenhydramine (123 and 0.4 at M1 and H1 receptors) in 
functional studies (Rekker et al., 1971). Very high inverse stereoselectivity was 
reported for a set of benzothiazepinone derivatives (3981 and 0.16 at M1 and H1, 
respectively; Eltze et al., 1989). Finally, reports were given concerning inverse 
stereoselecivity for dimethindene enantiomers (Pfaff et al., 1995) in functional and 
binding studies at native receptors. This was confirmed in binding studies at hM1-5 
and hH1 receptors stably expressed in CHO-K1 cells (Böhme et al., 2003). Further 
studies on derivatives of dimethindene were part of this work and will be discussed 
later.  
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It can be summarised that inverse stereoselectivity between H1 and M1 receptors is 
not a single phenomenon but may be a more general feature, as it was observed in 
several structures with a wide chemical diversity. As actually very few subtype-
selective muscarinic antagonists are available, racemic H1 antagonists may serve as 
a new starting point for SAR research. Resolution of these compounds into pure 
enantiomers may reveal completely new binding characteristics, which were 
previously not recognised and may result in new lead structures for the development 
of selective muscarinic antagonists. 
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5.5 Analogues of glycopyrronium 
The racemic mixture of (RS, SR)-glycopyrronium, named glycopyrrolate, is sold as 
Robinul
®. This drug has a long history as an antimuscarinic agent in pretreatment 
during general anaesthesia to reduce gastric acid production and salivation, where it 
is still in use (Ali-Melkkilä et al., 1993; Rautakorpi et al., 1999). First reports showing 
efficacy of glycopyrrolate as a potent bronchodilator in asthma patients were given in 
the end of the 1980s (Walker et al., 1987; Schroeckenstein et al., 1988). The first 
synthetic antimuscarinic drug that was used worldwide as a bronchodilator was the 
quaternary compound ipratropium (Pakes et al., 1980). This was a step forward in 
comparison to the formerly used tertiary tropa-alkaloids atropine and scopolamine 
with regard to the side effect profiles. Due to its quaternary structure, absorption of 
ipratropium in the GIT and airways is low, resulting in less dry mouth, blurred vision 
and CNS side effects. In the last ten years, chronic obstructive pulmonary disease 
(COPD) was recognised as a major problem in public health. As antimuscarinic drug 
therapy is currently one of the most effective therapies next to symphatomimetic 
drugs, interest in new compounds increased. Derivatives of glycopyrronium were 
discovered as highly potent antimuscarinic compounds. SAR studies were already 
performed in our laboratory by K. Kreutzmann. We continued the examination of 
recently synthesised derivatives of glycopyrronium at muscarinic receptor subtypes. 
  
5.5.1 Influence of N-alkylation  
Several analogues of glycopyrronium with pyrrolidinium structure were tested with 
modification in N-alkylation. Introduction of an allyl substituent (43D    Dia-44D) 
resulted in a approximately 2-fold decrease in affinity at all subtypes. A propargyl 
substituent with a triple bond (43D  Dia-45D) showed no change in affinities. One 
must notice that Dia-44D - Dia-48D were tested as mixtures of diastereomers with 
possibly different binding characteristic. Therefore one can speculate that isolation of 
the pure isomers would provide an eutomer with higher affinity and a distomer with 
lower affinity. This must be kept in mind when comparing 43D with these compounds. 
The eutomer of Dia-44D is likely to be equipotent to 43D and the eutomer of Dia-45D 
may even be more potent. Compound Dia-46D with an N-trifluorpropyl substituent 
had slightly decreased affinities (up to 4-fold at M2) comparable to the values of the  
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phenylethyl derivative Dia-47D (up to 3-fold). The phenylpropyl congener Dia-48D 
showed comparable affinities as the parent compound 43D. We further investigated 
some derivatives with a chinuclidine ring as a basic moiety. The phenylethyl 
derivative  50D was equipotent to the methyl substituted congener 49D. Slightly 
increased affinity values were found for the phenylpropyl derivative 51D in 
comparison to 49D (2.6-, 5.2-, 1.6-, 1.6- and 1.4-fold at M1-5, respectively).  
Taken together, substituents at the basic nitrogen atom were shown to be not critical 
for binding affinities at M1-5 receptors in derivatives containing a pyrrolidine or 
chinuclidine ring in our series of compounds. The affinities of all compounds were in 
the range of that of the parent compound 43D (values ranging from 9.4 - 10.0, K. 
Kreutzmann, personal communication). Introduction of aromatic substituents was 
tolerated without major changes in affinity. Comparable or slightly increased affinities 
were measured for the phenylpropyl congeners Dia-48D and 51D as an optimum 
among the tested derivatives in comparison to their N-methyl congeners 43D and 
49D, respectively. 
 
5.5.2 Influence of the amino-alcohol 
A direct comparison of the four stereosisomers of glycopyrronium 43A-D (Fig. 
5.10 (B)) with its chinuclinide congeners 49A-D (Fig. 5.10 (A)) was performed. Fig. 
5.10 (C) gives the differences in affinity values for 43A-D and 49A-D. It could be 
seen that changing the amino-alcohol from a pyrrolidine ring (43A-D) into a 
chinuclidine ring (49A-D) led to minor differences with only slightly decreased 
affinities for compounds 49A-C. However, for the most important stereoisomer 49D, 
affinities were equal or increased. Comparing the pyrrolidine compounds Dia-47D 
and Dia-48D with their chinuclidine analogues 50D and 51D a slightly increase in 
affinity was found in favour of compounds 50D and 51D displaying a chinuclidine 
structure. Taken together, slightly improved affinities were measured for chinuclidine 
analogues in comparison to their pyrrolidine congeners for the (3R, 2’R)-configurated 
compounds.  
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Fig. 5.10 Affinity values (pKi) of the chinuclidine derivatives 49A-D (A) and the parent 
compounds  43A-D ( B) and differences between these data sets (C) at hM1-5 
receptors. 
a) Values were measured by K. Kreutzmann (personal communication). 
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5.5.3 Dimerised molecules and synthesis precursors 
Connecting two molecules of 43D by an alkyl spacer led to compound 52. 
Pronounced decreases in affinities were measured (59-fold at M5 up to 120-fold at 
M1). 52 was tested as a diastereomeric mixture. Very interesting were the results 
obtained with Dia-53, lacking the cyclopentyl ring in the acid part. Losses of affinities 
compared to 43D were found (between 1047-fold at M5 and 3802-fold at M1). As 
affinities were dramatically decreased, it can be concluded, that an alicyclic ring in 2’-
position is a necessary structural feature for high affinity ligands in this series of 
muscarinic antagonists. Only small differences were observed between Dia-53 and 
(R)-54 (up to 6-fold), showing the exchange of a hydroxy group into a ketone function 
being of little influence. 
 
5.5.4 Tiotropium - glycopyrronium hybrids 
Tiotropium has been reported to be a highly potent antagonist at muscarinic receptor 
subtypes in binding studies in several human tissues (Haddad et al., 1994). 
Unfortunately, never a full paper was published concerning the binding affinities of 
tiotropium at recombinant human receptors. It was of interest to investigate hybrid 
molecules consisting in parts of chemical properties of glycopyrronium and tiotropium 
to obtain new information about the pharmacophore at muscarinic receptor subtypes. 
Compound  (R)-55 consisted of the acid part of glycoyrronium and the tropanyl 
substituent of tiotropium. This compound had marginally decreased affinities in 
comparison to the pyrrolidinium parent compound 43D  at the most subtypes (up to 
4-fold) and a 2-fold increase at M2. Building up an affinity rank order for different N-
methyl-substituted compounds containing the acid part of the parent compound 43D 
we found: (R)-55 < 43D < 49D = tropanyl < pyrrolidine < chinuclidine. However, the 
differences of affinities were only small. Interestingly, compound (R)-56 with the 
achiral dithienyl acid part of tiotropium had equal affinities to its congener with the 
glycopyrronium acid part, 50D. We conclude that the acid part of tiotropium and 
glycopyrronium are exchangeable concerning binding affinity at M1-5 receptors and 
that it is of minor importance, whether there is an alicyclic or an aromatic substituent 
attached in 2’-position in the acid part of the molecules.  
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5.5.5 Stereochemical aspects 
Highly interesting was to notice the influence of the absolute configuration at the two 
chiral centres of compounds 43A-D and 49A-D, for which all 4 possible 
stereoisomers were tested (43A-D, and 49D by K. Kreutzmann, personal 
communication). We found for both sets of derivatives an at least 2 orders of 
magnitude higher affinity for isomers with a (2’R)-configuration (compounds C and D) 
in comparison to the (2’S)-configurated analogues (compounds A and B). In addition, 
only minor influence of the absolute configuration in the amino-alcohol on affinity was 
observed in both series. Compounds C, D and, respectively A, B had almost identical 
affinities at M1-5 receptors. We conclude that the chiral centre in pyrrolidinium and 
chinuclidnium amino-alcohols, tested in our series, was not a very critical part 
concerning equilibrium binding affinity. Similar findings concerning the preference of 
(2’R)-configurated benzil acid derivatives  at muscarinic receptor subtypes has been 
reported. In a series of ether analogues with tropanyl amino-alcohol structures, the 
(2’R)-configurated compounds were at least one order of magnitude more potent 
than their (2’S)-congeners (Gao and Liu, 1995). In this series, influence of the second 
centre of chirality located in the basic structure was of minor importance, as seen in 
our series. Reports on chinuclidine-ester of benzil acid analogues showed the (2’R)-
configurated enantiomers to be more potent, too (Kiesewetter et al., 1995). 
Interestingly, the (3R, 2’R)-isomer was shown to possess a  selectivity for the M1 
subtype. We could not confirm this finding in our series. 
Taken together, our data confirm the importance of absolute configuration at the 
chiral centre in the acid part of the molecules for affinity to muscarinic receptor 
subtypes. The (2‘R)-configurated compounds were generally reported to be more 
potent compared to there (2’S)-stereoisomers. Only little influence was seen for the 
absolute configuration in the basic amino moiety. In our series the following ranking 
was found: D ≥ C >> B = A. 
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5.6 Characterisation of [
3H](3R, 2’R)-glycopyrronium 
Diagnosis of COPD is becoming more and more frequent at this time and is expected 
to become one of the most important therapeutic problems in the near future. 
However, only symptomatic therapy is currently possible, improving quality of daily 
life and reducing exacerbations, wherein antimuscarinic agents build the backbone in 
therapy (Campillo and Paez, 2002). Only few antimuscarinic drugs are available at 
the moment for inhalation therapy. All these medicinces are quaternary compounds 
which are poorly absorbed in human airways and the GIT, resulting in very few 
systemic side effects next to dry mouth (Corne and Anthonisen, 2002; Beeh et al., 
2002). In preliminary studies with unlabelled, cold drugs carried out in our laboratory, 
43D, the (3R, 2’R)- stereoisomer of glycopyrronium turned out to be one of the most 
interesting compounds, being a highly potent muscarinic antagonist displaying kinetic 
selectivity for M3 receptors. In the following paragraphs, binding profile and kinetic 
properties of the labelled compound [
3H]43D will be discussed next to other 
compounds currently in use in the field of COPD therapy with a special focus on 
ipratropium and tiotropium as reference drugs. Additionally, a comparison with 
previous data obtained in our laboratories in functional and binding experiments is 
given. 
 
5.6.1 Muscarinic receptors in human airways 
In human airways, M1-3 receptors were identified and their function was extensively 
investigated (Barnes, 1993; Caulfield and Birdsall, 1998; Eglen et al., 2001; Corne 
and Anthonisen, 2002).  
Fig. 5.11 shows the cholinergic innervation found in human airways. M3 receptors 
were detected on smooth muscles being most important for direct parasympathetic 
bronchoconstriction (Bymaster et al., 2003). Additionally, M3 receptors mediate 
mucus secretion in human airways. M2 receptors were identified on cholinergic 
neurons mediating a negative feedback loop on endogenous ACh release and on 
smooth muscle cells reversing the sympathetic β-adrenergic tone. M1 receptors were 
detected in the soma-dendritic region of postganlionic cholinergic neurons facilitating 
excitation. With knowledge of the function of each subtype it is of greatest interest for 
COPD management to achieve a prolonged blockade of M3 receptors without  
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blocking the prejunctional M2 autoreceptors, because this would result in increased 
ACh release possibly counteracting the postjunctional M3 blockade.  
 
ACh
ACh
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M2 (-)
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Airway
smooth muscle
Postganglionic
cholinergic nerve
Preganglionic
cholinergic nerve
Parasympathetic
ganglion
 
 
Fig. 5.11  Cholinergic innervation in human airways (adapted from Hansel and 
Barnes, 2002). (+) = neuronal excitation or increase of smooth muscle tone; (-) = 
inhibitory influence. 
 
M2 receptors controlling the endogenous ACh release were found to be fully 
functional in stable COPD (On et al., 2001). However, reports showed the M2 
receptors to be dysfunctional in viral infections causing acute exacerbations in 
asthma and COPD patients (Jacoby and Fryer, 1999; Fryer et al., 1999). Receptor 
deglycosylation by viral neuraminidase and release of major basic protein from 
eosinophils were demonstrated to change M2 function. M3 receptors were found to be 
unchanged in patients with hyperresponsiveness in airway smooth muscles (Fryer 
and Jacoby, 1998). These findings may account for potentiated reflex 
bronchoconstriction in patients. Reports concerning paradoxical bronchoconstriction 
following application of ipratropium were published (Eglen and Watson, 1996; Corne 
and Anthonisen, 2002). This may be due to blockade of prejunctional M2 receptors 
leading to increased ACh release, reducing effectiveness of postjunctional M3 
antagonism. Interesting findings were reported about the nondepolarising 
neuromuscular blocking agent rapacuronium, used to block nicotinic ACh receptors  
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to facilitate intubation during anaesthesia. This drug was removed from the market 
due to high incidence of bronchospasm resulting in deaths. Recently it was 
demonstrated that the reason for this bronchoconstriction was a selective blockade of 
M2 autoreceptors in the airways (Jooste et al., 2003). 
 
5.6.2 Binding profile at M1-5 receptors 
As shown (Fig. 4.25 and Fig. 4.26) saturation binding isotherms of [
3H]43D were in 
good agreement with a one-site binding model according to the law of mass action. 
The obtained KD values (Table 4.10) were in the range of the affinity values (pKi) 
found with the cold drug previously in our lab in competition binding experiments with 
[
3H]NMS (K. Kreutzmann, personal communication). The labelled drug’s KD values  
(9.67 - 10.55) were approximately by factor 3 higher than the cold drugs pKi values 
(9.35 - 9.95) (Fig. 5.12). No pronounced selectivity was seen in binding affinities to 
M1-5 receptors. 
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Fig. 5.12 Affinity values (pKD) of labelled [
3H]43D determined in saturation binding 
experiments and affinity values (pKi) of cold 43D  determined in competition 
experiments with [
3H]NMS at hM1-5 receptors stably expressed in CHO-K1 cells. 
a) Data from K. Kreutzmann (personal communication). 
 
In comparison to affinity values of ipratropium recorded in competition experiments 
with [
3H]NMS, an at least 9-fold higher affinity was measured for [
3H]43D at  
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muscarinic receptor subtypes. Our values for ipratropium (Fig. 5.13) were in good 
agreement with previously reported data (Haddad et al., 1999). 
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Fig. 5.13 Affinity values (pKD) of labelled [
3H]43D determined in saturation binding 
experiments and affinity values (pKi) of cold ipratropium  calculated in competition 
experiments with [
3H]NMS at hM1-5 receptors stably expressed in CHO-K1 cells. 
 
No complete comparison of the affinity profiles at muscarinic receptor subtypes of 
tiotropium and 43D could be done, since no full paper reports a complete affinity 
profile of tiotropium at M1-5 receptors. However, for [
3H]tiotropium, pKD values of 9.57, 
9.92 and 9.48 at CHO cells expressing M1-3 receptors were reported (Disse et al., 
1993). This showed tiotropium to be less potent than 43D at these subtypes. 
 
To check the usefulness of [
3H]43D as a novel muscarinic radioligand, we performed 
a comparative study of binding characteristics of several reference drugs with 
[
3H]43D and [
3H]NMS. In Fig. 5.14 (A) affinities for the non-selective compound 
atropine, the M1-selective drug pirenzepine, the M2-preferring drug (S)-dimethindene 
and the M2/4-selective compound himbacine are given in studies with [
3H]43D. In Fig. 
5.14 (B) values in studies with [
3H]NMS are given. As shown in Fig. 5.14 (C), almost 
no difference was found between the measured affinities at M1-5 receptors with the 
two radioligands. It is concluded that [
3H]43D recognised the same binding site as 
other muscarinic ligands and may serve as a useful radioligand in future studies. 
  
Discussion 
 
 
180 
Atropine Pirenzepine S-Dimeth. Himbacine
6
7
8
9
10
M1
M2
M3
M4
M5
A [
3H]43D
p
K
i
a)  
-0.5
0.0
0.5
C
A-B A-B A-B A-B
D
e
l
t
a
 
p
K
i
 
Atropine Pirenzepine S-Dimeth. Himbacine
6
7
8
9
10
M1
M2
M3
M4
M5
a)
B [
3H]NMS
p
K
i
a)  
Fig. 5.14 Affinity values (pKi) of reference drugs recorded in competition binding 
experiments with [
3H]43D (A) or [
3H]NMS (B) and the differences between the 
calculated pKi values (C). 
a)  Data measured by Dr. C. Keim (personal 
communication). 
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5.6.3 Kinetic properties 
In our kinetic binding studies with [
3H]43D we were able to confirm the findings of 
previous research in our laboratory with the unlabeled drug 43D. A dissociation half-
life of 17 and 131 min was determined by K. Kreutzmann at M2 and M3 receptors 
(personal communication). We found almost identical t1/2 values of 23 and 145 min at 
these subtypes with the labelled compound [
3H]43D. Dissociation at M3 was 6-fold 
slower in comparison to the M2 subtype resulting in a kinetic selectivity for the M3 
receptor. The following rank order concerning dissociation half-lifes was found: M3 > 
M5 > M4 > M1 >> M2. For [
3H]ipratropium, and [
3H]tiotropium dissociation half-lifes 
were reported at M1-3 receptors stably expressed in CHO cells (Disse et al., 1993). 
For ipratropium a rapid dissociation was found with 6.6, 2.1 and 16 min at M1-3 
receptors, respectively. Much slower dissociation was determined for tiotropium with 
15, 3.6 and 35 hours (!) at M1-3, respectively. This equals a 8- and 10-fold slower 
dissociation at M3 versus M2 for ipratropium and tiotropium. Findings for tiotropium 
are in contrast to the results published in studies at human lung tissue preparations, 
labelling M1 and M3 receptors (Haddad et al., 1994). A simple exponential function 
provided the best description for the measured data and no biphasic dissociation 
profile was seen. The calculated half-life was 414 min. This value is neither in 
agreement with the previously published value for M1 (15 h) nor with that for the M3 
subtype (35 h). No explanation for this discrepancy is given by the authors. In 
preliminary experiments in our laboratory with tiotropium at M3 receptors, a 
dissociation half-life of 212 min was found which is in range of the values found in 
human lung tissue (K. Kreutzmann, personal communication). Reasons for these 
discrepancies remain unclear as kinetic data for tiotropium were never published in a 
full paper. For ipratropium, 43D and tiotropium a slower dissociation was found at M3 
versus M2. However, for ipratropium dissociation at M3 was fast, too. Therefore, no 
kinetic selectivity for M3 receptors resulted for this compound. 43D had a much 
slower dissociation than ipratropium at M3 (145 versus 16 min) resulting in prolonged 
time of action at this subtype. Compared to tiotropium, dissociation was more rapid. 
Due to the discrepancies between the reported values for tiotropium it remains to be 
elucidated how great the difference really is in fact between the dissociation half-life 
at M3 for 43D and tiotropium.  
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Using the results of our kinetic experiments we calculated the kinetic KD values 
(kinKD) for [
3H]43D as described in material and methods. kinKD values were almost 
identical to those measured in saturation binding experiments (satKD). Fig. 5.15 gives 
a comparison of kinKD, satKD obtained with [
3H]43D and pKi values derived in 
competition experiments with unlabelled 43D in competition binding studies with 
[
3H]43D and [
3H]NMS as radioligands. 
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Fig. 5.15 Comparison of kinKD, satKD obtained with [
3H]43D and pKi values derived 
in competition experiments with cold 43D in competition binding studies with [
3H]43D 
and [
3H]NMS. 
a) K. Kreutzmann (personal communication). 
 
KD values determined in saturation studies were absolutely identical to those 
calculated in kinetic studies, proving the high validity of the kinetic data. pKi values 
calculated for 43D in competition experiments with [
3H]43D were approximately 2-fold 
below the obtained KD values. Competition data with [
3H]NMS were approximately 3-
fold below KD values. Taken together, binding data obtained in competition and 
kinetic experiments are in good agreement with each other and prove a good validity 
of our data. 
 
5.6.4 SAR based on kinetic properties 
Due to experimental complexity and demand on time only little is known about SAR 
concerning kinetic properties of compounds at a special receptor site. To obtain 
kinetic binding constants of a compound there are two possible ways: Firstly, using a  
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radioactively labelled molecule which is extremely expensive. Secondly, performing 
highly sophisticated cold kinetic experiments and fitting of the obtained data to 
complex mathematical equations, describing the influence of an unlabelled drug on 
the known binding kinetic properties of a radioligand. However, both methods 
demand great expense of time and material. In our laboratory research at muscarinic 
receptors with unlabelled drugs was carried out by K. Kreutzmann with the 
stereoisomers of 43 and several derivatives. He found the following dissociation half-
lifes for 43A-D at M3 receptors: < 1, 2, 75 and 131 min, respectively.  The (2’R)-
configurated stereoisomers 43C and 43D dissociated much slower than their (2’S)-
congeners. Based on these findings patents were filed worldwide with the (3R, 2’R)-
isomer of 43 and several analogues, as compounds with kinetic selectivity at M3 
receptors. In the following time, research with several (3R,  2’R)-configurated 
analogues of 43 possessing piperidine and pyrrolidine ring systems as basic moiety 
was done. However, no prolonged time of action was achieved. Recently, a series of 
chinuclidinol esters was claimed in a patent from Almirall Prodesfarma as long acting, 
kinetic selective M3 antagonists for use in COPD ([Anon], 2003). In our laboratory, 
the chinuclidinol analogue 49D was examined at M3 receptors and an extremely slow 
dissociation rate at M3 receptors was found (364 min, K. Kreutzmann, personal 
communication). This compound had the slowest dissociation half-life of all 
compounds tested in our laboratory and is the most interesting candidate for further 
development as a potential drug in COPD therapy. Dissociation half-life of 49D was 
2.5-fold increased in comparison to 43D which was completely characterised in this 
work. The influence of stereochemistry on kinetic properties was impressively 
demonstrated in our series of compounds at muscarinic receptors. Recently, an 
interesting finding was reported for the well known racemic H1 antagonist cetirizine. 
Separation into enantiomers resulted in two completely different acting compounds 
concerning the dissociation half-life at H1 receptors. (R)-cetirizine was reported with a 
t1/2 of 142 min, whereas (S)-cetirizine had only a t1/2 of 6 min (Gillard et al., 2002).  
Taken together, in our series of compounds we demonstrated a dramatic influence of 
stereochemistry on kinetic properties at muscarinic receptor subtypes. Size and 
shape of the basic moiety are important as well as the substituents in the acid part of 
the molecules. As some modifications are tolerated (compare tiotropium versus 43D 
and  49D) further studies are necessary to clearly demonstrate the influence of  
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special parts of the tested molecules on binding kinetics at a special receptor 
subtype. 
 
5.6.5 Functional studies 
In previous work in our laboratory, the stereoisomers of 43 were investigated in 
functional studies in rabbit vas deferens (M1), guinea-pig atria (M2) and guinea-pig 
ileum (M3). In contrast to atropine, ipratropium and 43A, compounds 43C, 43D and 
glycopyrrolate (which is a racemic mixture of 43B and 43C) did not behave as simple 
competitive muscarinic antagonists at muscarinic M3 receptors (Czeche, 2000). A 
concentration-dependent decrease in maximum response to the agonist arecaidine 
propargyl ester was observed and a very slow offset of action, determined as time to 
recover 100% response to agonist after washout of the antagonist. The determined 
kinetic data may serve as a reasonable explanation for these findings. For the (3R, 
2’R)-configurated compound 43D a very slow dissociation was shown in cold kinetic 
experiments (131 min, K. Kreutzmann, personal communication) which was 
confirmed in our studies with [
3H]43D (145 min). Additionally, in cold kinetic 
experiments an extremely fast dissociation was found for the (2’S)-configurated 
compounds 43A and 43B (t1/2 < 1 and 2 min, respectively) and an intermediate value 
for  43C (t1/2 = 75 min) was found (K. Kreutzmann, personal communication). It 
seems, as if the slow dissociation profiles of the (2’R)-configurated analogues 43C, 
43D account for the non-selective behaviour at M3 in functional studies. In the case of  
glycopyrrolate the isomer 43C (present in this racemic mixture of 43B and 43C) is 
likely to account for these findings. Functional data for 43B are not further discussed 
as an impurity with 43D was found later on. Previously reported functional data with 
glycopyrrolate were not in good agreement with those obtained in our laboratories 
(Lau and Szilagyi, 1992; Fuder and Meincke, 1993) which is possibly due to 
impurities with the other stereoisomers (43A and 43D). Results of functional studies 
carried out in our laboratory were in good agreement with our findings in binding 
experiments, confirming a kinetic selectivity at M3 receptors. An interesting study was 
carried out comparing glycopyrrolate with ipratropium in functional studies in guinea-
pig and human airways (Haddad et al., 1999). Glyopyrrolate was more potent and 
had a longer duration of action than ipratropium, most likely due to the slow 
dissociating isomer 43C.  
Discussion 
 
 
185 
5.6.6 In vivo studies 
Only little data is available concerning 43D in animal studies. Some studies were 
carried out at the Department of Pharmacology 2, Arzneimittelwerk Dresden GmbH, 
Radebeul, Germany. Results were reported by Prof. Dr. I. Szelenyi in personal 
communication to Prof. Dr. G. Lambrecht. The potency and duration of action of 43D 
were determined in a methacholine-induced bronchoconstriction model in 
anaesthetised guinea-pigs. An intravenous bolus application of methacholine 
(20  µg/kg) was given and the change of bronchial response before and after 
application of 43D was determined as percent change of lung resistance. In a first 
study methacholine was repeatedly applicated intravenously in 30 min intervals for 
4 h. In a second study arm, guinea-pigs were pretreated with 43D i.m. 18 h before 
methacholine challenge. Glycopyrrolate served as a reference drug. It was shown 
that 43D at a dose of 0.3 µg/kg i.v. potently inhibited the increase in lung resistance 
induced by methacholine. This effect was more pronounced compared to 
glycopyrrolate at a dose of 1.0 µg/kg intravenous. Very interestingly, 18 h after 
pretreatment with 43D at 1.0 µg/kg i. m., there was still a 58% inhibition of the 
methacholine effect, whereas glycopyrrolate at 3.0 µg/kg i.m. showed a much lower 
effect (36%). In addition, in the same model of bronchoconstriction a shorter time of 
action was measured for ipratropium in comparison to 43D (Pfister et al., 1985). 
Taken together, in vivo studies showed 43D  to be a highly potent muscarinic 
antagonist with a prolonged time of action compared to ipratropium and 
glycopyrrolate. 
Much more data is available for glycopyrrolate which is in clinical use to reduce 
salivation and release of gastric acid in general anaesthesia (Ali-Melkkilä et al., 1993; 
Rautakorpi et al., 1999). Studies concerning pharmacokinetic and pharamcodynamic 
properties were recently reported (Penttilä et al., 2001). Research concerning its use 
as a bronchodilator was carried out. A prolonged effect up to 12 h was seen in 
asthma patients (Walker et al., 1987; Schroeckenstein et al., 1988). In COPD, benefit 
to patients of glycopyrrolate was shown, too (Tzelepis et al., 1996).  
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5.6.7 Therapeutic implications 
Since the introduction of ipratropium in the late 1970s only very few compounds were 
added to the market for inhalation therapy as antimuscarinic drugs. At present, two 
non-selective compounds, ipratropium and oxitropium, are in use, needing a 4-times 
and 3-times daily dosing regimen of 200 µg in general. With the introduction of 
tiotropium a step forward was made in therapy. A once daily dosing regimen with 
18 µg was sufficient to obtain superior bronchodilation in comparison to the older 
drugs in use (Disse et al., 1993; Barnes et al., 1995; Panning and De Bisschop, 
2003). Due to better efficacy and a more convenient dosing regimen it is likely that 
tiotropium will become more important than the older drugs. Tiotropium was shown to 
be a non-selective compound as well as the older drugs in equilibrium binding 
experiments. However, due to its slow dissociation at the M3 subtype a kinetic 
selectivity and prolonged time of action was achieved. Studies with glycopyrrolate 
showed already superiority to ipratropium in functional experiments in guinea-pig and 
human airways as a bronchodilator (Haddad et al., 1999) with a prolonged time of 
action. One should notice, that the enantiomer 43C (which is most likely accounting 
for the prolonged time of action in this studies) had only a dissociation half-life of 75 
min at M3 receptors. As written in 5.6.6 43D was superior in animal studies to 
glycopyrrolate. Therefore it is likely that studies with 43D (dissociation half-life 145 
min at M3) will result in an additional gain in the duration of action. It will be very 
interesting to see the results of the first clinical trials in humans carried out with 43D. 
One can expect a duration of action of at least 12 h, allowing a twice daily dosing, 
perhaps a once daily dosing comparable to tiotropium. 
Further therapeutic fields apart from COPD were investigated with glycopyrrolate. 
Studies on topical use for gustatory sweating in diabetic patients (Frey syndrome) 
were carried out (Hays et al., 1982; Atkin and Brown, 1996; Shaw et al., 1997) 
showing good results. Perhaps further studies with 43D will bring up even better 
results not only for use in diabetic patients but in hyperhidrosis in general. This would 
be an interesting new therapeutic target as topical appliation of AlCl3 preparations 
show little efficacy and application of botulinum toxin is very expensive. Additionally, 
a potential use in bladder dysfunction and urinary incontinence seems possible. 
Sepracor Inc. has filed use patents for the four isomers of 43 for bladder dysfunction 
(Butera and Argentieri, 1998).    
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5.7 M2-selective antagonists related to dimethindene 
5.7.1 Modification of side chain length 
As mentioned above, the most difficult task in the development of M2-selective 
antagonists related to dimethindene was to increase the affinity to the M2 subtype 
and maintain high selectivity and specificity. In a series of analogues with reduced 
side chain length (n=1) we found an increase in affinity to M2 receptors for all tested 
compounds in comparison to their analogues with normal chain length (n=2). Fig. 
5.16 gives a comparison of affinity values at M2 and H1 receptors in a series of 
analogues tested with n=2 (“A” series) and n=1 (“B” series) (see Table 2.23). In 
addition to the increased affinity to M2 receptors, affinity to H1 receptors was reduced 
with exception of 59B where a slightly increased H1 affinity was determined. Increase 
in affinity to the M2 subtype lay between approximately 3 - 10-fold, whereas variability 
was observed at the decrease in  affinity to the H1 subtype. 
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Fig. 5.16 Affinity values (pKi) to M2 (left) and H1 (right) receptors for a set of 
compounds tested with n = 2 (“A” series, solid line) and n = 1 (“B” series, dashed 
line) (see Table 2.23). 
 
In summary, reduction of side chain length to n=1 resulted in increased affinity to 
muscarinic receptor subtypes and at the same time decreased H1 affinity in most 
cases. Unfortunately, the n=2 congener of the most interesting compound within this 
series 72B, was not available until the end of this work.  
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5.7.2 Modifications at the amino moiety 
As a consequence of the above findings, several compounds were synthesised with 
reduced chain length and various modifications of the substitution pattern at the basic 
amino moiety. Compound 72B with an isopropyl and a phenylethyl substituent in the  
basic moiety was found to be an optimum within our series of compounds, with high 
affinity to M2 receptors, good selectivity and excellent specificity versus the H1 
subtype. All tested modifications led to reduced affinity or decreased selectivity. This 
was also true for the closely related compounds 76B, with a fluoroethyl instead of the 
isopropyl substituent, and 77B, with an additional p-methyl group in the phenylethyl 
ring. Thus, it is concluded, that size and shape of substituents attached to the amino 
moiety are highly critical to binding characteristics. It is also noteworthy, that tested 
compounds of the “B” series with an aromatic substituent at the basic nitrogen had 
comparably low affinities to the H1 subtype (all below pKi = 6.46). Additionally, 
introduction of halogen substituents in m- or p-position of the phenylethyl moiety 
(78B - 83B) led to decreased affinity to M2 and reduced selectivity in comparison to 
72B, too. 
 
5.7.3 Stereochemical aspects 
Three compounds were examined as pure enantiomers. These were the parent 
compound 57A, the diisopropyl congener 75A and the most interesting compound 
72B. Affinity to the M2 subtype, selectivity versus M1,3,4,5 and specificity versus H1 for 
the eutomers at muscarinic receptor subtypesare shown in Table 5.2.  
 
Table 5.2 Affinities to M2 receptors of the eutomers at muscarinic subtypes (+)-57A, 
(-)-75A (Böhme et al., 2003) and (+)-72B and calculated subtype selectivity and 
specificity ratios. 
No. pKi M2 M 2 / M1 M 2 / M3 M 2 / M4 M 2 / M5 M 2 / H1 
(+)-57A  7.52 6  5  10 25  2 
(-)-75A  7.37  36 95 42  275  38 
(+)-72B  8.59 79 102 31 120  1349 
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As can be seen in Table 5.2, compound (+)-57A had little selectivity and no 
specificity versus H1. The diisopropyl congener (-)-75A revealed much better 
selectivity and specificity. However, the absolute affinity to M2 receptors was not 
increased. In (+)-72B good selectivity was maintained and at the same time a 17-fold 
increase at affinity to M2 receptors was achieved with superior specificity (1349-fold 
versus H1). With (+)-72B a highly potent and selective M2 antagonist was found. 
 
For the enantiomers of these compounds stereoselectivity were calculated (Table 
5.3). These values ranged from 3 - 41 for muscarinic receptors and 0.006 at H1 for 
the parent compound 57A. Comparable results were found for 75A and 72B with 
highest stereoselectivity ratios within the muscarinic family calculated for the M2 
subtype and inverse stereoselectivity at H1 receptors.  
 
Table 5.3 Stereoselectivity ratios for enantiomers of 57A, 75A  and 72B. 
No. M1 M 2 M 3 M 4 M 5 H 1 
57A  10 41 25 13  3  0.006 
75A  3 18 2  6  6 0.2 
72B  4 13 5  3 0.4  0.07 
 
Fig. 5.17 summarizes the M2 and H1 affinities of 57A,  75A and 72B and their 
enantiomers. The eutomer at muscarinic receptors is placed to the left of the 
corresponding racemic mixture, the eutomer at H1 receptors on the right hand side. In 
theory, a maximum 2-fold increase in affinity can be observed from the racemic 
mixture to the eutomer. That was exactly found for the parent compound at M2 and 
H1 receptors (Fig. 5.17 left side). In the case of 75A (Fig. 5.17 middle) the racemic 
mixture was more potent than the pure enantiomers. The muscarinic eutomer was 
slightly less potent than the racemate, the eutomer at histamine receptors was 
equipotent. This might be due to chemical instability of the free bases of the pure 
enantiomers tested. For 72B (Fig. 5.17 right hand side) the muscarinic eutomer was 
slightly more potent than the racemic mixture. For the eutomer at H1 receptors a 6-
fold increase was calculated with regard to the racemate.   
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Fig. 5.17 Affinity values (pKi) of racemic compounds (±)-57A, (±)-75A and (±)-72B 
and the pure enantiomers at muscarinic M2 receptors (dashed line) and histamine H1 
receptors (solid line). 
 
5.7.4 Comparison of 72B with other M2-selective antagonists 
With the discovery of the M4 subtype several formerly considered M2-selective 
compounds were shown to be unable to discriminate between M2 and M4 receptors, 
for example himbacine, AF-DX384 and methoctramine (Dörje et al., 1991). 72B is 
one of to the most potent M2-selective compounds published to date with good 
selectivity, only exceeded by some compounds recently synthesised by Schering-
Plough (Wang et al., 2002a). Fig. 5.18 gives a comparison to some of the strongest 
competitors in the field of M2-selective compounds.  
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Fig. 5.18 Affinity profiles of selected M2-selective antagonists determined in 
radioligand binding studies at M1-5 receptors. 
a) Doods et al., 1993; 
b) Lachowicz et 
al., 1999; 
c) Wang et al., 2002a. 
 
In summary, (+)-72B can be considered as a major break-through in our studies of 
development of M2-selective antagonists related to dimethindene. At present, (+)-72B 
is together with some recently published compounds by Schering-Plough one of the 
most potent, highly selective M2 antagonists worldwide. 
 
5.7.5 Therapeutic implications 
With (+)-72B not only an interesting pharmacological tool was discovered but also a 
potential drug for use in AD. M2-selective antagonists were shown to facilitate ACh 
release in the brain of several animals. Furthermore, improvement of cognition was 
demonstrated in a couple of animals from rat to monkey (Lachowicz et al., 2001; 
Carey et al., 2001). However, a therapeutic long-term benefit in human AD therapy is 
questionable as cholinergic neurons die with proceeding of AD (Sheardown, 2002). 
Further studies in humans are needed to verify, whether M2 antagonists provide a 
useful therapeutic approach in AD or not. Tachycardia as a side effect might be a 
problem. Animal studies with SCH57790 showed an increase in cognition at drug 
doses well beneath cardiac effects. Perhaps a combination therapy with M2-selective 
antagonists and AChE inhibitors will result in a synergistic benefit in AD. Apart from 
therapeutic implications per se, (+)-72B might be an interesting tracer for PET  
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studies, quantifying M2 receptors in the brain. Unfortunately, all tested derivatives 
with a fluorine atom in the molecule (to be exchanged into a 
18F in a PET tracer) were 
less potent and/or selective. Studies carried out by radiochemists may find a way to 
label the isopropyl group (with 
11C) of (+)-72B. An M2-selective PET-tracer would be 
a milestone in AD as a safe in vivo diagnosis might become possible. Additionally, 
monitoring of success or failure of new disease modifying therapies to slow down AD 
progression (measured as a decrease of M2 receptor density on cholinergic fibres) 
might be possible. If no way is found to directly label (+)-72B as a PET tracer, further 
studies with fluorine congeners are needed to find a suitable molecular structure, 
combining binding characteristics of (+)-72B with a good possibility for PET-labelling. 
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6.1 General considerations 
GPCRs and ligand-gated ion channels mediate a great variety of physiological 
effects within the human brain and periphery. The search for selective ligands at 
these target sites as pharmacological tools or new drug candidates is of great 
interest. With increasing knowledge of the great diversity of some receptor families, 
compounds formerly considered to be selective, turned out to be non-selective with 
regard to recently identified subtypes, splice variants or additional receptor subunits. 
This work provides SAR studies by means of radioligand binding experiments at 
serotonergic h5-HT3A and h5-HT4(b) receptors, histamine hH1 receptors and 
muscarinic hM1-5 receptors. 
 
6.2 Compounds related to ondansetron 
Ondansetron (1) is well known as a highly potent 5-HT3 antagonist and served as 
lead structure for the development of other 5-HT3 receptor antagonists. In our study a 
series of ondansetron congeners (2 - 18) with modification in the imidazolyl part or 
the side chain were investigated at recombinant h5-HT3A receptors and data were 
compared to preliminary functional studies at native 5-HT3 receptors in guinea-pig 
ileum. It could be clearly demonstrated within a series of regioisomers (2A/B - 6A/B) 
that compounds with substituents at position 4 of the imidazole moiety displayed 
higher affinities than their isomers with substituent in position 5. An optimum within 
our series was the 4-methyl substituted congener 2A displaying the highest 
measured affinity value (pKi = 9.05) equaling a 2-fold increase in comparison to the 
parent compound. Expanding the size of the substituents led to decreased affinities.  
Side chain length had an optimum with n=2. Pronounced stereoselectivity was 
determined for the enantiomers (+/-)-14 with a stereoselectivity ratio of 26. 
Comparison of functional data in guinea-pig ileum with binding studies at h5-HT3A 
receptors revealed a low correlation and confirmed these receptors to be true 
species orthologues. Consequently, further studies in the drug development process 
of 5-HT3 ligands should not use guinea-pigs as laboratory animals, because the 
obtained results have only little predictive power for human therapy.  
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6.3 Compounds related to metoclopramide 
The prokinetic actions of the benzamide metoclopramide (MCP) were discovered 
long before 5-HT4 receptors were described for the first time. In our study, we 
examined a series of compounds (20 - 30) related to the MCP ester congener 
SDZ205-557 (19) regarding their affinities to h5-HT4(b) receptors. The obtained 
binding data were compared with functional data derived in experiments at native 
5-HT4 receptors in guinea-pig ileum and rat oesophagus. Insertion of substituents in 
the side chain decreased binding affinity enormously and was not tolerated (20, 21). 
Exchange of the amino moiety into a piperidine ring (22) led to a 4-fold increased 
affinity. A stereoselectivity ratio of 8 was calculated for the p-methyl substituted 
piperidine congeners (+/-)-23. In contrast to the 5-HT3A subtype, bulky substituents in 
p-position of the basic ring were tolerated well and highest affinities within this series 
was found for compound (±)-26 (pKi = 8.43). Side chain length had an optimum with 
n=2. In contrast to 5-HT3 receptors, binding data correlated well with functional data 
obtained at rat and guinea-pig 5-HT4 receptors, suggesting these receptors to be 
species homologues. 
  
6.4 Analogues of McN-A-343 
Congeners of McN-A-343 (31) were extensively studied as ligands at muscarinic 
receptors. In our studies we examined a series of analogues (32 - 42) for their 
binding affinities to 5-HT3A, 5-HT4(b) and H1 receptors. At the 5-HT3A subtype, 
compound (R)-33
+ had the highest affinity among the tested compounds (pKi = 5.74). 
Very low affinities were detected at the 5-HT4(b) subtype. All compounds were less 
potent than the parent compound 31 (pKi = 5.73). At both subtypes, no preference 
was found for tertiary compounds over their N-methylated, quaternary congeners. 
More interesting findings turned out at H1 receptors. Introduction of substituents 
within the chain had an optimum at a 4-F-phenyl substituent (±)-38 (pKi = 6.98), 
which displayed the highest affinity within this series. Tertiary compounds had higher 
affinities than their quaternary congeners. For six pairs of enantiomers (33, 33
+, 36, 
36
+, 37, 37
+), pronounced inverse stereoselectivity was found between M1 and H1 
receptors. This was most pronounced for compound (R/S)-37 with stereoselectivity 
ratios of 1660 and 0.09 at M1 and H1, respectively. Inverse stereoselectivity between  
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M1 and H1 receptors was reported for several chemically different compounds and is 
perhaps more common as generally assumed. Resolution of well known racemic H1 
antagonists into pure enantiomers might provide new starting points as novel lead 
structures in the search for selective muscarinic antagonists. 
 
6.5 Compounds related to glycopyrrolate 
A mixture of the enantiomers (3S, 2’R)- and (3R, 2’S)-glycopyrronium, named 
glycopyrrolate (Robinul
®), is approved to the market and in therapeutic use as a 
parasympatholytic drug for premedication prior to surgical operations. 
Glycopyrronium (43) exists in 4 stereoisomers 43A-D, which were investigated in 
preliminary studies in our laboratory. In this study, we investigated a series of 
congeners (44 - 56) for affinity to M1-5 receptors. Exchange of a methyl substituent at 
the quaternary nitrogen by other groups, Dia-44D - Dia-48D, left affinities 
unchanged. Compounds 49A-D, with a chinuclidine system instead of a pyrrolidine 
ring, displayed a stereochemical behaviour at M1-5 receptors comparable to the 
parent compound. The (2’S)-configurated compounds 49A and 49B had lower 
affinities in comparison to the (3R, 2’R)-configurated compound 49D (K. Kreutzmann, 
personal communication), whereas only minor losses in affinities were found for the 
(3S, 2’R)-configurated isomer 49C. The highest affinities within this series were 
measured for 51D (pKi = 10.71 at M2). Hybrid molecules, consisting of parts of 
glycopyrronium and tiotropium, (R)-55 and (R)-56, were potent antagonists, too. Most 
tested compounds had very high affinities to muscarinic receptor subtypes, but 
displayed no selectivity for a single subtype in equilibrium binding studies. 
 
6.6 Characterisation of [
3H](3R, 2’R)-glycoyrronium 
Preliminary studies in our laboratory revealed the (3R, 2’R)-configurated enantiomer 
43D to possess kinetic selectivity for M3 versus the M2 receptors, based on 
pronounced differences in dissociation half-lifes at these subtypes. In this study, the 
most interesting compound (3R, 2’R)-glycopyrronium (43D) was labelled 
radioactively and completely characterised at M1-5 receptors. [
3H]43D was found to 
be a highly potent, non-selective compound  in competition and saturation    
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experiments (pKD = 9.67 - 10.55), recognising the same receptor site as the standard 
radioligand [
3H]NMS. Results of kinetic studies with [
3H]43D confirmed the findings 
with the cold drug at M2 and M3 receptors and proved a kinetic selectivity for the M3 
subtype. Dissociation half-lifes at M1-5 were 71, 23, 145, 77 and 100 min, 
respectively. Preclinical in vivo data demonstrated superior bronchodilator effects 
and prolonged time of action in comparison to ipratropium. Planned clinical studies 
with inhaled 43D for use in COPD will elucidate whether a once- or a twice-daily 
dosing regimen will be suitable for human therapy. 43D is to our knowledge the first 
compound following tiotropium with kinetic selectivity for M3 receptors and is a 
promising candidate for COPD therapy in humans. 
 
6.7 M2-selective antagonists related to dimethindene 
Since the discovery of inverse stereoselectiviy between muscarinic receptors and the 
H1 subtype for the enantiomers of dimethindene (57A), studies in our laboratories 
were carried out in order to develop M2-selective antagonists related to 57A. It turned 
out to be difficult to obtain compounds with high affinity to the M2 subtype and at the 
same time to reach high selectivity and specificity. In this study, we examined several 
analogues (57B and 58 - 83) with special focus on side chain length and substitution 
pattern of the basic amino moiety. It was demonstrated that compounds with reduced 
chain length had increased affinities at the M2 subtype and at the same time 
decreased H1 affinities in most cases. As an optimum for the substitution pattern at 
the basic amino moiety an isopropyl group and a phenylethyl substituent were found 
in (+)-72B. This compound is a major break-through in our studies, combining high 
affinity to M2 receptors (pKi = 8.59) with good selectivity (M2 versus M1,3,4,5 79-fold, 
102-fold, 31-fold, 120-fold, respectively) and specificity versus H1 receptors (1349-
fold). (+)-72B is one of the most selective M2 antagonists known today. (+)-72B is a 
potential candidate as a PET-ligand for diagnostic use in AD or as a  therapeutic drug 
in AD.  
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7.1 Generelle Aspekte 
G-protein-gekoppelte Rezeptoren und Liganden-gesteuerte Ionenkanäle vermitteln 
eine Vielzahl physiologischer Effekte im menschlichen Gehirn und der 
Körperperipherie. Selektive Liganden an diesen Rezeptoren sind nicht nur als 
pharmakologische Werkzeuge, sondern auch als Arzneistoffkandidaten von 
Interesse. Mit zunehmendem Wissen über die Komplexität einzelner Rezeptor-
familien stellte sich heraus, dass Stoffe, die zuvor als selektive Liganden angesehen 
wurden, nicht zwischen den altbekannten und neu entdeckten Subtypen, 
Splicevarianten oder Untereinheiten unterscheiden können. Diese Arbeit stellt einen 
Beitrag auf dem Gebiet der Struktur-Wirkungs Beziehungen an muskarinischen, 
serotonergen und histaminergen Rezeptoren mittels Radioligandbindungsstudien 
dar. 
 
7.2 Analoga des Ondansetrons 
Ondansetron (1) hat als hochpotenter 5-HT3 Antagonist bei der Entwicklung anderer 
5-HT3 Blocker als Leitstruktur gedient. In unserer Studie wurden Analoga des 
Ondansetrons (2  -  18) mit Modifikationen im Imidazolring oder der Seitenkette 
untersucht und mit vorherigen Ergebnissen aus funktionellen 5-HT3 Studien am 
Meerschweinchen-Ileum verglichen. In einer Reihe von 4/5-Stellungsisomeren 
(2A/B -  6A/B) konnte eindeutig gezeigt werden, dass die Verbindungen mit 
Substituenten in 4-Position höhere Affinitäten aufwiesen als ihre Stellungsisomere. 
Die höchste Affinität innerhalb dieser Serie wurde für die 4-Methyl-substituierte 
Verbindung 2A gemessen (pKi = 9.05), die 2-fach potenter als die Muttersubstanz 
war. Größere Substituenten führten zu verringerter Affinität. Eine Kettenlänge von 
n=2 wurde als Optimum bestimmt. Hohe Stereoselektivität wurden für die 
Enantiomere  (+/-)-14 mit einem Quotienten von 26 bestimmt. Ein Vergleich der 
Bindungsdaten am h5-HT3A Rezeptor mit den funktionellen Daten am 
Meerschweinchen-Ileum, zeigte eine schlechte Korrelation. Die 5-HT3 Rezeptoren 
von Mensch und Meerschweinchen können als echte Spezies-Orthologe betrachtet 
werden. Als Ergebnis dieser Studie sollte bei der weiteren Entwicklung von 5-HT3 
Liganden das Meerschweinchen als Labortier vermieden werden, da die so  
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ermittelten Werte von nur geringer Vorhersagekraft für die Therapie beim Menschen 
sind.  
 
7.3 Analoga des Metoclopramids 
Die prokinetischen Eigenschaften des Benzamids Metoclopramid (MCP) wurden 
lange vor der ersten Beschreibung von 5-HT4 Rezeptoren entdeckt. In unserer Studie 
wurde eine Serie von Derivaten (20 - 30) des MCP Ester-Analogons SDZ205-557 
(19) auf ihre Bindungseigenschaften an h5-HT4(b) Rezeptoren untersucht und mit 
funktionellen 5-HT4 Daten am Ileum des Meerschweinchens und der Speiseröhre der 
Ratte verglichen. Das Einfügen von Substituenten in der Seitenkette (20, 21) wurde 
nicht toleriert und führte zu einer deutlichen Affinitätsabnahme. Das Einbeziehen des 
basischen Stickstoffs in ein Piperidinringsystem (22) führte zu einem 4-fachen 
Anstieg der Affinität. Ein Stereoselektivitätsquotient von 8 wurde für die p-Methyl- 
substituierten Piperidinderivate (+/-)-23 bestimmt. Im Gegensatz zum 5-HT3A 
Rezeptor wurden große Substituenten in p-Position toleriert. Der höchste Wert 
innerhalb dieser Gruppe wurde für (±)-26 (pKi= 8.43) bestimmt.  Eine Kettenlänge 
von n=2 wurde als Optimum gefunden. Im Gegensatz zum 5-HT3 Rezeptor wurde 
beim Vergleich der Bindungsdaten mit den funktionellen Daten von Ratte und 
Meerschweinchen am 5-HT4 Rezeptor eine gute Korrelation gefunden. Die 
Rezeptoren können als Spezies-Homologe betrachtet werden. 
 
7.4 Analoga des McN-A-343 
Verwandte des McN-A-343 (31) wurden ausgiebig auf ihre Affinität zu 
muskarinischen ACh Rezeptoren untersucht. In dieser Studie wurde eine Gruppe von 
Derivaten (32 - 42) auf ihre Affinitäten an 5-HT3A, 5-HT4(b) und H1 Rezeptoren 
untersucht. An 5-HT3 Rezeptoren hatte (R)-33
+ die höchste Affinität aller 
untersuchten Substanzen (pKi =5.74). Sehr geringe Affinitäten wurden am 5-HT4 
Rezeptor gemessen, wobei für die Muttersubstanz 31 der höchste Wert bestimmt 
wurde (pKi = 5.73). Bei beiden Rezeptoren wurde keine Präferenz für tertiäre oder 
quartäre Verbindungen festgestellt. Interessantere Ergebnisse wurden am H1 
Rezeptor gefunden. Die Einführung eines Restes in der Kette zeigte ein Optimum bei  
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(±)-38 (pKi = 6.98) mit einen 4-F-Phenylrest. Die tertiären Verbindungen waren stets 
potenter als ihre quartären, N-Methylierten Analoga. Für sechs Enantiomerenpaare 
(33, 33
+, 36, 36
+, 37, 37
+) wurde eine inverse Stereoselektivität zwischen M1 und H1 
Rezeptoren beobachtet. Am stärksten war dieser Effekt bei (R/S)-37 ausgeprägt, wo  
Stereoselektivitätsquotienten von 1660 and 0.09 für M1 bzw. H1 bestimmt wurden. 
Inverse Stereoselektivität zwischen muskarinischen und Histamin H1 Rezeptoren 
wurde schon für strukturell verschiedene Moleküle beobachtet und ist vielleicht weiter 
verbreitet als generell angenommen wird. Das Auftrennen von bekannten, 
racemischen H1 Antagonisten in reine Enantiomere könnte neue Ausgangpunkte für 
Leitstrukturen auf der Suche nach selektiven muskarinischen Antagonisten liefern. 
 
7.5 Analoga des Glycopyrroniums 
Derzeit ist ein Gemisch der Enantiomere (3S, 2’R)- und (3R, 2’S)-Glycopyrronium als 
Parasympatholytikum zur Prämedikation vor chirurgischen Eingriffen auf dem Markt 
zugelassen (Robinul
®). Glycopyrronium (43) existiert in vier verschiedenen 
Stereoisomeren 43A-D, die in vorangegangen Studien in unserem Labor untersucht 
wurden. In der vorliegeden Studie wurden eine Reihe verwandter Substanzen (44 - 
56) auf ihre Affinität zu muskarinischen Rezeptoren untersucht. Der Austausch eines 
Methylsubstituenten am quartären Stickstoff durch andere Reste führte bei Dia-44D - 
Dia-48D zu keiner nennenswerten Veränderung der Affinitäten. Die Verbindungen 
49A-D, mit einem Chinuclidin-System anstelle des Pyrrolidinrings der 
Muttersubstanz, zeigten das gleiche stereochemische Verhalten wie die 
Muttersubstanz. Die (2’S)-konfigurierten Stereoisomere 49A und 49B hatten 
drastisch geringere Affinitäten im Vergleich zur (3R, 2’R)-konfigurierten Verbindung 
49D (K. Kreutmann, persönliche Mitteilung), wohingegen nur eine geringe Abnahme 
der Affinität beim (3S, 2’R)-konfigurierten Stereoisomer 49C beobachtet wurde. Die 
höchsten Affinitäten innerhalb dieser Serie wurde für 51D (pKi = 10.71 an M2) 
bestimmt. Auch die Tiotropium-Glycopyrronium-Hybrid Moleküle (R)-55 und (R)-56 
wiesen sehr hohe Affinitäten auf. Die meisten der untersuchten Verbindungen waren 
hochpotente, muskarinische Antagonisten, jedoch zeigten sie keinerlei Selektivität in 
Bindungsexperimenten. 
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7.6 Charakterisierung von [
3H](3R, 2’R)-Glycopyrronium 
Vorangegangene Studien in unserer Arbeitsgruppe hatten gezeigt, dass das (3R, 
2’R)-konfigurierte Isomer des Glycopyrroniums (43D) kinetische Selektivität für M3 
gegenüber M2 Rezeptoren aufweist, die auf unterschiedlichen 
Dissoziationshalbwertszeiten an diesen Subtypen beruht. In der vorliegenden Studie 
wurde diese Verbindung radioaktiv markiert und komplett an M1-5 Rezeptoren 
charakterisiert. Dabei erwies sich [
3H]43D als hochpotenter, unselektiver Antagonist 
in Verdränguns- und Sättigungsexperimenten (pKD = 9.67 - 10.55), wo er an die 
gleiche Bindungsstelle angriff wie der Referenz-Radioligand [
3H]NMS. Die 
Ergebnisse der kinetischen Untersuchungen bestätigten die Verhältnisse, die mit der 
nicht markierten Verbindung an M2 und M3 Rezeptoren gefunden worden waren und 
belegten eine kinetische Selektiviät für den M3 Rezeptor. Die berechneten 
Dissoziationshalbwertszeiten betrugen 71, 23, 145, 77 und 100 min an M1-5 
Rezeptoren. Präklinische in vivo Daten zeigten eine überlegene Bronchodilatation 
und eine verlängerte Wirkdauer für 43D im Vergleich zu Ipratropium. Die geplanten 
klinischen Studien zur Therapie der COPD mit inhaliertem 43D werden zeigen, ob 
eine 2x tägliche Gabe oder sogar eine Einmalgabe zur Therapie beim Menschen 
ausreichend sind. Nach unserem Wissen ist 43D die erste Substanz nach Tiotropium 
mit kinetischer Selektivät für M3 Rezeptoren und ist ein vielversprechender Kandidat 
für die COPD Therapie beim Menschen. 
 
7.7 M2-selektive Antagonisten abgeleitet von Dimethinden 
Nach der Entdeckung der inversen Stereoselektivität zwischen muskarinischen 
Rezeptoren und dem H1 Subtyp bei den Enantiomeren des Dimethindens (57A), 
wurden in unseren Labors Untersuchungen durchgeführt, mit dem Ziel, einen 
hochaffinen M2-selektiven Antagonisten ausgehend von 57A zu entwickeln. Es stellte 
sich jedoch als äußerst schwierig heraus, eine Substanz zu finden, die eine hohe 
Affinität zum M2 Rezeptor in Kombination mit einer guten Selektivität und Spezifität 
aufwies. In unserer Studie wurde eine Reihe von Derivaten (57B und 58 - 83) mit 
unterschiedlicher Länge der Seitenkette und verändertem Substitutionsmuster an der 
Aminogruppe untersucht. Es konnte gezeigt werden, dass Verbindungen mit 
verkürzter Seitenkette eine erhöhte Affinität zum M2 Rezeptor aufwiesen und  
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gleichzeitig in den meisten Fällen eine verringerte Affinität zum H1 Subtyp zeigten. 
Als optimale Substituenten an der Aminogruppe wurden ein Isopropyl- und ein 
Phenylethylrest bei (+)-72B  identifiziert. Diese Verbindung stellt einen großen 
Durchbruch dar, da sie eine hohe Affinität zu M2 (pKi = 8.59) mit guter Selektivität (M2 
versus M1,3,4,5 79-fach, 102-fach, 31-fach, 120-fach) und Spezifität gegenüber H1 
(1349-fach) vereint. (+)-72B ist einer der selektivsten derzeit bekannten M2 
Antagonisten. (+)-72B stellt einen hoffnungsvollen Kandidaten, zur Entwicklung eines 
PET-Liganden zur Diagnose der Alzheimer Erkrankung dar und ist darüber hinaus 
ein potentielles Arzneimittel zur Therapie dieser Krankheit. 
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AC     Adenylate  cyclase 
ACh     Acetylcholine 
AChE     Acetylcholine  esterase 
AD     Alzheimer’s  disease 
AF-DX116 11-[[2-[(Diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-
dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one 
AF-DX384 5,11-Dihydro-11-[[[2-[2-(dipropylamino)methyl)-1-
piperidinyl]ethyl]amino]carbonyl]-6H-pyrido(2,3-b) 
(1,4)benzodiazepin-6-one 
APP     Amyloid  precursor  protein 
sAPP     Soluble  APP   
BIBN99 5,11-Dihydro-8-chloro-11-[[4-[3-[(2,2-dimethyl-1-oxopentyl) 
ethylamino]propyl]-1-piperidinyl]acetyl]-6H-pyrido(2,3-b) 
(1,4)benzodiazepine-6-one 
BIMU1 Endo-N-(8-methyl-8-azabicyclo[3.2.1]-oct-yl)-2,3-dihydro-
3-ethyl-2-oxo-1H-benzimidazol-1 carboxamine 
cAMP     Cyclic  adenosine-3’,5’-monophosphate 
ChAT     Choline  acetyletransferase 
CHO-K1 cells    Chinese hamster ovary cells 
CPM     Counts  per  minute 
COPD        Chronic obstructive pulmonary disease 
DAG     Diacylglycerol 
4-DAMP     4-Diphenylacetoxy-N-methylpiperidinium  methoiodide 
GPCR     G-protein  coupled  receptor 
GPI     Guinea-pig  ileum 
G-protein      Guanine nucleotide binding protein 
GR113808   1-methyl-1H-indole-3-carboxylic acid, [1-[2-[(methyl-
sulfonyl)amino]ethyl]-4-piperidinyl]methyl ester 
HEK293 cells    Human embryonic kidney cells 
HHSiD   Hexahydro-sila-difenidol 
5-HT     5-Hydroxytryptamine,  Serotonin 
IBS  Irritable bowel syndrome  
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IC50  Concentration of an antagonist producing halfmaximal 
inhibition 
IP3     Inositol-1,4,5-triphosphate 
IOP     Intraocular  pressure 
IUPHAR      International Union of Pharmacology 
KD     Equilibrium  dissociation  constant 
kinKD     K D value determined in kinetic binding experiments 
satKD     K D value determined in saturation binding experiments 
Ki  Inhibition constant (equilibrium dissociation constant of the 
inhibitor) 
KO Knock  out 
kon     Association  rate  constant 
koff     Dissociation  rate  constant 
McN-A-343 4-(3-Chlorophenylcarbamoyloxy)-2-butynyltrimethyl-
ammonium chloride 
MCP Metoclopramide 
MDL72222 (bemesetron)  Tropanyl 3,5-dichlorobenzoate 
n        Number of individual experiments 
NMS     N-methyl  scopolamine 
PET     Positron  emission  tomography 
PD     Parkinson’s  disease 
PD102807 9-Methoxy-2-methyl-11,12-dihydro-3H,6α H,13H-6-oxa-
3,12α -diaza-benzo[a]cyclopenta(h)anthracene-1-
carboxylic acid ethyl ester 
PD150714 1-Ethyl-4-phenyl-1,2,3,6-tetrahydropyridine-3-carboxylic 
acid hexyl ester ethanediolate 
PKA     Proteinkinase  A 
PLC     Phospholipase  C 
ROS     Rat  oesophagus 
RS23597-190   3-(Piperidin-1-yl)propyl 4-amino-5-chloro-2-
methoxybenzoate hydrochloride  
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RS39604 1-[4-Amino-5-chloro-2-(3,5-dimethoxyphenyl)methyloxy]-3-
[1-[2-methylsulphonylamino]ethyl]piperidin-4-yl]propan-1-
one hydrochloride 
SAR     Structure-activity  relationship 
SB203186       1-Piperidinylethyl-1H-indole-3-carboxylate hydrochloride 
SCH57790 4-Cyclohexyl-α-[4-[4-methoxyphenyl]-(S)-sulfinyl]-phenyl]-
1-piperazineacetonitrile 
SD     Standard  deviation 
SR57227A     4-Amino-(6-chloro-2-pyridyl)-1  piperidine  hydrochloride 
TM       Transmembrane  domain 
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